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Abstract 
 
Targeted tumor therapy with multispecific antibody formats bears great potential to improve the 
efficacy of cancer immunotherapy: The simultaneous interaction of antibody derivatives with 
immune effector cells and multiple tumor-associated antigens is expected to increase cancer cell 
selectivity, to block cancer cell survival mechanisms and to hamper immune escape. For this purpose 
a large number of bi- and multispecific molecular platforms have been developed including the 
single-chain triplebody format. Triplebodies are composed of three antibody-derived single-chain 
variable fragments interconnected by flexible glycine-serine peptide linkers. They are used for re-
targeting of cytotoxic immune effector cells towards cancer cells, which are bound bivalently by the 
triplebody. 
 
In the present work the triplebody-mediated engagement of T cells for the lysis of B lymphoid 
leukemia cells was established. A prototype with specificity for B lymphoid differentiation antigen 
CD19 and T cell trigger antigen CD3-epsilon – triplebody 19-3-19 – was shown to activate 
T lymphocytes at picomolar concentrations and to engage them for the efficient, serial lysis of target 
antigen-positive cancer cells. The triplebody 19-3-19 also induced T cell proliferation, which can lead 
to the partial regeneration of a patient’s immune effector cell pool. In these capacities the triplebody 
19-3-19 was comparable to the bispecific T cell engager (BiTE®) blinatumomab, which is approved for 
the treatment of relapsed or refractory acute precursor B lymphoid leukemia in the USA and in the 
European Union since late 2014/2015. Furthermore, it was shown with the trispecific triplebody 
33-3-19 that dual targeting of CD19 and myeloid surface marker CD33 on biphenotypic leukemia 
blasts results in selective lysis of these target cells. The CD19 and CD33 double-positive blasts were 
145-fold more sensitive to treatment with the triplebody 33-3-19 than CD19 single-positive cells. 
Parts of the author’s work also contributed to the functional characterization of two previously 
developed NK cell-recruiting triplebodies – SPM-1 (19-16-19) and SPM-2 (33-16-123) – which are 
candidates for clinical development. 
 
The results of this thesis project have established the triplebody format as a molecular platform, 
which can be employed for the recruitment of any cytotoxic effector cell population as required in a 
particular therapeutic setting. Furthermore, the improved target cell selectivity that was achieved in 
vitro with the dual-targeting triplebody 33-3-19 adds weight to the concept of improved therapeutic 
efficacy of multispecific antibodies. 
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Zusammenfassung 
 
Die gezielte Behandlung von Patienten mit multispezifischen Antikörperformaten kann die Effizienz 
der Krebs-Immuntherapie verbessern: Die simultane Interaktion von Antikörperderivaten mit 
Immuneffektor-Zellen und mehreren Tumor-assoziierten Antigenen soll die Selektivität dieser 
Wirkstoffe für Krebszellen erhöhen, Überlebensmechanismen der Krebszellen blockieren und 
verhindern, dass Krebszellen der Elimination durch das Immunsystem entgehen. Zu diesem Zweck 
wurde bereits eine große Zahl an bi- und multispezifischen molekularen Plattformen entwickelt, die 
auch das Single-chain Triplebody-Format mit einschließt. Triplebodies bestehen aus drei einkettigen 
variablen Fragmenten, die von Antikörpern abgeleitet sind. Diese sind durch flexible Glycin-Serin 
Peptid-Linker miteinander verknüpft. Triplebodies werden dazu eingesetzt, zytotoxische 
Immuneffektorzellen gegen Krebszellen zu richten, welche bivalent von dem Triplebody gebunden 
werden.  
 
In der vorliegenden Arbeit wurde die Rekrutierung von T Zellen mithilfe von Triplebodies zur Lyse von 
B lymphatischen Leukämiezellen etabliert. An einem Prototypen mit Spezifität für das B Zell 
Differenzierungs-Antigen CD19 und das T Zell-Trigger Antigen CD3-epsilon – Triplebody 19-3-19 – 
wurde gezeigt, dass T Lymphozyten schon bei picomolaren Konzentrationen aktiviert und zur 
effizienten seriellen Lyse von Antigen-positiven Krebszellen eingesetzt werden können. Außerdem 
induzierte der Triplebody 19-3-19 die T Zell-Proliferation. Diese Eigenschaft kann zu einer partiellen 
Regeneration der Immuneffektorzellen eines Patienten führen. Hierbei war der Triplebody 19-3-19 
vergleichbar mit dem bispezifischen T Zell-Engager (BiTE®) Blinatumomab, der in der Europäischen 
Union und den USA für die Behandlung von rezidivierter oder refraktärer akuter Vorläufer 
B lymphatischer Leukämie zugelassen ist. Darüber hinaus wurde für den trispezifischen Triplebody 
33-3-19 gezeigt, dass das duale Targeting von CD19 und dem myeloiden Oberflächen-Antigen CD33 
auf biphänotypischen Leukämie-Blasten zur erhöhten selektiven Lyse dieser Zielzellen führt. Die 
CD19-CD33 doppelt-positiven Blasten waren gegenüber der Behandlung mit Triplebody 33-3-19 
145-fach sensitiver als CD19 einfach-positive Zellen. Teile der Arbeit der Autorin haben des Weiteren 
zu der funktionellen Charakterisierung von den bereits entwickelten NK Zell-rekrutierender 
Triplebodies SPM-1 (19-16-19) und SPM-2 (33-16-123) beigetragen, welche Kandidaten für die 
klinische Entwicklung sind. 
 
Die Ergebnisse dieses Promotionsprojektes etablieren das Triplebodyformat als eine molekulare 
Plattform, welche für die Rekrutierung jeder zytotoxischen Effektorzell-Population genutzt werden 
 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  4 
 
kann, die für eine bestimmte Anwendung erforderlich ist. Des Weiteren betont die erhöhte 
Selektivität für Zielzellen, die mit dem dual-targeting Triplebody 33-3-19 in vitro erreicht wurde, das 
Konzept der verbesserten therapeutischen Effektivität durch multispezifische Antikörper. 
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1 Introduction 
 
1.1 Aim of the experimental studies 
 
New strategies to improve the effectiveness and specificity of cancer immunotherapy are currently 
under development. One such approach is the re-targeting of immune effector cells with 
multispecific antibodies for the rapid and selective elimination of cancer cells by cellular cytotoxicity. 
It was the aim of the present study to develop T cell-engaging trispecific antibody derivatives in the 
molecular format of single-chain triplebodies (triplebodies, scTb). Triplebodies that are capable of 
NK cell-recruitment already existed, but whether these antibody derivatives were also capable of 
T cell-engagement had never been tested prior to this work. 
 
T cell-engaging triplebodies for the cytolysis of CD19-positive acute leukemia blasts, in particular for 
the selective lysis of blasts with aberrant antigen co-expression of CD19 and CD33, were developed. 
This co-expression is associated with specific genetic abnormalities and confers a poor prognosis.1,2 
Initially, the experimental procedures for the production, purification and functional analysis of 
T cell-engaging triplebodies were established at the example of the CD19- and CD3ε−specific 
prototype triplebody 19-3-19 (Roskopf et al. Oncotarget 2014 [references to own publications 
indicated with journal]). Subsequently, the dual-targeting capacity of triplebodies was implemented: 
The triplebody 33-3-19 with specificity for CD33, CD19 and CD3ε was designed with the aim of 
achieving not only efficient, but also selective cytolysis of CD19 and CD33 double-positive leukemia 
cells, while avoiding the lysis of healthy bystander cells. One aim of the present study was to 
establish reliable experimental methods for the in vitro analysis of the selectivity of lysis by 
dual-targeting triplebodies (Roskopf et al. Oncotarget 2016). The final aim of the present work was to 
contribute to the pre-clinical development of NK cell-engaging triplebodies SPM-1 (Schiller et al. 
Oncotarget 2016) and SPM-2 (Braciak et al. J Exp Med 2013 and Chatzopoulou et al. Analyst 2016). 
 
 
1.2 Acute Leukemias 
 
Cancer results from abnormal cells that grow beyond their usual tissue boundaries and that are 
capable of invading adjoining parts of the body and metastasizing to distant organs.3 The types of 
cancer that arise from the hematopoietic system are as diverse as the cell types, which comprise this 
tissue: Lymphoid and myeloid cells at different developmental stages and in different compartments 
of the body (i. e. bone marrow or extramedullary sites) can undergo malignant transformation and 
Introduction 
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cause disease. Blood cancer thus includes multiple entities such as Hodgkin’s disease and 
Non-Hodgkin lymphomas (NHL), multiple myeloma (MM), myelodysplastic and myeloproliferative 
diseases (MDS and MPS) as well as chronic and acute forms of leukemia.3-5  
In Germany, the cumulative incidence of hematologic malignancies among cancer patients is 
approximately 6 to 7% in both females and males. Leukemia is diagnosed, when more than 20% of 
the nucleated cells in a diagnostic peripheral blood or bone marrow sample are blasts and affects 
half of the patients with hematologic neoplasias.5 In Germany, 12,640 adults with an average age of 
approximately 70 years were diagnosed with leukemia in 2012. Chronic lymphocytic leukemia (CLL) 
struck a third of these patients. Another quarter was diagnosed with acute myeloid leukemia (AML).4 
In children under the age of 15, leukemias especially acute lymphocytic leukemias (ALL) are by far the 
most common form of cancer and account for 33% of all malignancies (ALL: 26%; AML: 4%; 
others: 3%).4  
 
 
1.2.1 Pathogenesis and clinical presentation 
 
Acute leukemias are distinguished into AML and related precursor neoplasms, acute leukemia of 
ambiguous lineage and precursor lymphoid neoplasms of the B and T lymphoid lineages.5 They arise 
in the bone marrow upon malignant transformation of hematopoietic progenitor cells, which 
deregulates differentiation, proliferation and apoptosis and can confer stem cell-like properties.6 The 
leukemia blasts populate the bone marrow, displace healthy hematopoietic cells and thereby 
hamper normal hematopoiesis. Eventually the cancer cells emigrate, enter the peripheral blood and 
invade extramedullary sites such as the central nervous system (CNS), lymphoid organs, the lung and 
bones.7,8 In the majority of patients the obstruction of normal hematopoiesis results in anemia, 
thrombocytopenia and granulocytopenia. Accordingly, acute leukemia patients present with 
abnormal blood test values, since the numbers of leukocytes, thrombocytes and erythrocytes are 
affected. The pancytopenia gives rise to some of the typical symptoms including fatigue, paleness, 
tachycardia, fever, frequent infections and bleeding symptoms such as petechia, epistaxis and 
ecchymosis.7,8 The involvement of distant organs may then produce various additional symptoms and 
abnormal diagnostic parameters.7,8 
 
 
1.2.2 Acute myeloid leukemia 
 
Diverse innate immune effectors from the granulocytic lineage (neutrophils, eosinophils and 
basophils), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages comprise the 
myeloid cells.5 Accordingly, acute myeloid leukemia (AML) is a highly heterogeneous disease. The 
Introduction 
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distinct morphologic characteristics of AML blasts were employed by the French-American-British 
(FAB) cooperative group for the classification of this type of leukemia into eleven subtypes (M0 - M7) 
(Table 1).7 However, the individual entities of AML can also be defined by precise molecular 
alterations and not only by the healthy counterparts of the neoplastic cells alone.9 The identification 
of specific genetic aberrations, which are the most prominent prognostic factors for this type of 
cancer, thus led to the introduction of a new classification scheme by the World Health Organization 
(WHO) in 2008. It is based on criteria that comprise morphologic, cytochemical, immunophenotypic, 
genetic and clinical features. Resultantly, AML is subdivided into AML with recurrent genetic 
abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms and 
AML, not otherwise specified (NOS) (Table 1).5 
 
Table 1: Currently used classification systems of Acute Myeloid Leukemia (AML). 
 
French-American-British (FAB) Classification (1976/85) WHO Classification (2008) 
AML-M0 Undifferentiated acute myeloblastic leukemia AML with recurrent genetic abnormalities 
AML-M1 Acute myeloid leukemia with minimal maturation  with t(8;21)(q22;q22), RUNX1-RUNX1T1 
AML-M2 Acute myeloid leukemia with maturation  with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11 
AML-M3 Acute promyelocytic leukemia (APL)  with t(15;17)(q22;q12), PML-RARA (APL) 
AML-M3v Atypical APL with microgranula  with t(9;11)(p22;q23), MLLT3-MLL 
AML-M4 Acute myelomonocytic leukemia  with t(6;9)(p23;q34), DEK-NUP214 
AML-M4Eo Acute myelomonocytic leukemia with eosinophilia  with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), RPN1-EVI1 
AML-M5a/b Acute monocytic leukemia  with t(1;21)(p13;q13), RBN15-MKL1 (megakaryoblastic) 
AML-M6 Acute erythroid leukemia  (AML with mutated NPM1) 
AML-M7 Acute megakaryocytic leukemia  (AML with mutated CEBPA) 
  AML with myelodysplasia-related changes 
  Therapy-related myeloid neoplasms 
  AML, not otherwise specified (NOS) 
 
AML is an aggressive disease and fatal within a short period of time, when untreated. The 
conventional treatment approach upon diagnosis is chemotherapy, which is subdivided into two 
phases: induction and consolidation. During the induction phase the absolute tumor load is reduced 
by 3 to 4 logs from a total of 1012 to 108 or 109 leukemic blasts. During consolidation the residual 
leukemia cells are eliminated in order to prevent relapse.7 Currently, intense chemotherapeutic 
regimens employ pyrimidine analogues (i. e. Cytarabin/Ara-C), cytostatic antibiotics (i. e. dauno-
rubicin) and topoisomerase inhibitors (i. e. Etoposide) among others.7,10 Hematopoietic stem cell 
transplantation (HSCT) is indicated for younger patients with high risk AML (i. e. aberrations of 
chromosome 3, 5 and/or 7, complex karyotype, involvement of the mll-gene) and with relapsed 
and/or refractory disease.6,7 
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While the majority of patients (more than 80%) initially respond to chemotherapy and achieve 
complete remission, there is a high rate (50 to 60%) of relapse and the long-term survival rate is only 
30 to 40%.7 The leukemia cell clone that is responsible for relapse is frequently refractory to the 
chemotherapeutic agents that were used during first line therapy. Furthermore, a large number of 
patients cannot cope with intense chemotherapy regimens or remain minimal (measurable) residual 
disease (MRD)-positive post induction. This especially concerns the elderly, who often display 
unfavorable genetic aberrations and a poor general condition of health. These patients have a very 
poor prognosis and urgently require new treatment options.6,7,11 As an alternative to chemotherapy 
and the treatment-related mortality-prone HSCT, immunotherapeutic approaches have been 
developed for the treatment of AML. The myeloid differentiation antigen CD33 (see chapter 1.5.2) 
and the alpha-chain of the IL-3 receptor, i. e. CD123 (see chapter1.5.3), are the most prominent 
targets at present.12 Thus far the only approved immunotherapeutic agent was the anti-CD33 
antibody-drug-conjugate (ADC) gemtuzumab ozogamicin (Mylotarg®), which was, however, volun-
tarily withdrawn by Pfizer in 2010 due to the lack of additional benefit but occurrence of hepatic 
toxicity.13,14 Nevertheless, the ADC was recently reapproved at a lower dose and for a limited patient 
population.15 The development of an anti-CD33 antibody, i. e. Lintuzumab, was discontinued in 
2010.16,17 Since then the development of a bispecific T cell engager (BiTE®), which is also directed 
against CD33, and of T cells with CD33 or CD123-targeting chimeric antigen receptors (CAR-T) have 
been the most promising immunotherapeutic approaches in AML.18-20  
 
 
1.2.3 Acute leukemia of ambiguous lineage 
 
Very rarely the blast population of an acute leukemia patient cannot be assigned to a specific 
hematopoietic lineage, either because of the lack of differentiation markers or because of the 
simultaneous expression of differentiation markers from multiple hematopoietic lineages. The WHO 
grouped these types of leukemias, which affect approximately 3 to 5% of all acute leukemia patients, 
together into the new class of “acute leukemia of ambiguous lineage”.5,21,22 This new class comprises 
acute undifferentiated leukemias (AUL), which do not display differentiation antigens but often 
express early progenitor markers (i. e. CD34, HLA-DR, CD38 and TdT), acute bilineage leukemias, 
which present with two blast populations of different hematopoietic lineages, and finally mixed 
phenotype acute leukemias (MPAL).5,21-23 
 
The diagnosis of MPAL is based exclusively on immunophenotypic characteristics of the blast 
population (Table 2) and can only be applied, if all other types of acute leukemia have been excluded. 
This concerns acute leukemias with recurrent genetic abnormalities that often display aberrant 
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antigen expression in particular.5,21,22 There appears to be a high incidence (approximately 83 to 87%) 
of cytogenetic abnormalities among MPAL patients.23,24 Some of these are also recurrent including 
the translocation t(9;22) (q34;q11.2) (Philadelphia chromosome), which produces the BCR-ABL-1 
fusion protein, and rearrangements of the mixed lineage leukemia gene (mll; t(v;11q23)), which 
frequently occur in infants younger than 10 months.5,21-23,25 Rubnitz and colleagues reported that the 
gene expression profiles of blasts from eight out of thirteen MPAL patients were clearly different 
from those of ALL or AML blasts, thereby highlighting the distinct nature of MPAL.24 
 
Table 2: Requirements for assigning more than one lineage to a single blast population in mixed phenotype 
acute leukemia according to the WHO 2008 classification. 
 
Criteria for the diagnosis of mixed phenotype acute leukemia (MPAL) 
Myeloid lineage  
 Myeloperoxidase 
or Monocytic differentiation (at least 2 of the following: nonspecific esterase, CD11c, CD14, CD64, lysozyme) 
T lineage  
 Cytoplasmic CD3 
or Surface CD3 
B lineage (multiple antigens required) 
 Strong CD19 with at least 1 of the following strongly expressed: CD79a, cytoplasmic CD22, CD10 
or Weak CD19 with at least 2 of the following: CD79a, cytoplasmic CD22, CD10 
 
 
In clinical practice, MPAL is subdivided into B-myeloid, T-myeloid, B/T or trilineage leukemia based 
on the immunophenotype of the blast population.21,23,24,26,27 The relative frequencies of these 
subgroups vary in different studies, but the B-myeloid phenotype appears to be the most common 
(approximately 54%), followed by the T-myeloid (approximately 37%) and the very rare B/T 
(approximately 5%) and trilineage (approximately 3%) cases.21,24-27 Lineage infidelity in MPAL raises a 
serious problem for clinicians, because the classical treatment protocols cannot be applied with 
confidence. HSCT is not a reliable curative option for MPAL patients either, but it can be beneficial, if 
patients display an incomplete molecular response, in Philadelphia chromosome-positive MPAL and 
in infants.24,26,28,29 Prospective clinical studies to establish a consensus regarding the therapy regimen 
for MPAL patients have not been performed to date due to the rarity of this disease. Even 
retrospective analyses of this patient population are complicated, because of the discord regarding 
the diagnostic criteria for MPAL prior to the new WHO classification in 2008.21,22 However, the clinical 
outcome of adult MPAL patients appears to be generally worse than that of adult ALL and AML 
patients. Among children it is worse than that of pediatric ALL patients.24,30 Thus this particular 
subgroup of acute leukemia patients requires new therapy approaches. At this, the aberrant 
co-expression of myeloid, B and/or T lymphoid antigens turns MPAL blasts into a particularly 
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interesting cancer cell population for selective immunotherapeutic targeting with multispecific 
antibodies. 
 
 
1.2.4 Precursor lymphoid neoplasms 
 
Both lymphoid lineages, i. e. T and B lymphocytes, can give rise to precursor lymphoid neoplasms 
upon malignant transformation of early lymphoid progenitor cells.5,8 The present work focuses on 
precursor B lymphoid neoplasms. A classification system by the FAB cooperative group from 1976 
was based on cytologic criteria (Table 3), however, it had few clinical implications with regard to 
disease progression, prognosis or treatment strategy.8 As new diagnostic techniques became 
available, immunophenotypic criteria such as CD10 positivity/negativity and cytogenetic features 
(i. e. rearrangement status of immunoglobulin (Ig) heavy and light chain genes) were taken into 
consideration for the further sub-classification of precursor B lymphoid neoplasms into pro-B, 
common-B, pre-B, and mature B-ALL. This system is still used today (Table 3).8 Advances in genetic 
profiling in the past two decades additionally led to the introduction of a new WHO classification 
scheme of ALL in 2008 that puts strong emphasis on prognostically valuable recurrent genetic 
abnormalities (Table 3).5,8 
 
Table 3: Classification systems used for B precursor lymphoid neoplasms. 
 
FAB Classification (1976)  WHO Classification (2008) 
L1 Small blasts with homogeneous nuclear chromatin, no or small 
nucleoli and scanty cytoplasm 
B lymphoblastic leukemia/lymphoma, not otherwise 
specified (NOS) 
L2 Large, heterogeneous cells with variable nuclear chromatin, one or 
more nucleoli and a variable amount of cytoplasm 
B lymphoblastic leukemia/lymphoma with recurrent 
genetic abnormalities 
L3 Large, homogeneous cells with fine, stippled chromatin, prominent 
nucleoli and basophilic cytoplasm; prominent cytoplasmic vacuolation 
 with t(9;22)(q34;q11.2), BCR-ABL 1 
 with t(v;11q23), MLL rearranged 
  with t(12;21)(p13;q22), TEL-AML1 (ETV6-RUNX1) 
Immunophenotypic Classification (EGIL 1995)  with hyperdiploidy 
 Immunophenotype Morphology  with hypodiploidy 
All B-ALL HLA-DR+; TdT+; CD19+, CD22+ and/or CD79a+    with t(5;14)(q31;q32), IL3-IGH 
Pro-B-ALL No additional differentiation markers L1 or L2  with t(1;19)(q23;p13.3), TCF3-PBX1 
Common B-ALL CD10+ L1 or L2   
Pre-B-ALL CD10±; cyIg+ L1 or L2   
Mature B-ALL CD10±; sIg+ L3   
 
Half a century ago the diagnosis of ALL was equivalent to a death sentence, but due to carefully 
developed intensive and risk-adapted chemotherapy regimens with multiple cytostatic agents more 
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than 80% of ALL patients can nowadays be cured from their disease.31 Chemotherapy of ALL consists 
of three phases: During the induction phase the blast number in the bone marrow is reduced to less 
than 5% of nucleated cells using the ALL-specific agent asparaginase, mitosis inhibitors (i. e. 
vincristine), prednisone and anthracycline derivatives (i. e. daunorubicin). During consolidation a 
further reduction of blast numbers is achieved and the development of drug resistance prevented by 
applying new combinations of these or alternative cytostatic agents or high dose chemotherapy. 
Finally, during the maintenance phase, 6-mercaptopurine and methotrexate are employed for up to 
two and a half years to prevent relapse.8 To relieve and/or prevent CNS-affliction, which occurs in 
approximately 7% of ALL patients, methotrexate can also be given intrathecally or the patients 
undergo radiation therapy for local tumor control.8,31 Furthermore, supportive therapy is provided to 
relieve bleeding symptoms, to reduce the risk of infection and to speed up hematologic 
reconstitution.8 This therapeutic strategy has resulted in 15-year survival rates as high as 89% among 
pediatric ALL patients.4,32 In adults, however, ALL is still difficult to treat, because unfavorable 
biologic features such as the Philadelphia chromosome are frequent and heavy chemotherapy 
regimens are poorly tolerated.8,32,33 Furthermore, there are still numerous cases of high risk leukemia 
patients as well as those with refractory and/or relapsed B-ALL that succumb to their disease.30,32,34 
For these patients a further intensification of chemotherapy is impractical due to treatment-related 
toxicity, morbidity and mortality. Furthermore, long-term survivors have an increased risk to develop 
secondary neoplasias (presently 4% in 25 years) and the rate of secondary relapses is greater than 
50%.4,31,35 Thus, there is an urgent need to develop new, more selective forms of therapy to cure high 
risk and elderly patients and to prevent the development of therapy-related malignancies. 
 
Aside from specific tyrosine kinase inhibitors such as the BCR-ABL-1 inhibitor imatinib, 
immunotherapeutic approaches are the focus of drug development in B-ALL.8,36 The B cell 
differentiation antigens CD19 (see chapter 1.5.1), CD20, CD22 and HLA-DR were identified as the 
most promising targets for antibody therapy of B cell neoplasias and the first approved 
immunotherapeutic agent, anti-CD20 antibody rituximab, is applied successfully to treat B cell 
lymphomas.1,37,38 However, monoclonal antibodies (mAb) directed against CD19 in precursor 
B lymphoid neoplasms, whose blasts are characterized by dim CD20 but strong CD19 expression, 
failed to display therapeutic efficacy.38-40 Other antibody derivatives, T cell-recruiting agents and 
modified T cells have been developed to combat relapsed and/or refractory B-ALL.36 One 
CD19-targeting immunotherapeutic agent, the BiTE® blinatumomab, was approved by the FDA and 
EMA in late 2014 and 2015, respectively.41,42 The adoptive transfer of CD19-specific CAR-Ts is also a 
highly efficient treatment option and the first CD19 CAR-T Kymriah™ (tisagenlecleucel by Novartis 
Pharmaceuticals Corp.) was approved in the United States in August 2017.20,43,44 However, both of 
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these immunotherapeutic strategies have serious drawbacks (see chapter 1.4.2), and thus further 
developments of next generation immunotherapeutics are desirable. 
 
 
1.3 Cancer stem cells and clonal evolution in acute leukemia 
 
Within any leukemia cell population there is a significant level of inter- and intraclonal genetic and 
epigenetic heterogeneity. As a result thereof and due to microenvironmental influences clonal 
subpopulations have different functional properties, for example with regard to differentiation, 
proliferation potential and drug sensitivity.45-49 To explain the rise of clonal heterogeneity, several 
models have been proposed, two of which are of particular relevance in acute leukemia (see Figure 
1): (1) According to the cancer stem cell (CSC) model, self-renewing, immature tumor cells, which are 
capable of asymmetric cell division, give rise to more differentiated clonal progeny and maintain the 
tumor tissue in a manner similar to the development and maintenance of normal tissues. CSCs are at 
the apex of a malignant clonal hierarchy48-51 and acute myeloid leukemia behaves largely in 
accordance with this model.48,52-54 Quiescence, drug insensitivity and other stem cell properties 
enable leukemia stem cells (LSC) to survive therapy and cause relapse. Therefore, the targeted 
elimination of LSC is paramount, especially because relapse propagating clones are often more 
aggressive than the diagnostic ones and are therefore more difficult to combat.49,51 (2) Acute 
lymphocytic leukemia, however, is described more accurately by the second model, i. e. clonal 
evolution45,46,55,56, which suggests that genetic alterations accumulate in malignantly transformed 
cells and can provide leukemia initiating potential to different coexisting subclones. In a Darwinian 
fashion, interclonal competition and environmental bottlenecks lead to the development of a 
nonlinear, branched clonal architecture.45,46 Properties, which are usually attributed to stem cells 
such as self-renewal and chemoresistance, arise spontaneously and are selected, because they 
provide survival advantages.47 Unlike the CSC model, the clonal evolution model does not propose a 
fixed leukemia initiating clonal subpopulation that can be targeted to prevent disease recurrence. 
Instead these properties may be gained by any subclone, which results in a transient stem cell 
phenotype. 
 
Evidence for each of these models has been provided in acute leukemia and it is likely that they are 
not mutually exclusive, but that clonal heterogeneity emerges due to a combination of both plus 
additional phenomena such as pre-leukemic stem cells, tumor cell plasticity and interconvertibility. It 
has for example been proposed that clonal evolution may take place within the CSC compartment.46 
Other authors suggest that CSC initiate the disease, but that the entire cancer cell population 
acquires beneficial stem cell properties throughout disease progression and thus the CSC model 
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becomes obsolete at advanced disease stages.47,48 Finally, cancer cells may move fluidly into and out 
of stem cell states, which has been described in solid tumors.50,57 The elimination of CSC may thus be 
essential to cure patients, but continues to be a difficult goal because they are a highly complex 
moving target.47-49 Nonetheless efforts to develop CSC-targeting therapies are underway and for 
some cancers, including AML, targetable stem cell markers have been described. 
 
 
Figure 1: Models of tumor heterogeneity. Tumors are composed of phenotypically and functionally heterogeneous cells. 
There are two theories as to how this heterogeneity arises, which are particularly relevant in acute leukemia. The clonal 
evolution model and the cancer stem cell model [based on John E. Dick, 2008]48 
 
 
1.3.1 AML initiating cells 
 
In the 1990s the group of John Dick identified a leukemia initiating subpopulation within the lineage 
negative (Lin-) CD34+ CD38-/low cell compartment of AML patients based on its serial transplantability 
in NOD/SCID mice. While the majority of leukemia blasts was post-mitotic, this subpopulation, which 
reflected the immunophenotype of healthy hematopoietic stem cells (HSC), self-renewed and 
repopulated the tumor tissue. It was found at a (highly variable) frequency of approximately 1 in 106 
leukemia blasts.58,59 This discovery started a period of intense research into the nature of leukemia 
initiating cells (LIC) and into potential therapeutic targets in order to eliminate this persistent cell 
population. In 2000, Jordan and colleagues demonstrated that the interleukin-3 receptor alpha chain 
(IL-3Rα/CD123; see chapter 1.5.3), but not its hetero-dimerization partner CD131, was more strongly 
expressed on CD34+ CD38-/low LIC compared to normal hematopoietic stem cells (HSC), though 
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signaling through the IL-3R was not active.60 Vergez et al. later found that a percentage of 
CD34+ CD38-/low CD123+ cells greater than 1% at diagnosis already correlated with a poor disease-free 
and overall survival in a retrospective study.61 Thus CD123 is one of the most promising surface 
antigens for targeted elimination of AML LIC. In line with these observations, monoclonal antibody 
(mAb) 7G3 directed against CD123 prevented engraftment of AML LIC in NOD/SCID mice.62 However, 
the antigen is also expressed on healthy hematopoietic progenitors to a lower extent. To prevent 
“on-target off-tumor” effects that hamper or destroy normal hematopoiesis, immunotherapeutic 
approaches targeting CD123 need to be developed very carefully.63 Further potential surface antigen 
targets that are preferentially expressed by CD34+ CD38-/low LIC rather than normal HSC include CLL1, 
CD25, CD32, CD33 (Siglec-3), CD44 (hyaluronan), CD47, CD96, CD157 and TIM3.64-66 In addition to 
targetable surface markers, other LIC-specific characteristics such as their metabolic and epigenetic 
properties and their interactions with the microenvironment are also investigated to identify new 
potential therapy targets.65,67 This has become necessary since more sensitive detection methods for 
LIC have proven that LIC are also present in the CD34+ CD38+ and even in the CD34- compartment. 
These experiments include functional repopulation tests in NOD/SCID/β2mnull or NOD/SCID/IL2Rγnull 
(NSG) mice as well as using intra-femoral instead of tail vein injection of leukemia cells.67-69 Thus AML 
LIC display phenotypic diversity between patients and even within the blast population of an 
individual patient and may not always be eliminated entirely by therapeutic approaches targeting 
surface molecules.67 Moreover, pre-leukemic stem cells as well as LIC can undergo clonal evolution in 
response to therapy, which may shift their immunophenotype.67,68,70 To prevent this, it has been 
proposed that LIC-directed therapy should already be included at early treatment stages and that 
suitable read-outs for the efficacy of LIC-directed therapies are disease-free (DFS) and overall survival 
(OS) rather than response rate and complete remission.52,67 
 
 
1.3.2 ALL initiating cells 
 
After it had been ascertained that AML initiating cells reside mostly in the Lin- CD34+ CD38/low cell 
compartment, similar attempts to discover LIC in B-ALL were undertaken. However, a distinct 
immunophenotype could not be identified.46 B-ALL initiating potential was detected in      
CD34+ CD38-/low CD19+ leukemia blasts71,72, in CD34+ CD38+ CD19+ and CD34+ CD38-/low CD19+ (even 
though the CD34+ CD38+ CD19+ predominantly reproduced themselves)73 and in CD34+ CD19, 
CD34+ CD19+ and CD34- CD19+ cell compartments.74,75 As few as 2*103 CD34+ CD19- blasts sufficed to 
produce leukemia in up to four serial recipient NOD/SCID mice.75 In mll-rearranged B-ALL the 
co-expression of the myeloid antigen CD33 was not indicative of leukemia-initiating potential 
either.74 It was, however, confirmed in these studies that the CD34+ CD38- CD19- (CD33-) 
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compartment is enriched for healthy HSC, which can regenerate normal hematopoiesis.73,74 These 
results highlight that neither CD34, nor CD38 or CD19 are robust markers for potential B-ALL LIC and 
contest the existence of a distinct LIC compartment in B-ALL. Numerous studies on evolutionary 
relationships of B-ALL subclones46,56,76 and of monozygotic twins one or both of whom develop 
leukemia71,77-79 rather indicate that the existence of pre-leukemic subclones and ongoing clonal 
evolution that leads to the acquisition or retention of stem cell properties play a more important role 
in B-ALL. Nevertheless B-ALL clones displaying “stemness” need to be eradicated to prevent relapse 
and refractoriness.  
 
1.4 Immunotherapy of cancer 
 
Because chemo- and radiotherapy of cancer are not specific but rather aggressive systemic 
treatment approaches, they have two serious drawbacks: systemic toxicity, including secondary 
neoplasias, and the development of long-term resistance.80 Moreover, cancer cells with a low 
proliferation rate and an intrinsic drug insensitivity such as LIC frequently survive systemic therapy 
aimed at rapidly proliferating cells and can subsequently cause relapsed disease that is refractory to 
the original treatment.49 In contrast to chemo- and radiotherapy, immunotherapy is a more specific 
approach that does not only aim at eliminating cancer cells directly. Instead the immune system is 
enabled to specifically detect and kill cancer cells.81 The human immune system has a natural cancer 
suppressive function, especially via NK cell surveillance82, and is intact in most cancer patients except 
at advanced stages.81,83 Thus it can be harvested for therapy. Targeted immunotherapy is highly 
selective, which does not only allow the potential elimination of specific cell (sub-)populations such 
as LIC, but also decreases toxic side effects on non-target tissues and reduces dosage requirements 
compared to systemically active substances.84 In all forms of acute leukemia, however, the displaced 
leukocyte populations and inhibition of normal hematopoiesis weaken the immune system 
significantly.7,8 Targeted immunotherapeutic approaches against acute leukemia thus need to 
overcome this additional hurdle.  
 
The first systematic application of cancer immunotherapy was described in the late 19th century by 
William B. Coley. He observed tumor regression in sarcoma patients after the injection of soluble 
bacterial toxins.85,86 Coley’s results are attributed to the (re-)activation of the sarcoma patients’ 
immune system (including tumor-infiltrating lymphocytes (TIL)) in response to the feigned bacterial 
infection.86 In line with this explanation, the engagement of autologous cytotoxic T lymphocytes (CTL) 
and NK cells as immune effectors is considered to be a particularly promising therapeutic approach 
due to the high cytotoxic potential of these leukocytes.87 
Introduction 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  20 
 
A successful adaptive immune response against cancer is raised, when three prerequisites are 
fulfilled: First, tumor antigen-specific lymphocytes need to be present that can recognize cancer cells, 
but would not cause severe autoimmunity upon activation. Second, these lymphocytes need to be 
activated by professional antigen-presenting cells (APC) and need to expand. And third, they need to 
infiltrate the tumor tissue, overcome local immunosuppression and kill the cancer cells.88  
 
Unfortunately, general immune activation by Coley’s toxin or other adjuvants, cytokines and growth 
factors or via immune activators such as TLR agonists and unmethylated CpG is rarely able to induce 
tumor regression by itself.89 One of the reasons is the dependence of such approaches on the 
intrinsic immunogenicity of the underlying malignancy: Some cancer entities are more immunogenic 
than others, because they display tumor-specific antigens (TSA). Among these are neoplasias with 
high mutational frequencies, which can result in the generation of neo-antigens (e. g. malignant 
melanoma and NSCLC).90 Other immunogenic cancer entities express cancer/testis (CT) antigens (e. g. 
NY-ESO1, MAGE1/3) or are caused by oncogenic viruses and thus display viral antigens (e. g. HPV in 
cervical cancer), which can be recognized by the adaptive immune system.89 Patients suffering from 
immunogenic cancer entities naturally develop TILs that can be recruited upon immune stimulation 
or expanded ex vivo and adoptively transferred in order to reject the tumor.81 Another approach in 
such cases is cancer vaccination via peptide-, DNA/RNA- or dendritic cell (DC)-based vaccines.91,92 
However, within such cancer entities there is a high level of heterogeneity with regard to their 
immunogenicity. As a result only modest therapeutic benefits were achieved with general immune 
stimulation and vaccination approaches in the past.81 
 
Aside from the lack of immunogenicity, two other important mechanisms prevent immunologic 
eradication of established tumors that have escaped immune surveillance by NK cells: The first one is 
immunoediting, which refers to the progressive loss of immunogenic surface markers under selective 
pressure mediated by T cells.82 The second one is immunosuppression. 
 
Cancer cells achieve immunosuppression by multiple mechanisms: (1) They downregulate 
MHC class I molecules. (2) They hijack immune checkpoints, which prevent autoimmunity in healthy 
subjects, by upregulating immunosuppressive surface markers (e.g. CTLA4, PD-L1). (3) They secrete 
immunosuppressive molecules (e.g. anti-inflammatory cytokines, IDO). (4) They recruit 
immunosuppressive cells (i. e. myeloid-derived suppressor cells (MDSC), tumor-associated 
macrophages (TAM) and regulatory T cells (Treg)). (5) And finally, most cancers promote hypoxia.88 
 
Immunosuppression has to be overcome to enable an effective anti-cancer immune response. This is 
the goal of immune checkpoint blockade, which is commonly referred to as “releasing the break”80: 
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Anti-tumor immunity is enhanced upon blocking immune checkpoints, for example the inhibitory 
CD80/CD86 ligand cytotoxic T lymphocyte antigen-4 (CTLA4)93, with monoclonal antibodies94,95, 
which was discovered by the group of James Allison. The blockade of immune inhibiting interactions 
such as CTLA4 and CD80/CD86 or PD-L1/-L2 and PD-1 (also innate immune checkpoint: SIRPα and 
CD47) by monoclonal antibodies96-100 is an effective new method for oncologists to fight cancer and 
leads to long-term remission in a significant proportion of patients with different immunogenic 
malignancies including malignant melanoma100,101 and NSCLC.102 Recently, checkpoint blockade has 
also become an experimental treatment for acute leukemia103-105 since leukemia blasts upregulate 
immunosuppressive surface markers upon treatment.105-107 
 
However, in many less immunogenic tumor entities the cancer cells resemble “self” too closely to 
raise a natural immune response that may be “released” by checkpoint blockade.90 In the absence of 
TSAs, tumor-associated antigens (TAA), such as tissue-specific differentiation markers (including 
CD19 and CD33), have therefore been in the focus of developing targeted immunotherapeutic 
approaches. The induction of adaptive immunity via APC is circumvented and an effective immune 
response is raised by applying TAA-specific immune effector cell-engaging agents. These can be in the 
form of therapeutic monoclonal antibodies (mAb) and antibody derivatives (see chapter 1.4.1) or in 
the form of cellular therapeutics modified with tumor-specific receptors (see chapter 1.4.2). 
 
The impressive therapeutic results that have been achieved with immune checkpoint blockade and 
other novel targeted therapies that are described in the following chapters have strongly increased 
the applicability and value of immunotherapy in the past two decades. This led to the recognition of 
immunotherapy by the journal “Science” as “breakthrough of the year - 2013”.108,109 
 
 
1.4.1 Therapy with monoclonal antibodies and antibody derivatives 
 
The history of antibody therapy begins in the late 19th century, when Emil A. von Behring and 
Kitasato Shibasaburo discovered active blood serum components for the treatment of tetanus and 
diphtheria.110 Their discovery resulted in the establishment of passive vaccination with anti-sera, 
which they developed together with Paul Ehrlich, and thus in the first therapeutic application of 
antibodies. Paul Ehrlich later proposed two concepts that had a significant impact on antibody 
therapy: The “side chain theory” (1891)111, which suggests that selective structure-based receptor-
ligand interactions, for example between antibodies and antigens, result in specific pharmacological 
activities, and the “magic bullet” concept (1908)112, which states that disease-specific drug 
substances that spare healthy tissues are required for cure. In his time, Paul Ehrlich referred to small 
chemical compounds for the treatment of infections such as syphilis and tuberculosis as “magic 
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bullets”, but the concept soon became a guiding general principle in modern pharmacology. 
Nowadays, the most selective drug substances are specific tyrosine kinase inhibitors (TKI) and 
monoclonal antibodies or derivatives thereof. 
 
Antibodies, which are also referred to as immunoglobulins (Ig), are antigen-recognition molecules 
that are produced by terminally differentiated B lymphocytes, i. e. plasma cells. Each plasma cell 
produces an antibody of a single specificity.113 In human beings there are five classes (or isotypes) of 
antibodies, which can be distinguished based on their constant regions: IgM (membrane-bound 
immunoglobulin or B cell receptor (BCR)), IgD, IgG, IgA and IgE. The most abundant isotype is the 
secreted immunoglobulin G (IgG) format, which is also most frequently used for therapeutic 
applications and can be further subdivided into four subclasses with different Fc-receptor (FcR) 
affinities, i. e. IgG1, IgG2a/b, IgG3 and IgG4.114,115 The typical structure of an antibody is depicted in 
Figure 2. 
 
(a)  (b)  
Figure 2: Schematic representation of IgG domains and 3D structure of IgG based on x-ray crystallography studies. (a) IgG 
is composed of 2 heavy and 2 light chains. V domains (VL/VH) at the N-terminal end of the polypeptide chains, which form 
the antigen-binding clefts, are followed by one (CL) or three (CH1-3) constant domains, respectively. Each domain has one 
internal disulfide bond. The two heavy chains are linked via two cystines in the highly flexible hinge region. The light and 
heavy chains are also connected via a disulfide bond between the CL and CH1 domains. The CH2 and CH3 domains form the 
fragment crystallizable (Fc), while the V domains plus the CL and CH1 domains in the two identical arms with antigen binding 
activity form the antigen-binding fragments (Fab). (b) Three-dimensional structure of mouse IgG2a antibody Mab231 based 
on x-ray diffraction data (blue shades: constant domains; orange shades: variable domains). The distinct barrel-shaped 
structure that is constructed from two β sheets in each Ig domain is clearly discernible. The junction between the V 
domains and the CL/CH1 domains (elbow region) confers additional flexibility [adapted from Harris et al., 1997].
116 
 
IgGs are roughly Y-shaped and have a molecular mass of approximately 150 kDa. Two of the three 
equal-sized arms of an IgG are responsible for antigen-binding (antigen-binding fragments (Fab)) via 
the variable or V region, while the third arm (fragment crystallizable (Fc)) binds to effector molecules 
or cells via the constant or C region. IgG are composed of two identical heavy chains (approximately 
50 kDa) with 4 domains each that are linked via two disulfide bonds in a highly flexible hinge region, 
and of two identical light chains (approximately 25 kDa) with 2 domains that are each paired with 
one heavy chain and covalently bound to it via a single disulfide bond. All domains of the heavy and 
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light chains are constructed from anti-parallel β−strands that form two β−sheets with an intra-
domain cystine to form a barrel-shaped structure (i. e. β−barrel). This is known as the 
immunoglobulin fold and is the hallmark of members of the immunoglobulin superfamily of proteins. 
Each of the variable domains at the N-terminal ends of the light and heavy chains (VL/VH domain) 
possesses three unique hypervariable loops, which combine into the complementarity-determining 
regions (CDR) that are responsible for binding the antigenic determinants known as epitopes.117 
While the CDR determine antigen-specificity, the surrounding, less variable framework regions are 
species-specific and may thus be immunogenic, when transferred from one species to another. The 
constant domains of the light and heavy chains (CL/CH1-3 domains) are slightly smaller than the VL/VH 
domains, because they lack the hypervariable loops.114,115 
 
Immunoglobulins have several effector functions (Figure 3): Upon binding to soluble ligands or cell 
surface receptors they can activate or silence signaling pathways and neutralize pathogens by coating 
(i. e. opsonizing) them. Moreover, the glycosylated Fc-fragment of antibodies can interact with 
several components of the innate immune system and thus provoke complement-dependent 
cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular 
phagocytosis (ADCP). The Fc-mediated effector functions have proven to be of particular value in 
cancer immunotherapy and the cross-presentation of tumor antigens to T cells by DCs or 
macrophages that have phagocytosed antibody-coated cancer cells can even induce an adaptive anti-
tumor immune response (Figure 3).118 
 
Modern antibody technology, which allows the careful design, engineering and large scale 
production of therapeutic mAb with a predefined antigen-specificity, has been carefully developed 
over many decades. One of the most important milestones was the introduction of hybridoma 
technology, i. e. the fusion (and thus immortalization) of plasma cells with myeloma cells, by Köhler 
and Milstein in the 1970s.119,120 This technology allowed the production of monoclonal antibodies 
with a single specificity for the first time. Initially, the majority of mAb was generated by immunizing 
rodents, which was of limited therapeutic use: Patients treated with mAb that originated from 
different species often developed immune responses (i. e. autologous antibodies) against the foreign 
framework regions of the therapeutic antibodies and thus became not just severely ill, but also 
resistant to therapy.121-123 
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Figure 3: Anti-tumor mechanisms mediated by IgGs. (a) IgGs bind to pro-tumorigenic chemokines and cytokines and 
thereby neutralize them. (b) Antibodies opsonize (i.e. coat) the tumor cell and block pro-tumorigenic receptors and/or 
interactions with the tumor microenvironment. (c) Tumor-specific antibodies recruit complement to the tumor cell surface, 
thereby labeling the cell for destruction. (d) Antibody-dependent cellular cytotoxicity (ADCC) is initiated by the recognition 
of IgG-coated tumors by FcR, which are expressed on immune effector cells such as NK cells, macrophages and neutrophils. 
These interactions lead to ADCC and tumor cell apoptosis through the delivery of perforin and granzymes. (e) The IgG-
coated apoptotic tumor cells can bind FcR on phagocytes and initiate Fc-dependent phagocytosis, leading to the lysosomal 
degradation of the tumor cell. (f) Peptides derived from lysosomal degradation of tumor cells can be loaded onto MHC class 
II molecules, leading to the activation of CD4+ T helper cells. In addition to CD4+ T cell activation, DCs can cross-present 
tumor antigen-derived peptides and prime cytotoxic CD8+ T cells [based on Weiner et al., 2010].118 
 
Moreover, the interaction between antibodies from foreign species and other components of the 
human immune system such as complement or Fc-receptor (FcR)-bearing leukocytes was poor.123 
Thus therapeutic antibodies needed to become more “human”. With the advent of recombinant DNA 
technology this goal became achievable124: The first approach towards more human, less 
immunogenic mAb was the development of chimeric antibodies, which were composed of human 
immunoglobulin constant regions and murine variable domains with defined specificity.125,126 While 
such chimeras displayed considerably less immunogenicity than murine antibodies, an even higher 
degree of immunotolerance of therapeutic mAb was achieved by CDR-grafting.127 This technique 
developed by Jones et al. (1985) generated mAb that were 85 to 90% human, i. e. “humanized”, by 
grafting the hypervariable loops and adjacent framework residues from the VL and VH domains of 
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antigen-specific murine antibodies onto human immunoglobulin frameworks. Today, fully human 
antibodies can also be generated by means of phage libraries and transgenic mice.128 
 
Recombinant DNA technology not only enabled humanization of mAb, it also allowed the transfer of 
immunoglobulin-production from hybridoma cell lines to highly efficient and stable eukaryotic 
expression systems such as Chinese Hamster Ovary (CHO) cells.129 Thereby the large scale production 
of therapeutic antibodies became feasible. Moreover, the effector functions of mAb can be tuned by 
modern technologies such as Fc-130 and glycoengineering.131,132 
 
As a result of these developments, therapeutic monoclonal antibodies have emerged as a fast 
growing and valuable biopharmaceutical branch. The murine anti-CD3 antibody muronomab was the 
first therapeutic mAb to receive approval by the FDA in 1985 for the prevention of graft-versus-host 
disease (GvHD) upon organ transplantation.133,134 A few years later, in 1994, the first humanized 
antibody for the treatment of cancer was approved, i. e. the anti-CD20 antibody rituximab 
(MabThera®).135 Since the early 1990s, four to nine therapeutic mAb received marketing 
authorization in Europe and the USA annually, with a record of nine approvals in 2015.136,137 47 
antibodies were available on the market in November 2014 and the global sales revenue of 
antibodies had already reached $75 billion by 2013.136 These numbers continue to rise rapidly as 
more than 60 therapeutic antibodies are commercially available in 2017 and 52 mAb for cancer and 
non-cancer indications (20 and 32 mAb, respectively) have entered late stage clinical trials.137 
 
Furthermore, a number of antibody-derived agents, including antibody-drug-conjugates (ADC), 
radioimmunoconjugates, immunocytokines and bispecifics, have been developed and begin to enter 
the biopharmaceutical market. These major classes of antibody derivatives are reviewed by Christian 
Hess and colleagues (2014)84 in detail and combine the target specificity of full-length antibodies or 
antigen-binding antibody fragments with additional therapeutic functions to overcome some of the 
limitations of the classical IgG-format. In the context of acute leukemia, the first ADC that received 
regulatory approval is of particular interest: the CD33-specific agent gemtuzumab ozogamicin (GO; 
Mylotarg®). GO is a humanized IgM antibody that is conjugated to the bacterial cell toxin 
calicheamicin via a composite hydrazine/disulfide linker. It achieved promising responses in 30% of 
AML patients in clinical trials. However, at a dose of 9 mg/m2 the patients experienced dose-limiting 
hepatotoxicity. In post-approval trials, the balance between clinical benefit and toxicity tipped 
towards the latter leading to the voluntary withdrawal of GO by Pfizer in 2010.13,14 However, the 
agent was recently (September 1st 2017) re-approved at lower concentrations, with a different 
dosing schedule and for a different patient population with newly diagnosed AML.15 Next-generation 
ADC with more stable linkers and conjugated drugs that are only activated upon internalization are 
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being developed, three of which were approved as of August 2017.137 Aside from ADC, bi- and 
multispecific antibodies or antibody-derived agents that simultaneously target one or more TAA and 
recruit immune effector cells, in particular CTL,138,139 in an FcR-independent manner have shown 
promise for the treatment of acute leukemias.42,140-142  
 
The first bispecific full-length IgG that engaged T cells was the TriomAb® catumaxomab (Removab®), 
which consisted of half a murine IgG2a antibody with specificity for EpCAM paired with half a rat 
IgG2b antibody with specificity for CD3 (Figure 4, left panel). Catumaxomab efficiently induced ADCC 
and ADCP and also engaged CTL for the lysis of EpCAM-positive cancer cells in malignant ascites. 
However, the marketing authorization for catumaxomab from 2009 was withdrawn upon request of 
Neovii Biotech GmbH in 2017.84 Other companies developed alternative technologies for the 
generation of bispecific full-length antibodies (Figure 4, left panel) that have various advantages with 
regard to production or therapeutic properties and are currently investigated in clinical trials. These 
bispecifics are mostly intended for the treatment of solid tumors.84 
 
 
Figure 4: Schematic representation of bispecific antibody and antibody-derived formats that are investigated in clinical 
trials. Left panel: Bispecific full-length IgGs. Right panel: Bispecific antibody fragments [based on Hess et al., 2013].84 
 
Instead of employing full-length IgG, antibody-fragments can also be used for the generation of 
multispecifcs. In particular so-called single-chain variable fragments (scFv), which are constructed by 
connecting the VH and VL domains with a flexible linker and represent the smallest antigen-binding 
unit of an antibody.143 Numerous multispecifics based on antibody-fragments target hematologic 
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malignancies and have already entered the clinic. The molecular formats include BiTE® (Amgen Inc., 
formerly Micromet) and DART® (dual-affinity retargeting scaffold by MacroGenics Inc.), which each 
have two antigen-binding domains, TandAbs (Affimed GmbH) with four binding moieties, and  the 
Dock-and-Lock™ or DNL™ platform (Immunomedics, Inc.), which can generate multivalent antibody 
derivatives with multiple specificities (Figure 4, right panel).84 The majority of these bispecific 
antibody fragments engage immune effector cells for the elimination of cancer cells via a 
scFv-domain that is specific for a trigger antigen of the effector cell such as CD3 or TCR on 
T cells141,144,145, CD16 (FcγRIII) on NK cells and macrophages146, CD64 (FcγRI) on macrophages147 or 
CD89 (FcαRI) on neutrophil granulocytes.148 The smaller size of bispecific antibody fragments 
compared to full-length IgG comes with the advantage of penetrating tumor tissues more easily 
(though it also results in rapid blood clearance).149-151 Furthermore, they do not compete with other 
serum IgG for FcR and are therefore highly efficient activators of their engaged immune effector 
cells. Finally, they are not subject to an Fc-mediated antibody sink and can therefore be applied in 
lower dosages than bispecific full-length mAbs.87,152-154 Multivalent binding of more than one TAA on 
the cancer cell by multispecific agents can also enable the distinction of a malignant cell 
(sub-)population from its healthy counterpart, for example in biphenotypic leukemia (see 
chapter 1.2.3). Moreover, immune escape by the targeted tumor cells is hampered, because antigen 
double-negative cancer cell clones are less likely to arise than single-negative ones.139,155 
 
 
1.4.2 BiTE® and CAR-T 
 
With its approval by the FDA and EMA for the treatment of relapsed/refractory B-ALL in late 2014 
and 2015, respectively, the CD19/CD3-epsilon (CD3ε)-specific BiTE® blinatumomab (Blincyto®, 
formerly MT103) became the first-in-class bispecific antibody fragment for therapeutic use in 
patients. A CD19/CD3ε-bispecific scFv (bsscFv) and thus the molecular BiTE format was first described 
by the group of P. Kufer at the Ludwig-Maximilians-Universität in Munich.156 The preclinical157-161 and 
clinical162-176 development of this agent, i. e. blinatumomab (name derived from “B-lineage-specific 
anti-tumor mouse monoclonal antibody”), and other BiTE® was subsequently continued in the newly 
founded company Micromet AG, which was bought by Amgen GmbH in 2012. 
 
BiTE® are constructed from two scFv that are covalently linked by (Gly4Ser)n linkers. The 
CD3ε−specific domain is common to all BiTE®, but the TAA-specific domain varies depending on the 
indication (for example anti-CD19156-176, -CD3318,106, -EpCAM177-181, -CEA182,183, or -EGFR184). The 
CD3ε−domain has a lower affinity for its antigenic target than the TAA-specific domain (KD,CD3ε = 10-7 
M vs. KD, TAA = 10-9 M), therefore the target cells are preferentially coated by BiTE®, whereas the 
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T cells retain their mobility and can serially eliminate several coated cancer cells.160 The 
MHC : peptide-independent, but target cell-specific connection that BiTE® facilitate between effector 
T cells and cancer cells results in T cell activation by cross-linking, the production of an efficient 
cytolytic synapse (see chapter 1.6), as well as cytokine production (IFN-γ, TNF-α, IL-2, IL-6 and IL-10) 
and T cell proliferation.157-160 In contrast to full-length antibodies for the treatment of hematologic 
malignancies such as rituximab, which are effective at nanomolar concentrations, Blinatumomab 
displayed EC50-values in the high femto-/low picomolar range in vitro.157 In patients this translated 
into effective therapeutic concentrations of 15 µg/m2/day (at less than 45 kg body weight) or 
28 µg/day (at more than 45 kg body weight). However, due to its low molecular weight of 
approximately 60 kDa, the BiTE® is rapidly cleared from the blood by the kidneys and thus has to be 
administered as a continuous intravenous infusion in 4 week cycles.42,185 
 
The novel mechanism of action of blinatumomab, i. e. the redirection of CTL, can be accompanied by 
several immune-related adverse events that need to be carefully monitored. Aside from general 
flu-like symptoms due to the induced inflammatory reaction, blinatumomab can cause serious 
adverse events including cytokine-release syndrome (CRS)174,185-187, a condition that led to multi-
organ failure in six healthy volunteers upon treatment with the CD28-superagonist TGN1412 in 
2006188, and CNS-related events174,185,189, which may be the result of activated T cells crossing the 
blood-brain-barrier to eliminate malignant CD19+ CNS infiltrates.185 Because of the risk to induce CRS, 
blinatumomab administration is staggered (from 5 to 15 µg/m2/day or 9 to 28 µg/day) during the 
first cycle and is not indicated in patients with a high tumor burden. Moreover, toxicity management 
with corticosteroids and anti-IL-6 mAb is available for patients, who develop CRS.176,190 Similarly, 
blinatumomab-induced neurotoxic events in B-ALL patients with CNS involvement are managed by 
discontinuation of therapy with the possibility for reintroduction at a lower dose and with 
concomitant anticonvulsant treatment.176,185 Another phenomenon resulting from blinatumomab 
treatment is the emergence of CD19-negative ALL relapse clones in some patients as in the case of 
any other targeted therapy.191-195 
 
The next most advanced BiTE®, which entered its first clinical trial (NCT02520427) in August 2015, is 
AMG 330, a CD33-specific BiTE® for the treatment of relapsed/refractory AML.42,196 Preclinical data 
indicated a very high efficacy of the agent in combination with allogeneic as well as residual 
autologous T cells in vitro and in vivo. Moreover, AMG 330 can potentially be applied to more than 
99% of AML patients with CD33+/dim blasts.18,19 In addition, the efficiency of AMG 330 might even be 
enhanced by checkpoint blockade of the PD-1/PD-L1 axis.106 
 
Introduction 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  29 
 
Chimeric antigen receptor-modified T cells (CAR-T) represent an alternative, highly effective strategy 
for the engagement of cytotoxic T lymphocytes to eliminate cancer cells20,197: The widely used second 
generation CARs, which have entered the clinic, are artificial activating receptors for T cells that are 
constructed from several domains: (1) an extracellular scFv for TAA-recognition, (2) a 
transmembrane domain, (3) a costimulatory domain derived from TCR-coreceptors such as CD28, 
4-1BB or OX40, and (4) the intracellular signaling domain of the CD3ζ-chain.198 To introduce CAR-T 
into cancer patients, autologous T lymphocytes are isolated and modified with a TAA-specific CAR by 
retro- or lentiviral transduction or non-viral technologies such as the transposon-transposase or 
CRISPR-Cas systems. Subsequently the CAR-T are expanded ex vivo and reinfused into the patient 
where they eliminate target antigen-positive cells in a TCR-independent manner.20,198 
 
CAR-T display an even higher level of sensitivity for target antigen-positive cells than BiTE®199 and can 
generate immunologic memory.20,200 This results in a high efficacy on the one hand, but on the other 
hand in more pronounced immune-related adverse events (in particular CRS) and prolonged 
depletion of target antigen-positive healthy cells (“on-target off-tumor”-toxicity).190,198 Therefore the 
applicability of CAR-T is currently limited to TAA expressed by cancer cells and non-essential tissues 
only.20,198 Consequently, the CD19-specific CAR-T for the treatment of relapsed/refractory B-ALL201-204 
are the most successful ones to date, since prolonged lymphodepletion of B cells can be 
compensated by regular infusions of immunoglobulins.204,205 The first CD19-targeting CAR-T, i. e. 
tisagenlecleucel (Kymriah™ by Novartis) received marketing approval on August 30th 2017.44 CD33- 
and CD123-specific CAR-T for the treatment of myeloid malignancies are also investigated in 
preclinical206,207 and clinical settings (NCT01864902 and NCT03126864 for CD33 CAR-T; 
NCT03114670, NCT02623582, NCT02159495 and NCT03190278 for CD123 CAR-T). However, two 
ongoing phase I trials with allogeneic CD123-specific CAR-T (UCART123) by Cellectis Inc. with the 
ClinicalTrials.gov identifiers NCT03190278 and NCT03203369 were put on hold by the FDA in late 
August after one patient died following grade five CRS.208 It also remains to be determined whether 
the treated patients can survive prolonged myeloablation and depletion of CD33-/CD123-positive 
progenitors. To tackle some of these problems, a new generation of CAR is under development that 
incorporates suicide genes198 or depends on the combinatorial recognition of more than one 
antigen209,210, but none of these have entered the clinic yet. 
 
 
1.4.3 Single-chain triplebodies 
 
The antibody-derived single-chain triplebody format (scTb), which carries three scFv-domains in 
tandem, was developed by the research group of Prof. Fey at the University of Erlangen-Nuremberg. 
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The molecular design was first published by Kellner et al. in 2008211, who developed a triplebody with 
specificity for lymphoid differentiation marker CD19 and the activating FcγRIII (CD16) expressed by 
NK cells, macrophages and neutrophil granulocytes. ScTb carry two binding moieties for tumor 
antigens and one binding moiety for a trigger antigen to engage immune effector cells for the 
redirected lysis (RDL) of cancer cells. Thus they are capable of monospecific bivalent as well as 
bispecific bivalent binding of the targeted cancer cell. This “dual-targeting” capacity is one of the 
distinguishing features of the triplebody format and may allow selective binding and elimination of 
double-positive cancer cells rather than single-positive cells, as has been shown in vitro for a 
triplebody with specificity for CD19 and HLA-DR.212,213 The three scFv are connected by flexible 
(Gly4Ser)4 linkers in a single polypeptide chain, can be easily exchanged by standard cloning 
techniques and can carry different tags (Figure 5). This simplifies their production and purification 
considerably in comparison to other multispecific antibody fragments.211,212,214,215 
 
 
Figure 5: Domain arrangement and putative 3D shape of a single-chain triplebody based on small angle x-ray 
scattering (SAXS) data. (a) Block-structure of the gene cassette for a scTb is shown [based on Kellner et al., 
2008].211 (b) Schematic representation of a scTb. (c) An overlay of the shape of triplebody [19x16x19] predicted 
from SAXS data [Nadja C. Fenn, unpublished] and the three-dimensional structure of 3 scFv based on x-ray 
crystallography is shown. The two distal scFv have a putative spread of 20 nm [adapted from Georg H. Fey, 8th 
Fabisch-Symposium, March 21st 2012]. 
 
The molecular weight of scTb ranges between 80 and 90 kDa, which results in a plasma half-life of 
four hours in mice211, because the molecules are not immediately removed by renal clearance. The 
avidity that results from bivalent target cell binding by scTb is not as pronounced as that of 
antibodies, however, they still display cytotoxic efficacy at very low concentrations in the picomolar 
range.211,212,214,215 Thus far, NK cell-recruiting triplebodies with monospecific bivalent targeting of 
CD19211 and bispecific bivalent targeting of CD19 and HLA-DR212,213, of CD19 and CD33215, and of CD33 
and CD123214 have been described for the potential treatment of different forms of leukemia. 
Whether other immune effector cells can also be recruited by scTb has yet to be determined. 
Moreover, the question whether target antigen combinations other than CD19 and HLA-DR can lead 
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to selective lysis in vitro and in vivo is of interest for therapeutic applications. If so, and provided that 
the large scale production of highly pure protein is possible, then the single-chain triplebody format 
may be a suitable platform for a wide variety of effective and highly selective targeted 
immunotherapeutics. 
 
 
1.5 Target antigens for immunotherapy in hematologic malignancies 
 
Many antigens are specific for the hematopoietic system and not expressed by other tissues, which 
makes them suitable for targeted immunotherapy of hematopoietic malignancies. However, in the 
present work lymphoid differentiation marker CD19, myeloid differentiation marker CD33 and the 
interleukin-3 receptor alpha-chain (CD123) were chosen as TAA, because they are therapeutically 
validated targets and when combined, they may serve to distinguish particularly relevant malignant 
cell subpopulations. Their structure and biology is described in detail in the following paragraphs. 
 
 
1.5.1 B lymphoid marker CD19 
 
The B lymphoid marker CD19 (formerly B4 antigen) is a 95 kDa (556 amino acids) type I 
transmembrane-glycoprotein from the immunoglobulin (Ig)-superfamily that augments B cell 
signaling via both B cell receptor (BCR)-dependent and -independent mechanisms.216,217 The cd19 
gene is encoded on the short arm of chromosome 16 (gene locus 16p11.2) and is highly expressed 
during different maturation stages of healthy B cells, i. e. from the time of initial immunoglobulin 
heavy chain gene rearrangement to the terminal differentiation into plasma cells.217,218 CD19 
expression is absent from virtually all cells in the body other than B cells and follicular dendritic cells, 
but is homogenous and high in the majority of precursor B lymphoid blasts. Therefore it is ideally 
suited for targeted immunotherapy in B cell malignancies.217-219 
 
The CD19 protein is comprised of an extracellular region with two C2-type Ig-like domains, a single 
transmembrane region and a highly conserved cytoplasmic tail (see Figure 6). It does not display 
significant homology to any other proteins.216-218 The signaling functions of CD19 are exerted via 
differential phosphorylation of specific tyrosine residues in its cytoplasmic region, especially via 
residues Y391, Y482 and Y513.216,220,221 At the B cell surface, CD19 is present in a co-receptor complex 
with the BCR together with CD21/CD35, CD225 and CD81.216,217,222,223 While CD21 is involved in 
complement-modified antigen recognition, the tetraspanin membrane protein CD81 serves as a 
chaperone.216,223  
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Upon triggering of the pre-BCR complex by cell autonomous aggregation or of the mature BCR by 
ligand binding, the tyrosine residues in the cytoplasmic tail of CD19 are sequentially phosphorylated 
by membrane kinases LYN and SYK. The CD19 co-receptor complex then translocates into lipid rafts 
and serves as interaction partner for signaling proteins with Src-homology 2 (SH2) domains such as 
PI3K, LYN, FYN, VAV, GRB2 and PLCγ2. By activating multiple signaling cascades, the CD19 co-receptor 
complex enhances (pre-)BCR signaling and facilitates clonal proliferation, IgL gene recombination and 
further differentiation events.216,220,221 BCR-independent signaling via the CD19 co-receptor complex 
is for example induced by binding of complement component C3d via CD21. Thereby it links innate 
with adaptive immunity.216,217,222 While the interaction of the CD19 co-receptor complex with 
different interaction partners usually promotes B cell growth and differentiation, direct ligand-
binding of CD19-L – a 54 kDa high mobility group (HMG)-box protein – to the extracellular domain of 
CD19 led to the disruption of CD19-signaling and rapid apoptotic cell death.217,224 This mechanism 
might also play a role in the efficacy of anti-CD19 therapeutics.217 
 
 
Figure 6: Schematic representation of the molecular structure of CD19. The extracellular region of CD19 with its two C2-
type Ig-like domains forms a co-receptor complex together with CD21/CD35, CD225 and CD81. Signaling through CD19 can 
either be triggered upon cell autonomous aggregation or upon ligand-binding to the mature BCR. This results in sequential 
phosphorylation of the indicated tyrosine residues in the cytoplasmic tail of CD19 and subsequent activation of multiple 
signaling cascades that induce B cell proliferation and differentiation [based on Wang et al., 2012 and Carter et al., 
2002].216,220 
  
During malignant transformation of precursor B lymphocytes, a positive feedback loop between 
CD19 and cellular (c)-MYC appears to play a role in addition to its pro-proliferative function: CD19-
mediated activation of the RAS/ERK2 pathway via GRB2 or of the PI3K/PKB/GSK3β signaling cascade 
leads to the phosphorylation and stabilization of c-MYC and thus of important downstream effectors 
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(e. g. cell cycle regulator Cyclin D2). C-MYC in turn promotes CD19 overexpression and 
phosphorylation.217,225 During advanced stages of B cell malignancies, however, the contribution of 
CD19-signaling to cell proliferation appears to become dispensable, which may partially explain the 
rise of CD19-negative escape mutants under CD19-targeted immunotherapy.217 
 
The homogenous and high surface expression of CD19 that is restricted to healthy and malignant 
B cells, its easy accessibility and its internalization and potentially pro-apoptotic function upon direct 
ligand binding have prompted the development of multiple and diverse targeted immunotherapeutic 
approaches.216,217,219 After the initial limited success with conventional anti-CD19 monoclonal 
antibodies, new strategies using multispecific antibody derivatives, antibody-drug-conjugates, Fc-
engineered antibodies and CAR-Ts have produced more promising results219 and may be improved 
even further by rational design. 
 
 
1.5.2 Myeloid marker CD33 
 
The CD33 (alternatively Siglec-3) differentiation antigen (gene locus 11q13.1) is a type I 
transmembrane-glycoprotein that is expressed by myeloid cells from early to late stages of 
development.226,227 The 67 kDa protein (364 amino acids) is a member of the Ig-superfamily, more 
particularly of the sialic acid-binding immunoglobulin-like lectins (Siglecs), which are involved in 
mediating cell-cell interactions and modulating intracellular signaling.227,228 Each member of the 
Siglec family specifically recognizes a sialylated glycan.228 CD33 is one of nine CD33-related Siglecs 
expressed by human immune cells and it functions as a negative regulator of cell proliferation and 
differentiation.228 
 
The protein carries two disulfide-linked Ig-like folds of the V- and C2-set in its extracellular region, has 
a single transmembrane region and a cytoplasmic tail with a membrane-proximal immunoreceptor 
tyrosine-based inhibitory motif (ITIM) and a membrane-distal ITIM-like motif (see Figure 7).227,228 An 
alternative splice variant of CD33, i. e. CD33m, lacks the extracellular V-set Ig-like domain and 
disulfide-bridges to the C2-set Ig-like domain. Since the V domain is immunodominant, CD33m is not 
recognized by the majority of early anti-CD33 antibodies.227 Furthermore, a soluble CD33 protein has 
been detected in AML patients, however, its prognostic value and potential impact on CD33-targeted 
therapies are unknown.227 
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Figure 7: Schematic representation of the molecular structure of CD33. The extracellular region of CD33 is 
composed of two Ig-like domains of the V- and C2-set with intra-domain disulfide-links. CD33 recognizes specific sialylated 
glycans and thereby mediates cell-cell interactions. Intracellular signaling is modulated by CD33 upon phosphorylation of 
specific tyrosine residues within the ITIM and ITIM-like motifs in its cytoplasmic tail and upon ubiquitination [based on 
Laszlo et al., 2012].227 
 
Though CD33 has been implicated as a potential inhibitory receptor in multiple cellular processes 
including cellular activation, secretion of pro-inflammatory cytokines and proliferation, the signaling 
pathways that the myeloid antigen employs are poorly understood.227,228 It is known, however, that 
phosphorylation of the ITIM and ITIM-like motif by Src-family kinases such as LCK leads to the 
recruitment of SH2-domain containing phosphatases SHP1 and SHP2. These phosphatases dephos-
phorylate CD33 and adjacent membrane receptors in a negative feedback loop and thereby, as well 
as by their downstream effectors, dampen tyrosine kinase signaling and cytokine secretion.227-229 
Alternatively, the competitive binding of suppressor of cytokine signaling-3 (SOCS3) to the 
phosphorylated ITIM-motif of CD33 results in the recruitment of the E3 ubiquitin ligase complex and 
proteasomal degradation of CD33.227,228 Importantly, CD33 can also act as an endocytic receptor 
upon ligand-binding.227,228 Under normal physiological conditions this is thought to help the clearance 
of sialylated antigens and may promote or inhibit antigen presentation.227,228 Furthermore, CD33 
ligand-binding and internalization affect cytokine secretion by monocytes.227,230 
 
In AML, CD33 is present on the blast surface of the majority of patients. High CD33 expression is 
generally associated with inferior disease-free and overall survival.227 Though the myeloid antigen 
displays strongly variable densities in the plasma membrane, it is an attractive target for 
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immunotherapy of AML and other myeloid neoplasias.19,227 Furthermore, CD33 is expressed by at 
least a subset of leukemia stem cells, but is largely absent from healthy hematopoietic stem cells. 
12,61,227 
 
The endocytic properties of CD33 have been carefully studied in order to exploit them for 
immunotherapy with unconjugated antibodies, ADCs such as gemtuzumab ozogamicin (Mylotarg™) 
and radiolabeled antibodies227: Bivalent binding and cross-linking of CD33 results in slow and limited 
internalization of the antigen and can inhibit proliferation and induce apoptosis.227,228,231,232 The slow 
internalization kinetics, however, may have limited the therapeutic success of CD33-targeting agents 
in addition to shortcomings in their design.227 New approaches with monoclonal antibodies 
engineered for enhanced ADCC, with improved ADCs, with bispecific T cell-engaging agents and with 
CAR-T are hoped to improve the success of CD33-based immunotherapy in AML.227 
 
 
1.5.3 CD123, the alpha-chain of the interleukin-3 receptor 
 
The interleukin-3 receptor is a type I cytokine receptor of the βc family, which also comprises the 
interleukin-5 and the GM-CSF receptors.233,234 The heterodimeric complex is composed of a beta 
common chain (βc), which it shares with the other βc family members, and of a highly ligand-specific 
alpha-chain, the IL-3Rα or CD123 (see Figure 8). While CD123 by itself only has low affinity for IL-3 
(KD ~ 100 nM), a high-affinity complex with a KD-value of 100 pM that can bind the cytokine at 
physiological concentrations is formed upon hetero-dimerization with the βc.234,235 Upon ligand 
binding, higher order structures, i. e. dodecamers, are likely assembled – as is the case for the 
GM-CSF receptor.236 The dodecamers would be composed of two hexamers containing a βc 
homodimer that is associated with two IL-3Rα chains and two IL-3 molecules in a head-to-head 
configuration.236 The IL-3R complex transduces pro-proliferative, anti-apoptotic and multi-directional 
differentiation signals.234,235 
 
Intracellular signaling of the IL-3R is mostly transduced via the beta common chain: Upon ligand 
binding and subsequent multimerization, the βc-associated JAK2 kinases are brought into close 
proximity, which enables βc transphosphorylation.234,236 Intracellular signals are transmitted via two 
important pathways: (1) The kinases SHC, GRB2 and SOS are recruited to the phosphorylated βc. This 
leads to the activation of RAS, which in turn stimulates RAF signaling and thereby the activation of 
the MAPK pathway. As a result transcription factors c-FOS and c-JUN are upregulated and induce 
proliferation.234,237 Additionally, MAPK-activated p38 and JNK/SAPK signaling induce the expression of 
BCL-2 family member MCL-1, which has anti-apoptotic functions.234,237 (2) PI3K/AKT signaling is also 
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activated upon association of the PI3K subunit p85 with the phosphorylated Serine residue 585 of the 
IL-3R βc. p85 then recruits PKB/AKT. This signal transduction pathway also leads to the expression of 
MCL-1.234,237 Furthermore, AKT can phosphorylate the IκB kinase, which phosphorylates IκB and 
initiates its proteasomal degradation. Resultantly, NFκB can translocate to the nucleus and induce 
the expression of BCL-2, BCL-XL and A1, thereby enhancing cell survival.234,237 
 
 
Figure 8: Schematic representation of the molecular structure of CD123, the alpha-chain of the IL-3 receptor. 
Two isoforms of CD123 exist with three (SP1) and two (SP2) extracellular domains, respectively. Both isoforms have a 
transmembrane domain and identical short cytoplasmic domains with a membrane-proximal proline-rich region. CD123 is 
involved in activation of the STAT signaling pathway and in cell survival. The N-terminal Ig-like D1 of the SP1 isoform of 
CD123 is flexible and can adopt an open and a closed conformation, whose biological function is unclear [based on 
Blalock et al., 1999].237 
 
CD123 itself is a heavily glycosylated membrane protein with an apparent molecular weight of 
75 kDa (378 amino acids) that is mostly expressed by hematopoietic cells, in particular by 
hematopoietic stem and progenitor cells, monocytes, megakaryocytes, B lymphocytes and 
plasmacytoid dendritic cells.234,238 The gene encoding CD123 is composed of 12 exons and is located 
on the short arms of the x and y chromosomes, i. e. Xp22.3 and Yp11.3.238 Abnormalities in IL-3R 
expression are frequently observed in AML and B-ALL and are associated with lower complete 
remission rates and a shorter overall survival.234,238,239 Moreover, CD123 is a particularly interesting 
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target antigen for the immunotherapy of AML, because elevated expression levels of the IL-3Rα 
chain have been reported on the surface of AML stem cells (see chapter 1.3.1).60,61,240,241 
 
Two isoforms of CD123 exist, which are composed of three (SP1) or two (SP2) extracellular domains, 
a transmembrane domain and a short cytoplasmic domain, which does not contribute to the stability 
of the ligand-receptor complex, but whose proline-rich membrane-proximal region is indispensable 
for downstream signaling events.233,234,238 The extracellular domains D1, D2 and D3 adopt fibronectin 
type III-like folds and form the cytokine receptor module.236 Via the immunoglobulin-like N-terminal 
D1 of the SP1 isoform, CD123 can adopt an open or a closed conformation. These two conformations 
differ by an angle of 40° and the open conformation is unique to the IL-3 receptor.236 While the 
functional role of these two different conformations is not clear, they do offer two additional modes 
of action to CD123-targeting immunotherapeutic agents, which mediate cytotoxicity. These modes of 
action are the inhibition of multimerization and competitive binding with IL-3. Thereby CD123-
targeting agents can block signaling and prevent IL-3-dependent proliferation.236 
 
 
1.6 Cell-mediated cytotoxicity and the immunological synapse 
 
Cytotoxic immune effector cells such as CTLs and NK cells induce caspase-dependent apoptosis in 
cancer cells by two mechanisms: (1) The injection of cytotoxic effector molecules into the target cell, 
and/or (2) the direct induction of apoptosis via binding of Fas ligand (FasL) on the immune effector 
cell surface to the Fas receptor (FAS) on the target cell surface.114 For efficient cytolysis it is necessary 
that a cytolytic immunological synapse is formed at the contact site between effector and target 
cell.242 This cytolytic synapse has a width of approximately 14 nm and is the focal point for the 
calcium-dependent release of lytic granules containing perforin, granzymes and granulysin by the 
cytotoxic effector cells.114,242 
 
In CTLs the formation of a cytolytic synapse is initiated upon specific MHC:peptide recognition via the 
T cell receptor (TCR) complex, which results in prolonged cell-cell contacts.243,244 In NK cells the 
balance between activating (i. e. NCRs, NKG2D, CD16) and inhibiting (i. e. inhibitory KIR) receptor 
signals during dynamic cell contacts is the determining factor, which can also be mediated by 
antibodies.244 Upon target recognition, intracellular signaling events downstream of the activating 
immunoreceptors result in a massive and rapid reorganization of the actin and microtubule 
cytoskeletons as well as of adhesion molecules, signaling molecules and receptors in the plasma 
membrane into a supramolecular activation cluster (SMAC) with three concentrical zones.242,244 In the 
central SMAC (cSMAC), microclusters of immunoreceptors and their associated signaling molecules 
are gathered. Here they are subject to the interaction with their respective activating or inhibitory 
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ligands on the one hand and to internalization and recycling on the other hand. The strength and 
quality of the ligand-immunoreceptor interaction in contrast to the recycling process determines 
whether apoptosis is efficiently induced.242,243 The cSMAC is surrounded by a zone of tight adhesion, 
i. e. the peripheral SMAC (pSMAC). Adhesion is mediated by interactions between molecules such as 
LFA1 and ICAM1.242,244 The pSMAC in turn is surrounded by a dense ring of actin filaments and 
microtubules (distal or dSMAC) that leave minimally sufficient clearances for lytic granule release.242 
The reorganization of the actin and microtubule cytoskeletons pulls the centrosomes of the immune 
effector cell towards the cytolytic synapse. In addition, some stacks of the Golgi apparatus and 
intracellular lytic granules are pulled towards the cytolytic synapse, which leads to a polarized 
secretion of cytotoxic effector molecules as well as cytokines such as IL-2, IL-4, IL-5 and IFN-γ into the 
synaptic cleft.242 While centrosomes and Golgi apparatus are associated with the actin cytoskeleton 
and experience polarization towards the cytolytic synapse via actin polymerization, the lytic granules 
are transported to the SMAC by dyneins along the microtubules in a retrograde manner. Once they 
are in plasma membrane proximity, non-muscle myosin II mediates the contact between the 
lysosomes and F-actin and thus their final delivery to the minimal clearance sites within the 
dSMAC.244,245 Here, they fuse with the plasma membrane and release their toxic load into the 
synaptic space. As a result, lysosomal membrane proteins including LAMP1 (CD107a) and LAMP2 are 
exposed at the cell surface.242 By exerting physical force on the target cell membrane, components of 
the pSMAC and dSMAC zones also allow perforin to penetrate the target cell membrane more easily 
and thereby increase the efficiency of cytolysis.246 Importantly, both CTL and NK cells are capable of 
serial lysis of several target cells. This is likely achieved by releasing only a fraction of the intracellular 
lytic granules into a single cytolytic synapse, by neosynthesis of cytotoxic effector molecules upon 
effector cell activation and possibly by the recycling and reuse of superfluous cytotoxic effector 
molecules from the synaptic space via endocytosis.244 
 
Since one of the activating receptors in NK cells is FcγRIII (CD16), which is stimulated by IgG, it is not 
surprising that scTb with a CD16 binding moiety can efficiently induce NK cell activation and partake 
in cytolytic synapse formation. However, CTL do not require soluble ligands for activation. They 
interact with their target cells directly via the CD3 : TCR-complex and co-stimulatory as well as co-
inhibitory receptors such as CD8 and PD-1. When stimulatory signals predominate, the T cell 
becomes active. However, the engagement of the CD3 : TCR-complex alone without co-stimulatory 
signals can lead to T cell anergy.247 Therefore it was unknown whether CTL could be efficiently and 
specifically activated by antibody-derived agents with only a CD3- or TCR-specific binding moiety in 
the presence of target cells. However, the BiTE® have proven that a cytolytic T cell synapse can be 
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formed efficiently, even without a co-stimulus and when an additional molecule is included into the 
synapse. A similar mode of action remains to be shown with the larger scTb. 
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2.1.1 Summary 
 
Immunotherapeutic agents that redirect the effector functions of a cancer patient’s autologous 
leukocytes, such as the natural killer (NK) cell-recruiting triplebody SPM-2 (33-16-123), can only be 
effective, when the recruited leukocyte population is unimpaired. It has been reported, however, 
that the functional NK cell compartment in AML patients is greatly reduced. This can, for example, be 
due to low cell surface concentrations of activating natural cytotoxicity receptors (NCR) or to low 
cytokine production and release levels. In this publication, a case study is reported, in which the 
cytolytic activity of NK cells from an AML-M1 patient at first diagnosis and during remission was 
compared to the cytolytic activity of NK cells from her healthy monozygotic twin. 
 
At diagnosis, the patient’s NK cell compartment accounted for only 1.4% of the mononuclear cells 
and NK cell enrichment by negative selection was unsuccessful due to poor differentiation of the 
blast population. As a result, merely 4.3 ± 3% of the blasts were depleted in a redirected lysis assay 
against autologous AML blasts with SPM-2. Encouragingly, however, the percentage of NK cells in the 
peripheral blood of the AML patient during remission had been almost restored to the level detected 
in the twin’s blood (6.3% vs. 7.7%, respectively). The cytolytic potential of the patient’s NK cells 
during remission was comparable to that of the healthy monozygotic twin (% lysis of AML 
blasts: 37.2 ± 2% vs. 47.7 ± 7% and % lysis of Raji: 26 ± 4% vs. 25 ± 8%, respectively). Triplebody 
SPM-2 also mediated the reduction of the CD34+ bulk AML blasts and even eliminated the 
CD34+ CD38-/low CD123+ cells, which includes potential leukemia stem cells. 
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The patient displayed the same expression pattern and intensity of activating NCRs NKp30, NKp44 
and NKp46 on her NK cells at diagnosis and during remission as the healthy monozygotic twin. Thus, 
differential expression was not a reason for a potential functional impairment. The release of TNF-α 
upon stimulation of the patient’s NK cells with SPM-2 was slightly reduced compared 
to the twin’s NK cells (1.1 and 4.7 pg/mL, respectively). However, this had no or a weak impact only 
on the cytolytic potential of SPM-2 together with the NK cells isolated in remission. 
 
In conclusion, the NK cells from this particular AML patient were not functionally impaired, but only 
reduced in total numbers compared to a healthy monozygotic twin. Thus functional impairment 
would probably not prevent a therapeutic benefit from SPM-2 treatment in this patient or 
comparable cases. Furthermore, SPM-2 treatment is a promising strategy to eliminate residual 
leukemia stem cells via autologous NK cells during remission. 
 
 
2.1.2 Contribution 
  
I collected information on the patient and her healthy twin, handled their blood samples and isolated 
peripheral blood mononuclear cells. Additionally, I performed antibody-dependent cellular 
cytotoxicity (ADCC) assays using the monoclonal anti-CD20 antibody rituximab. Finally, I determined 
the expression patterns of the NK cell receptors NKp30, NKp44 and NKp46 on the NK cells of the 
patient at first diagnosis and in remission as well as on the NK cells of the healthy monozygotic twin. 
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Background: The capacity of patient’s Natural Killer cells (NKs) to be activated for cytolysis is an important
prerequisite for the success of antibody-derived agents such as single-chain triplebodies (triplebodies) in cancer
therapy. NKs recovered from AML patients at diagnosis are often found to be reduced in peripheral blood titers
and cytolytic activity. Here, we had the unique opportunity to compare blood titers and cytolytic function of NKs
from an AML patient with those of a healthy monozygotic twin. The sibling’s NKs were compared with the patient’s
drawn either at diagnosis or in remission after chemotherapy. The cytolytic activities of NKs from these different
sources for the patient’s autologous AML blasts and other leukemic target cells in conjunction with triplebody
SPM-2, targeting the surface antigens CD33 and CD123 on the AML cells, were compared.
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SPM-2 and antibody-dependent cellular cytotoxicity (ADCC) assays using the therapeutic antibody RituximabTM
were performed with the enriched NKs. In addition, MACS-sorted NKs were analyzed for NK cell activating receptors
(NCRs) by flow cytometry, and the release of TNF-alpha and IFN-gamma from blood samples of both siblings after
the addition of the triplebody were measured in ELISA-assays.
Results: Patient NKs isolated from peripheral blood drawn in remission produced comparable lysis as NKs from the
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expression profiles on NKs from patient and twin were similar, but NK cell titers in peripheral blood were lower for
samples drawn at diagnosis than in remission.
Conclusions: Peripheral blood NK titers and ex vivo cytolytic activities mediated by triplebody SPM-2 were comparable
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AML patients in remission are sufficient in numbers and cytolytic activity to make triplebodies promising new agents
for the treatment of AML.
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Interest in the development of antibodies and antibody-
derived agents such as antibody-drug conjugates (ADCs) and
bispecific agents for the treatment of acute myeloid leukemia
(AML) has increased over the past years. A prototypical
agent, gemtuzumab ozogamycin (GO; MylotargTM), has been
effective in the treatment of AML, but was withdrawn from
the market because of side toxicities [1,2]. The problem
causing this withdrawal was not related to the suitability of
the myeloid surface antigen CD33 as a target, but rather to
the chemical linker connecting the toxin component of this
drug to the antibody carrier. CD33 remains a valuable and
clinically validated target for the therapy of CD33-positive
subtypes of AML with antibody-derived agents [3-5], and
consequently, several major drug developers currently study
new agents for the treatment of AML with specificity for
CD33. One class of such agents relies on potent new toxins
coupled with improved linkers to the antibody, such as the
agent SGN-CD33a [6]. Another class recruits effector cells
including NKs or T cells for the elimination of AML cells.
This class includes the agent AMG-330 [7] recruiting Tcells
as effectors, as well as our team’s single chain triplebodies
123-16-33 [8] and 33-16-33 [9], recruiting NKs. It
further includes CD33-specific antibodies with Fc domains
engineered for improved binding to Fc-receptors on
effector cells. Also, antibodies specific for CD123, the alpha
subunit of the receptor for Interleukin-3, an important
growth and differentiation factor for early hematopoietic
cells and the myeloid lineage, have produced promising
results in preclinical studies [10]. Antibodies against CD123
have mediated cytolysis of AML cells and in particular of
AML-Leukemia Stem Cells (AML-LSCs) [11,12].
Our team has developed a new class of antibody-
derived fusion proteins called triplebodies, suited for
the elimination of AML cells [8,9,13-17]. These agents
carry two binding sites for surface antigens on the
cancer cell and one for a trigger molecule on an effector
cell. They can bind two different tumor antigens on
the same target cell and through this mode of “dual
targeting” address the cancer cell with enhanced selectivity
[15,16,18]. In addition, they bind a trigger molecule on an
effector cell, such as CD16 on NKs, and thereby activate
the effector for cytolytic elimination of the cancer cell.
Triplebody SPM-2 employed in the present study carries
single chain Fv (scFv) antibody fragments specific for
CD33 and CD123 on AML cells linked in a single poly-
peptide chain to an scFv module specific for CD16,
the low affinity Fc gamma RIII receptor on NKs and
macrophages and a few other cells of the hematopoietic
system [8]. SPM-2 was designed for the elimination of
both bulk AML cells and AML-LSCs, because both are
double-positive for this pair of antigens.
LSCs from patients with most subtypes of AML however
carry a higher combined cell surface density of this pair ofantigens than bulk AML cells, normal hematopoietic cells,
and healthy hematopoietic stem cells (HSCs) [3,11,19,20].
SPM-2 was therefore designed for a preferential elimin-
ation of AML-LSCs in vivo. It is still unknown whether this
objective can be reached because the agent has still not
been tested in humans. It is important to eliminate not
only bulk AML cells, but also the LSCs, because the LSCs
are believed to be the relevant subset within the population
of minimal residual disease (MRD) cells, which are respon-
sible for relapse and poor disease outcome [4,21-23].
New agents intended to induce a deeper remission and to
prolong the time to relapse must therefore make a deliberate
effort to target the MRD cells. Currently available chemo-
therapeutic agents achieving remission for many AML
patients probably also act (at least in part) through
the elimination of some LSCs. However, most often
they do not achieve long-lasting complete remissions
and have not been designed with the intent to specifically
eliminate MRD cells but rather bulk AML cells. A
well-defined immunophenotype of MRD cells is not
available, which would lend itself as a specific address
for the design of antibody-derived agents. However, in
a retrospective clinical study the MRD cell compartment
responsible for early relapse was tentatively equated with
the CD34+ CD38- CD123+ subset of AML cells [24]. If
these results can be confirmed by prospective studies,
then triplebody SPM-2 could be especially promising for
the therapeutic removal of AML-MRD cells. Its ability to
reach this objective critically hinges upon the availability
of sufficient numbers of active NKs in AML patients at
the time of the intended use of the agent.
The compartment of functional NKs is often reduced in
AML patients [25-29]. This impairment has been attributed
to different causes, among them a down-regulated cell
surface expression of the activating natural cytotoxicity
receptors (NCRs) NKp30, NKp44 and NKp46 [25-27,29,30].
Low-level expression of NCRs (NCRdim) on patient-derived
NKs was correlated with poor prognosis in AML, as
patients with NCRdim NKs had significantly lower 5-year
survival rates than matched patients with NCRbright NKs
[26]. Deficiencies in cytokine release have also been linked
to an impairment of NK cell function in AML patients. The
capacity of NKs to secrete IFN-gamma was highly impaired
in AML patients and was correlated with suppressed
immune responses against autologous leukemic cells
[31-33]. Finally, in adult acute leukemia, impaired
production of cytokines by NKs was associated with
early relapse [34].
Triplebody SPM-2 was not designed as a frontline
therapeutic for the initial debulking of AML blasts.
This objective is reached in most cases by the initial
chemotherapy. Rather, SPM-2 was designed to be used
after chemotherapy when the blast titer is greatly reduced
for most patients and when the titer of functional NKs is
Braciak et al. Journal of Translational Medicine 2013, 11:289 Page 3 of 15
http://www.translational-medicine.com/content/11/1/289expected to have at least partially recovered towards
normal levels [28]. Therefore, here we studied the effective-
ness of SPM-2 to mediate lysis of an AML patient’s BM
blasts as targets, in combination with autologous NKs
drawn from peripheral blood at diagnosis and in remission.
The analysis was performed in comparison with NKs
isolated from the patient’s healthy monozygotic twin.
This exceptional situation provided us with a unique
opportunity to compare the activity of the patient’s
NKs with NKs genetically as closely identical as possible
from a healthy donor.
Here the patients NKs, drawn in remission, were
restored to titers in the blood comparable to those of
the healthy twin and were able to achieve effective lysis
of autologous AML blasts in conjunction with SPM-2.
Notably, they also achieved comparably effective lysis of
an established lymphoma-derived target cell line mediated
by the reference antibody RituximabTM, and had similar
expression profiles of NCRs as the healthy sibling’s cells.
The present study provides a precedent case in support of
our hypothesis that SPM-2, administered at appropriate
stages in the course of a standard therapy for AML, will
become useful as an adjuvant drug.
Methods
Expression in mammalian cells, purification and
protein-chemical characterization of triplebody SPM-2
The DNA construct coding for SPM-2 was based on the
published triplebody 123-16-33 [8] and was synthesized by
a commercial provider (Eurofins/MWG-Operon, Ebersberg;
Germany). The CD16-specific scFv was stabilized following
published procedures [8,35] and humanized. Humanization
of the CD123- and CD33-specific scFvs and the stabilization
of the CD123-specific scFv followed similar procedures
(S. Wildenhain, I. Schubert, A. Honegger et. al., unpublished
data). The N- and C-terminal CD33- and CD123-specific
scFvs were separated from the central CD16-specific scFv
by (G4S)x4 linkers. For expression purposes, human 293 F
cells (DSMZ; German Collection of Microorganisms and
Cell Lines; Braunschweig, Germany) were stably transfected
with plasmid DNA using the 293fectinTM transfection re-
agent (Life Technologies, Darmstadt, Germany) according
to the manufacturer’s instructions in a total volume of
30 ml. The cells were then cultured under continuous
selection with hygromycin C. The recombinant protein
was captured from culture supernatants via its C-terminal
hexahistidine tag by retention on a metal-ion affinity
matrix and purified by anion- and cation-exchange chro-
matography. Concentrations of the purified protein were
determined by spectrophotometry and calculated using
the molar extinction coefficient derived from the amino
acid sequence. The resulting final protein meets current
regulatory standards and industry norms, and was named
SPM-2 to indicate its status as a candidate for clinicaldevelopment. Equilibrium binding constants (KD) of each
of the individual scFvs of SPM-2 were in the 20–30 nM
range, and thus were similar to the values reported for the
initial agent [8].
Preparation of primary cells from blood and bone
marrow of human donors
Peripheral blood and bone marrow samples were drawn
from subjects into EDTA solution after receiving informed
consent. The project was approved by the Ethics Committee
of the University of Munich Medical Center. Bone marrow
mononuclear cells (BMMC) containing the leukemic
blasts and Peripheral Blood Mononuclear Cells (PBMCs)
were enriched by ficoll density centrifugation using the
Lymphoflot reagent (Biotest, Dreieich, Germany) according
to manufacturer’s instructions. Isolated cells were then
either suspended in RPMI medium (Life Technologies)
containing 10% fetal bovine serum (FBS) with penicillin
and streptomycin (PS) at 100 units/ml and 100 μg/ml,
respectively, for immediate use, or stored frozen in a
solution containing 90% FBS and 10% DMSO for future
use. Cell viability was assessed by trypan blue exclusion.
Ex vivo expansion of MNCs from healthy donors in the
presence of IL-2
PBMCs were expanded ex vivo in RPMI medium
containing Interleukin-2 (IL-2) plus 5% human serum
(Life Technologies) for 20 days as described [16,36],
and were then frozen in aliquots for subsequent use.
Prior to use in cytolysis experiments, the cells were
thawed and cultured overnight in RPMI medium
containing 5% human serum plus 50 units/ml and
50 μg/ml PS, respectively, but no additional IL-2.
Flow cytometric analysis
Flow cytometric analysis was performed with an Accuri
C6 flow cytometer (BD Biosciences, Heidelberg, Germany).
The CD3-, CD16-, and CD56-specific monoclonal anti-
bodies (mAbs) used for the analysis of NK cell content in
PBMC-preparations as well as isotype control mAbs were
from Immunotech (Marseille, France), while the NKp30-,
NKp44-, NKp46-specific and isotype control mAbs used
for the analysis of NK cell receptors (NCRs) [37] on iso-
lated NKs were from eBioscience (Frankfurt, Germany).
Cell surface densities of CD33 and CD123 were measured
using a calibrated cytofluorimetric assay as described
[8,35]. For this purpose, a commercial kit of fluorescent
beads with known numbers of fluorescent chromophores
per bead (QIFIKIT®; DAKO; Hamburg, Germany) was
employed, as well as fluorescent-labeled mAbs. This pro-
cedure allows the investigator to express the measured
fluorescent intensity of mAbs bound to the surface of the
patient’s cells in terms of average number of antigen copies
per cell [38].
Figure 1 Structure of single chain triplebody SPM-2. ScFv
domains (colored in the diagram) specific for CD33, CD16 and
CD123, respectively, were connected by two (Gly4Ser)x4 linkers
(black lines) into a single polypeptide chain. The distal scFv domains
specific for CD33 (orange) and CD123 (green), bind targets on the
same AML blast while the central scFv domain (blue) binds CD16 on
NK cells. Antigen binding sites are indicated by the triangular pockets.
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Redirected Lysis (RDL) assays using Calcein release
In this study we refer to cell-mediated cytolysis assays
with whole antibodies as “ADCC” and to tests with
antibody-derived agents such as triplebodies as “redirected
lysis (RDL)” assays. Non-radioactive cytolysis assays based
on the release of calcein from target cells pre-labeled with
calcein AM (Life Technologies) were performed as
described [16,39]. The cytolytic activity of NKs from
various sources was calibrated in standard ADCC assays
with the commercial CD20-mAb RituximabTM [39,40] as
the mediator of lysis and lymphoma-derived Raji cells [41]
as targets. This calibration allowed us to assess the
cytolytic activity of NKs from various sources using a
standard mAb and a commonly used target cell line, and
thus to make our results comparable to the current
benchmarks in the field. For the calibration reaction with
RituximabTM, untouched NKs were first enriched by the
MACS kit (Miltenyi kit; see above) from PBMC samples
and then used at a constant effector-to-target (E : T) ratio
of 2.5 : 1 against Raji targets. The same NKs were also
used in redirected lysis experiments with the patient’s autolo-
gous bone marrow AML blasts as targets in conjunction
with SPM-2. Specific lysis was measured by quantitating the
release of calcein from target cells using a fluorimeter/ELISA
plate reader and expressed in relative light units (RLU) at
485/535 nm. Calcein release was measured at 3 and 4 hour
time points for ADCC and RDL experiments, respect-
ively. Specific cellular cytotoxicity was expressed as
overall lysis minus the background of spontaneous
lysis mediated by the NKs alone, in the absence of
added antibody-reagents. Specific lysis was evaluated
by the formula:
% specific lysis = 100 * (Experimental Release RLU –
Background Release RLU)/(Maximal Release RLU –
Background RLU).
Enrichment of human NK cells by preparative sorting
with immunomagnetic beads
NKs were enriched by negative selection using a
commercial NK cell isolation kit (Miltenyi Biotec MACS
sorting kit, Bergisch Gladbach, Germany) according to
manufacturer’s instructions. The enriched cells are
referred to as “untouched” NKs, because as a result of
the negative selection, no residual mAb is bound to
their surface and they have not been eluted from an
affinity matrix with harsh reagents. Starting material
were ficoll-hypaque purified PBMCs from blood sam-
ples of the donors. The enriched NKs were then either
resuspended in RPMI medium containing 10% FBS
with PS at 100 units/ml and 100 μg/ml, respectively, for
use in ADCC and RDL assays, or placed in PBS solution
containing 1% bovine serum albumin (BSA) for flow
cytometric analysis.Measurement of IFN-gamma and TNF-alpha release into
peripheral blood samples by ELISA assays
Concentrations of human cytokines IFN-gamma and
TNF-alpha were measured with ELISA kits (eBioscience)
following manufacturer’s instructions. Triplebody SPM-2
was added to peripheral blood samples at concentrations
of 10, 1, or 0.1 nM , and the reaction mixtures were then
cultured for 6 h at 37°C in 96 well round bottom Nunc
plates in 200 ul volumes. Blood samples were frozen and
stored at −20°C and were thawed only immediately
before use in cytokine assays. In addition, cytokine release
was studied with the same ELISA kits in supernatants
from the 4 h RDL and 3 h ADCC assays, in which
MACS-purified NKs had been used as effectors against
autologous BM blasts as targets.
Statistics
All statistical analysis was performed by STATVIEW 4.5
programs from Abacus Concepts (Berkeley, CA) using
Student’s t-test for the final determination of significance
(p < 0.05).
Results
SPM-2 mediates efficient lysis of BM leukemic blasts from
a patient with FAB M1 AML in conjunction with effector
cells from a healthy unrelated donor
To evaluate the ability of SPM-2 (Figure 1) to mediate
lysis of blasts from a patient diagnosed with an AML
FAB M1, RDL experiments were performed with isolated
BMMCs obtained from the patient at diagnosis as targets.
The BMMCs prepared in this manner contained 89.7%
AML blasts, as determined by morphology and cytological
criteria (Table 1). Five hundred million (5 x 108) MNCs
were recovered from a 5 ml BM sample of this patient,
Table 1 Data and immunophenotype of AML FAB-M1 patient BMMCs
Gender Female
Age: 21 years old
Diagnosed with: AML FAB-M1; AML without maturation according to WHO classification [42]
Blast titer: 89.7% blast in the marrow at diagnosis
Case history One course of induction chemotherapy following HAM protocol
high dose cytarabine with mitoxantrone [49]
Current status: Complete remission acheived by induction chemotherapy (HAM)
Myeloid cells % (in blast gate) Co-expression (cross-lineage) % (in blast gate)
CD 34 89.6% CD34/CD56 47.9%
CD 33 <19% CD34/CD7 12.3%
CD 123 n.d. at diagnosis CD34/HLA-DR 90.5%
CD 117 < 1% CD34/CD7 12.3%
CD 38 89.9%
cy MPO 41.7
n.d. not determined.
Cy MPO cytoplasmic myeloperoxidase; flourescent marker enzyme for the myeloid lineage.
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for further analysis.
Among the isolated BMMCs, 89.6% expressed detectable
levels of CD34, consistent with the diagnosis of a FAB M1
AML. The FAB M1 AML subtype commonly displays very
immature blasts and a high percentage of CD34-positive
cells. It is called “AML without maturation” in the WHO
classification [42] and often leads to low white blood cell
counts. At diagnosis less than 1% of the BMMCs expressed
cell surface CD33, leading to the initial diagnosis of a
“CD33-negative AML”. Expression data for CD123 at
diagnosis are not available. Subsequent cytofluorimetric
analysis gated on the BMMC population (consisting of
approx. 90% AML blasts) performed under more sensitive
conditions (calibrated cytofluorimetry; Figure 2A) revealed
a mean expression of 130 and 230 copies per cell of
CD33 and CD123, respectively, in this population of cells.
These are very low levels, considering that blasts from
other AML subtypes can commonly carry up to several
thousand and sometimes several ten-thousand copies per
cell of these antigens [8,43,44].
This patient’s AML blasts were lysed efficiently by
SPM-2 in combination with MNCs expanded ex vivo for
20 days with IL-2 from a healthy unrelated donor used
as a source of effectors (Figure 2B). Net lysis of the
targets by the effector cells alone was 15 ± 11%, net lysis
in the presence of a saturating (10 nM) dose of SPM-2
plus effectors was 80 ± 20% (Figure 2B). Thus, specific
lysis induced by the triplebody was approximately 65%.
This is a surprisingly high value for a 4 h assay, considering
the low surface density of both target antigens.
The majority of AML-LSCs are contained in the
CD34-positive subset of bone marrow cells [11,45].
Therefore we analyzed, whether SPM-2 was capable ofmediating lysis of this subset, as a first step towards
answering the key question, whether SPM-2 can mediate
lysis of AML-LSCs. As a result, in a 4 h RDL-reaction using
isolated AML BMMCs as targets and ex vivo expanded
MNCs from an unrelated donor as effectors, SPM-2
mediated a significant reduction of the CD34-expressing
subset to 15%, down from 89.6% at the start of the reaction
(Figure 2C, right panel). Exposure to the MNC effectors
alone reduced the CD34-positive blasts down to only 62%
(Figure 2C, left panel). Thus, the net effect of treatment
with SPM-2 was a specific depletion of the CD34-bearing
cells by 47%.
Beyond the CD34-positive compartment, the majority
of AML-LSCs are typically found in the CD34pos
CD38neg subset, although some LSCs are also present in
other cellular subsets [19]. Moreover, the AML MRD
cells relevant for relapsed disease have been reported to
be predominantly contained in the CD34pos CD38neg
CD123pos compartment [24]. Therefore, in an attempt to
determine, whether SPM-2 was capable of eliminating
AML-MRD cells in a narrower cellular subset beyond
the broader CD34pos compartment, we analyzed whether
SPM-2 also affected the CD34pos CD38neg CD123pos
subset within the AML BMMC sample in combination
with IL-2 expanded effector cells from a healthy donor.
The experiment was performed using a similar 4-color
flow cytometric analysis as reported by others [24].
As an initial result, obtained with limited numbers of cells,
depletion of the CD34pos CD38neg CD123pos subset was
observed following treatment with SPM-2 plus allogeneic
effectors in comparison to treatment with MNCs alone
(data not shown). For this patient, the CD34pos CD38neg
cells represented approximately 1.4% of the total BMMCs.
This value falls into the typical range reported for this subset
Figure 2 (See legend on next page.)
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Figure 2 BM blasts from an FAB M1 AML patient are lysed efficiently in a RDL reaction by effectors from an unrelated donor,
mediated by SPM-2. (A) Patient isolated BMMC were stained with fluorescent antibodies specific for CD33 and CD123, respectively, in
comparison to isotype controls. P2: gate used for analysis of live BMMCs allowing their discrimination from dead cells. Mean fluorescence
Intensities measured for each antigen were converted to antigen densities by calibrating fluorescence intensities with the QuiFi kit (Methods).
(B) MNCs from an unrelated healthy donor, expanded ex vivo in the presence of IL-2 (Methods), were used as effectors at an MNC : target (E:T)
ratio of 10 : 1 in a 4 h RDL assay. This corresponds to an E:T ratio of NK cells : targets of 2.5 : 1, because NK cells were 25% of all cells in this
expanded MNC population. Targets were BMMCs from the AML patient obtained at diagnosis, pre-labeled with calcein AM. SPM-2 was added
at 10 nM concentration (right bar). The control reaction was allowed to proceed without added agents (left bar; NKs alone). Cellular lysis was
measured by calcein release and plotted as fraction (%) of maximum release. Error bars: arithmetic means over 3 separate experiments (n = 3).
(C) Flow cytometric analysis after an RDL reaction. Patient’s BMMCs were treated with effector cells and SPM-2 in a 4 h RDL experiment as in
panel A. At the end of the reaction, cells were stained with a fluorescent-labeled CD34-specific mAb and analyzed by FACS. Numbers of CD34pos
cells are plotted against the intensity of CD34-specific fluorescence. Left panel: after reaction with effectors alone; right panel: after reaction with
effectors plus SPM-2. Numbers in upper right corner: percent of CD34pos cells surviving at the end of the reaction.
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provides a first indication in favor of our contention that
SPM-2 is capable of eliminating cellular subsets enriched in
AML-LSCs and MRD cells through the recruitment of
activated NKs. While this result is consistent with the claim
that SPM-2 can eliminate LSCs, definitive proof requires
further and more stringent analysis than we were able to
perform here due to the scarcity of this BMMC sample.
Cytolytic activity of patient’s NKs drawn at diagnosis and
in remission compared with NKs from a healthy
monozygotic twin
Next, we wished to determine whether SPM-2 was capable
of mediating lysis of the patient’s AML blasts by autologous
NKs. For this patient, we had the rare opportunity to
obtain NKs from peripheral blood both at diagnosis
and in remission after completion of the induction
chemotherapy, and to compare their titers and cytolytic
activities to NKs isolated from a healthy monozygotic twin.
As a result, MACS-purified NKs drawn from the sibling
and the patient in remission showed similar cytolytic
activity mediated by SPM-2 towards the patient’s AML
blasts (Figure 3A, red). Mean specific lysis obtained with
NKs from the sibling was 47 ± 7% versus 37 ± 2% for NKs
from the patient in remission. These values are arithmetic
means over 3 independent experiments (n = 3). By
contrast, the cytolytic activity of the NKs drawn from
the patient at diagnosis was significantly lower. With equal
numbers of effector cells used as an input for each reaction,
only 4.3 ± 2.6% specific lysis was observed with a saturating
dose of SPM-2 (10 nM; Figure 3A, left bar).
Finally, we wished to determine whether these com-
parable activities of the patient’s and sibling’s NKs were
only observed with the patient’s AML blasts as targets,
or whether this was an intrinsic property of these NKs,
also observed for other targets. Therefore, a benchmark
ADCC experiment was performed with CD20-positive Raji
lymphoma-derived cells as targets (Figure 3B, blue), the
commercial CD20 antibody RituximabTM as the thera-
peutic agent, and with immunomagnetically purifiedNKs as effectors. As a result, comparable lytic activity
was found again for NKs from the patient in remission
and the twin (Figure 3B). Here, NKs from the patient in
remission produced 26 ± 4% specific lysis using a standard
dose of RituximabTM compared to 25 ± 8% for the sibling’s
NKs. NKs from the patient at diagnosis also produced
lower specific lysis in this assay (4 ± 2%).
Taken together, these results indicate that the peripheral
blood NKs from the patient in remission are comparable
in cytolytic activity to those of the healthy twin in response
to SPM-2. One needs to bear in mind, however, that
this patient was younger than the average AML patient at
diagnosis and that response to therapy is usually better for
younger patients.
Titers of AML blasts and NK cells in peripheral blood at
diagnosis and in remission
To look for explanations for the apparent deficiency in
cytolytic activity of the NKs from the patient at diagnosis,
frequencies of NKs and leukemic blasts in the various
PBMC samples were assessed by flow cytometry (Figure 4).
Plots of side scatter (SSC) vs. fluorescence intensity of
cells stained with a FITC-labeled CD45 mAb revealed a
well-defined population of CD45-FITCdim x SSClow cells
(P1 in Figure 4A). These cells have been identified as
AML blasts by other authors [24,46]. Among the patient’s
PBMCs drawn at diagnosis, this subset was abundant
(58%; Figure 4A, left panel), while it accounted for only
about 1% of all PBMCs from the patient in remission and
the healthy twin (Figure 4A, central and right panels).
NKs were identified in cytofluorimetric studies as
CD16posCD56pos cells (Figure 4B). Only 1% of the patient’s
PBMCs at diagnosis fell into this gate (Figure 4B, left panel),
whereas 6.3 and 7.7% of all PBMCs had this phenotype for
the patient in remission and the healthy sibling (Figure 4B,
central and right panels). This finding supports our initial
expectation that for an AML patient in remission the NK
cell compartment should be restored to almost normal
levels. It also is the most likely explanation for the results
shown in Figure 3, where we observed that NKs from the
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Figure 3 NK cells from PBMCs of the patient in remission and
the healthy twin have comparable cytolytic activity. (A) MACS
sorted NKs isolated from PBMCs of the patient drawn at diagnosis
(left bar), in remission (central bar) and from the healthy twin (right bar)
were used in RDL assays against calcein labeled BMMCs from the
patient at diagnosis as targets (red). 4 h RDL reactions were run at an
E : T ratio of 2.5 : 1 and incubated with a 10 nM dose of SPM-2 versus
NKs alone as control. Error bars: arithmetic means over 3 separate
experiments (n = 3). (B) The same NK effector populations as in panel A
were also used in 3 h ADCC reactions at the same E : T ratios. Target cells
were calcein labeled Raji cells (CD20pos). Reactions mediated by
10 μg/ml (approx. 70 nM) of the commercial CD20-antibody RituximabTM
(blue). Error bars: arithmetic means over 3 separate experiments (n = 3).
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and RDL assays than the corresponding cells from the
patient in remission and her healthy twin. These data
suggest that the deficiency in cytolytic function observed at
diagnosis most likely was due to reduced NK cell titers.
Interestingly, a high percentage of CD56bright CD16low
cells were found in PBMCs of the patient at diagnosis
(Figure 4B, left panel, upper left quadrant). This populationhas previously been reported by other authors to be
increased in AML patients and has been described as a
characteristic NK cell subset with elevated production of
cytokines [30]. This result is consistent with the diagnosis
of this patient showing an unusually high percentage of
CD34posCD56pos cross-lineage cells amongst the AML
blasts (47.9% of blasts; Table 1).
Enrichment of NK cells by MACS sorting and titers of
T cells in PBMCs
After preparative enrichment by MACS sorting,
CD56brightCD16bright NKs accounted still for only 1.4%
of total cells in the sample from the patient at diagnosis
(Figure 5A, left). This poor enrichment probably reflects
the high content of AML blasts with very immature,
early progenitor phenotype, devoid of lineage markers,
in the PBMC sample taken at diagnosis. Therefore, negative
sorting using antibodies specific for lineage markers did
not remove these cells. In contrast, the MACS-enriched
CD56brightCD16bright NKs accounted for approx. 77% of all
cells in the corresponding samples from the patient in
remission and the healthy twin used in the RDL and
ADCC assays (Figure 5A; central and right panels). These
observations are consistent with previously reported
decreased frequencies of NKs in the blood of AML
patients [30].
Finally, an approximate 10-fold reduction of the T cell
compartment was also observed comparing PBMCs
from this patient drawn at diagnosis with those obtained
in remission and those from the healthy twin (Figure 5B).
Only 6.9% of the patient’s PBMCs drawn at diagnosis
were CD56negCD3pos T cells, compared with 65.2% and
78.7%, respectively, for the cells from the patient in
remission and the healthy twin. This finding indicates
that in the remission stage after the initial chemotherapy,
not only NKs are restored but also the T cell compartment
recovered to approximately normal levels.
Expression levels of natural cytotoxicity receptors (NCRs)
in PBMC samples
As impaired cytolytic activity of NKs from AML patients
had been proposed to be caused by reduced expression
of NCRs [25,26], expression of NKp30, NKp44 and
NKp46 on enriched NKs was studied (Figure 6). No
significant difference in the expression patterns was
observed between MACS enriched NKs from the patient
in remission versus the healthy sibling (Figure 6A). The
corresponding analysis for NKs from the patient at
diagnosis was rendered more difficult by the fact that
NKs were of low abundance in the MACS-enriched
sample at this time. This analysis was therefore refined
by further gating for CD16pos cells and then analyzing
the NCRs on this gated population of NKs. In this
manner, an essentially unchanged NCR expression profile
Figure 4 Analysis of AML blasts and NKs within PBMCs from the different donor samples. (A) Blast content among PBMCs from the
patient at diagnosis and in remission (left and central panels) or from the healthy twin (right) is shown. PBMCs were stained with a FITC-labeled
CD45 mAb and analyzed against side scatter (SSC) by flow cytometry. CD45dim x SSCLOW cells have been defined as AML blasts [24]. Dashed line:
P1 gate (blasts). Numbers in the corners of quadrants: fraction of total cells falling into this quadrant. (B) Analysis of NK cell content. PBMCs form
the same sources as in A were stained with FITC-labeled CD16 and PE-labeled CD56 mAbs. NKs were defined as CD16posCD56pos cells (upper
right quadrant). The population in the upper left corner in the left panel is the unusual population of CD56brightCD16neg cells, previously reported
in AML samples [30] as an NK subset that exclusively produces cytokines.
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strategy used for this analysis of the PBMC sample drawn
at diagnosis is shown in Figure 6C. From these combined
observations, we conclude that for this particular patient
the NCR expression profiles remained unchanged and
that changes in the levels of NCRs are unlikely to be the
cause of the impaired cytolytic functions recorded here.
Whole blood samples from the AML-patient and the
healthy sibling show different levels of cytokine release
after addition of SPM-2
Reduced cytokine (IFN-gamma) release by NKs from
AML patients had been reported to be correlated with
suppressed immune responses against autologous leukemic
cells [32,33,45]. Therefore, we tested whether differences in
cytokine release were detectable after addition of SPM-2
either to whole blood samples from the patient drawn at
diagnosis or those from the patient in remission and the
twin. Determinations of IFN-gamma release by ELISAproduced no signal above the detection threshold (4 pg/ml).
However, TNF-alpha was detected in the corresponding
samples after addition of SPM-2 (Figure 7A). Following
incubation for 6 h with a saturating dose of SPM-2
(10 nM), 4.7 ± 0.1 pg/ml of TNF-alpha were detected
in blood from the healthy sibling versus only 1.1 ± 0.1 pg/ml
in the patient’s sample drawn in remission (Figure 7A).
Thus, whole blood cells from the patient in remission
showed a reduced release of TNF-alpha in response to the
addition of SPM-2, compared to cells from the healthy
sibling. This differential cytokine response does not appear
to have affected the cytolytic activity mediated by SPM-2, as
these two sources of NKs did not show major differences in
our RDL and ADCC assays with autologous and allogeneic
leukemic cells as targets.
To investigate, whether cytokine release during cytolytic
reactions with MACS-purified NKs from these different
sources was similarly independent of target antigen and
the type of target cell line, we analyzed the cytokine
Figure 5 Analysis of MACS sorted NKs and T cells within PBMCs isolated from the different donor samples. (A) The CD16posCD56pos
NK cells enriched by immunomagnetic beads (MACS; Methods) are shown in the upper right quadrant. Events in the lower left quadrant in the
sample from the patient at diagnosis are considered to be very immature blasts devoid of lineage markers as discussed in the text. (B) CD3pos
CD56neg cells (lower right quadrant): T cells.
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by assaying the supernatants of these reactions in our
ELISA assay (Figure 7B and C). TNF-alpha production
was reduced for the reaction with NKs from the patient in
remission relative to the healthy sibling but even more so
with NKs from the patient at diagnosis. This result was
observed for the supernatants from both the ADCC and
RDL assays. IFN-gamma release was undetectable. These
results are consistent with previous reports indicating that
NKs from AML patients are attenuated in their release of
cytokines [27,29].
Discussion
The most important result of this study is that it helped
to dispel concerns raised by critics about the use of
triplebodies for the treatment of AML, because they rely
on NK cells as effectors. The main argument was that
too few NK cells were present in an AML patient for
triplebodies to be effective. The critics held that it would
be preferable to recruit T cells rather than NK cells as
effectors, because T cells were present in greater numbers,
because they have higher intrinsic cytolytic activity,are capable of serial lysis of several target cells in a
consecutive manner, and can be stimulated to proliferate
as a result of exposure to the agent. We cannot address all
of these points here in detail, and some of our arguments
regarding the relative merits of recruiting NK cells vs.
T cells have been reviewed elsewhere [17]. Suffice it to
state that NKs are also capable of serial lysis and that their
numbers can be increased in patients after treatment with
antibody-derived agents recruiting NKs as effectors [28,47].
Therefore, after clinical administration of agents related to
SPM-2 such as the tandem diabody AFM-13 specific for
CD30 and CD16, NKs can expand in human recipients
in vivo, and sufficient numbers can become available for
therapeutic effects, even for malignancies such as Hodgkin
Lymphoma that include semi-solid tumor masses [47].
Our results presented above (Figure 5B) suggest that
for the patient of the present study, CD3-positive T cells
were also greatly reduced in peripheral blood at diagnosis
and only recovered together with other leukocytes in the
remission phase. Finally, it is not known how many T cells
and how many NKs are needed for an effective therapy
with such agents. The absolute numbers of NK cells in
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Figure 6 Unaltered expression patterns of the NCRs NKp30, NKp44 and NKp46 on enriched NKs from the patient at diagnosis, in
remission and the healthy twin. (A) Expression pattern of NCRs on enriched NKs from the patient in remission (red) and the healthy twin (blue)
compared with cells stained with an isotype control mAb (black). (B) To analyze NCR expression on enriched NKs from the patient at diagnosis,
an additional sorting step for CD16 positive cells was performed to focus the analysis on the small subpopulation of NKs. NKs from the patient at
diagnosis (red) are compared with cells stained with an isotype control mAb (black). (C) Gates chosen to generate data shown in panels A) and
B). Left: gate chosen to identify MACS-sorted cells (negative selection for NK cells). Right: additional gate used for identification of the CD16 pos
subset (lower right quadrant) of the MACS sorted cells from the patient sample obtained at diagnosis (Methods).
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although absolute numbers have not been determined, but
even lower numbers of NKs may be sufficient for therapeutic
success.In the present study, the patient’s NK cells were
greatly reduced in relative abundance. At diagnosis their
frequency was at least 6–7 fold reduced compared to the
two reference samples obtained from the patient in
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Figure 7 Secretion of TNF-alpha from whole blood or from
supernatants of cytolysis reactions after treatment with SPM-2.
(A) Release of TNF-alpha into whole EDTA treated blood from the
patient in remission versus the healthy twin after addition of SPM-2.
200 μl samples of EDTA-blood were incubated for 6 h at 37°C with a
10 nM dose of SPM-2. Secretion of TNF-alpha was measured with a
commercial ELISA kit (Methods). (B) Supernatants from a 4 h RDL
assay using 10 nM dose of SPM-2 and the patient’s autologous BMMCs
drawn at diagnosis as targets (red). Effector cells were MACs enriched
NKs isolated from PBMCs taken from the patient at diagnosis (left), in
remission (center), or from the healthy sibling (right). Secreted
TNF-alpha was measured as in panel A. Plotted data are the
arithmetic means over 6 independent experiments (n = 6). Error bars
represent the standard error of the mean (SEM). Statistical significance
was reached with p = .002 (*) and .004 (**) for the differences between
cells from the healthy twin and the patient in remission versus
at diagnosis, respectively. (C) Supernatants from a 3 h ADCC assay using
10 μg/ml dose of Rituximab and Raji leukemia cells as targets were
assayed for TNF-alpha secretion using the same NK effector populations
as for panel A (blue). Plotted data are mean values over six independent
experiments (n = 6). Statistical significance was reached with p = .0001
(*) and .0003 (**), for the differences between healthy twin and patient
in remission versus at diagnosis, respectively.
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normal numbers of NKs with typical cytolytic activity
were found. This observation is important for us because
SPM-2 was not designed to debulk the mass of leukemic
blasts as a frontline agent. Instead, it was designed to act
as an adjuvant to further reduce the MRD pool after an
initial induction chemotherapy and thus to achieve
deeper and longer-lasting remissions.
In this context, the observation that not only the
total population of AML blasts from this patient was
efficiently lysed by SPM-2 together with MNC effectors
(Figure 2B), but that the CD34pos subset was also specifically
reduced (Figure 2C), is encouraging. This finding opens the
possibility that the AML-LSCs contained within the CD34
compartment were also affected by this treatment. If this
were true more generally beyond this single patient, then this
would be a welcome result, because AML-LSCs are reported
to have increased resistance to treatment with standard
chemotherapeutic agents [19,48]. AML-LSCs are typically
contained in the CD34pos compartment, and if the LSCs of
this patient were similarly sensitive towards cytolysis
mediated by SPM-2 in conjunction with NKs as the
overall population of CD34pos cells, then this would
suggest, that SPM-2 may become a useful new agent
for the removal of LSCs. However, these extrapolations
are made with due caution, because the AML-LSCs may
only account for a minor subset of all CD34pos blasts in
this patient and therefore may have escaped lysis in our
experiments.
We were further encouraged by our preliminary finding
reported here that SPM-2 mediated specific lysis of the
CD34posCD38neg CD123pos subset contained within the
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confines the relevant MRD cells than the broader CD34pos
compartment. Admittedly, this was only a single initial
experiment and further confirmation is needed. Yet, the
results obtained so far suggest that SPM-2 in conjunction
with functional NKs was capable of effectively eliminating
the CD34posCD38neg CD123pos subset, reported by others
[24] to include the MRD cells.
No major changes were observed here in the expression
profiles of NCRs on NKs between the samples from the
patient at diagnosis and in remission, and both profiles
were similar to those observed for the healthy sibling. This
result was somewhat surprising, because it had been
reported by others that differences in NCR expression
profiles could be a major cause for impaired functional
activity of NKs from AML patients [25-27,29]. One
possible explanation for our result is that the expression
profile of this particular patient is unique and differs from
those of the majority of patients reported elsewhere.
Another possible explanation is that in the cases published
by others, NCR expression levels were generally compared
between NKs from AML patients and those from
unrelated healthy donors. This comparison may be less
informative than the more rigorous comparison reported
here, because it is not excluded that patients in the
published studies expressed lower intrinsic NCR levels
than the average healthy donor, and that this reduced
expression may even have been a cofactor predisposing
them to the development of the disease.
Conclusions
Titers of peripheral blood NKs from a FAB M1 AML
patient had recovered to normal levels in remission after
induction chemotherapy, and these cells showed normal
functional activity in cytolytic assays mediated by the
therapeutic triplebody SPM-2. Comparable cytolytic
activity of NKs from the patient in remission and a healthy
twin were observed both for the patients autologous
leukemic blasts as targets, and in benchmark experiments
with the standard antibody RituximabTM against Raji
lymphoma cells as targets. The functional impairment
of this patient’s NKs obtained at diagnosis probably is
not caused by an altered expression pattern of the
NCRs, NKp30, NKp40 and NKp46, as suggested in the
literature. Expression profiles of these receptors were
unaltered in our case. The major cause for a func-
tional impairment of the patients NK cell response at
diagnosis appears to be the result of a reduced NK
cell titer. Overall, our results indicate that a useful
time point to administer SPM-2 for the treatment of
AML patients will be the remission phase after induc-
tion chemotherapy when blast titers are reduced and
titers and functional activity of normal leukocytes have
recovered.Abbreviations
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2.2.1 Summary 
 
T lymphocytes are one of the most effective cytotoxic immune effector cell populations and are thus 
very well suited for the depletion of cancer cells. Prior to this study, single-chain triplebodies had 
been successfully employed to recruit NK cells for tumor cell lysis, but it had not been tested whether 
the triplebody format is suitable for T cell engagement as well. Therefore a prototype triplebody with 
monospecific bivalent targeting of the B lymphoid TAA CD19, i. e. 19-3-19, was constructed and 
described in this publication. 19-3-19 recruits T cells via a central CD3-epsilon-specific binding moiety 
that is derived from the monoclonal antibody clone OKT3. The use of CD3-epsilon as trigger antigen 
on CTLs had previously been validated, for example in the BiTE®-format. 
 
Triplebody 19-3-19 as well as control triplebody Her2-3-Her2 and bispecific monovalent control 
proteins Her2-3 and 19-3 were produced and tested for biological activity in this study. All constructs 
displayed specific binding. The CD3-epsilon equilibrium dissociation constant (KD) of 19-3-19 was 
determined to be 53.3 ± 19 nM, which was higher than the KD-value of 19-3 (34.7 ± 14 nM) and 
suggested dependence on the molecular context of the scFv. Furthermore, the overall avidity of 
19-3-19 for CD19 was twice as high as that of 19-3. This implied simultaneous binding of the two 
CD19 binding moieties as well as an additive rather than a synergistic combination of the affinities of 
the individual scFv. 19-3-19 also mediated the specific lysis of several CD19+ cell lines, which 
represented different types of B cell malignancies. The EC50-values were in the low picomolar range 
(5.5 to 189.6 pM) and comparable to those that were achieved with the bispecific control molecule 
19-3. Since 19-3-19 also led to the lysis of 69 ± 13% SEM cells at an effector-to-target cell (E : T) ratio 
of 1 : 10, it was concluded that the triplebody induced serial lysis of several CD19-positive target cells 
by a single T cell. 19-3-19 mediated the activation of non-stimulated T cells in cytolysis assays as 
evidenced by the increase in cell surface levels of activation markers CD69 and CD25. T cell activation 
by 19-3-19 was dependent on the presence of CD19-bearing target cells. The subset of CD3+ CD45RO+ 
T cells, which was defined as the memory T cell population, proliferated. Maximum target cell 
depletion of 94.2% to 99.6% was achieved after 48 hours. 
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In combination with allogeneic pre-stimulated mononuclear cells (40% NK cells and 60% T cells), 
19-3-19 also led to the efficient depletion of primary target cells from patients with different 
hematopoietic malignancies. The response to 19-3-19 treatment was compared to that towards the 
standard-of-care treatment with monoclonal anti-CD20 antibody rituximab (MabThera®). The extent 
of the treatment response generally coincided with the copy number of CD19 or CD20 on the cancer 
cell surface of the patient samples. Here, EC50-values for 19-3-19 were 30- to 925-fold lower than 
those for rituximab. Further, in an autologous setting within an NHL patient sample, 19-3-19 led to 
the depletion of lymphoma cells and the notable 7-fold expansion of the entire T cell population. 
 
At the example of 19-3-19 this study has thus proven that the triplebody format is suitable for the 
engagement of T lymphocytes as immune effectors in cancer therapy in an MHC:peptide-
independent manner. Thus triplebodies may be a universal platform that is suited for the 
engagement of any desirable immune effector cell population with the added advantage of a longer 
plasma half-life than BiTE® and the potential for bivalent bispecific (i. e. dual) targeting.  
 
 
2.2.2 Contribution 
 
I designed, purified and characterized triplebody 19-3-19 and control molecules, performed binding 
studies and investigated the cytolytic potential of the molecules in combination with allogeneic pre-
stimulated effector T cells against cell line targets and primary patient target cells. Additionally, I 
investigated the activation of resting T cell subsets from healthy donors and patients with B cell 
malignancies upon treatment with 19-3-19 in cytolysis assays. I am also the author of the manuscript, 
which was edited by Prof. Fey and reviewed by all co-authors. 
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ABSTRACT
Triplebody 19-3-19, an antibody-derived protein, carries three single chain 
fragment variable domains in tandem in a single polypeptide chain. 19-3-19 binds 
CD19-bearing lymphoid cells via its two distal domains and primary T cells via 
its CD3-targeting central domain in an antigen-specific manner. Here, malignant 
B-lymphoid cell lines and primary cells from patients with B cell malignancies were 
used as targets in cytotoxicity tests with pre-stimulated allogeneic T cells as effectors. 
19-3-19 mediated up to 95 % specific lysis of CD19-positive tumor cells and, at 
picomolar EC50 doses, had similar cytolytic potency as the clinically successful agent 
BlinatumomabTM. 19-3-19 activated resting T cells from healthy unrelated donors and 
mediated specific lysis of both autologous and allogeneic CD19-positive cells. 19-3-19 
led to the elimination of 70 % of CD19-positive target cells even with resting T cells as 
effectors at an effector-to-target cell ratio of 1 : 10. The molecule is therefore capable 
of mediating serial lysis of target cells by a single T cell. These results highlight that 
central domains capable of engaging different immune effectors can be incorporated 
into the triplebody format to provide more individualized therapy tailored to a 
patient’s specific immune status.
BACKGROUND
Therapeutic antibodies such as MabThera®, 
Herceptin® and Avastin® are potent and successful 
tools in the fight against cancer.[1] Recombinant 
proteins derived from conventional antibodies have 
been designed to increase tumor cell selectivity and 
deeper penetration into tumor tissues, and to exploit the 
patients’ innate defense mechanisms against their disease.
[2, 3] Several of the new antibody-derived agents - 
including immunoligands[4-6], diabodies, bispecific (bs) 
scFvs[7, 8], single chain triplebodies[9-12] and, most 
recently, a modular targeting system[13] - are based on 
single chain variable fragment (scFv) building blocks and 
lack an Fc region. While maintaining target specificity, 
the scFv-based agents are expected to reach deeper 
tissue penetration due to their reduced molecular mass.
[14, 15] The lack of an Fc region is also thought to reduce 
undesired side effects, which are caused by binding to Fc 
receptors that are exposed on cells other than the desired 
cytolytic effectors.[2, 3]
Despite the lack of an Fc region, scFv-based agents 
have effective mechanisms of action. The anti-Her2/
anti-Her3 bsscFv MM-111[16], for example, relies on 
simultaneous blockage of two different growth factor 
receptors and the cooperative inhibition of essential 
growth-promoting and anti-apoptotic downstream signals. 
Other mechanisms of action include the induction of 
apoptosis via surface receptors such as FasR (CD95)[17] 
and target-specific delivery of a toxin or radioisotope 
cargo by internalization (receptor-mediated endocytosis). 
Another option is the engagement of autologous effector 
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cells, such as natural killer (NK)-cells and cytotoxic T 
lymphocytes (CTLs), for cytolysis.[2, 3]
NK cells can, for example, be recruited by the 
TandAb™ AFM-13 (CD30-CD16; Affimed) designed for 
the treatment of Hodgkin Lymphoma.[18] Examples for T 
cell recruitment via scFv-based agents are the bispecific 
T cell engagers (BiTEs; Micromet/Amgen). Antibody-
derivatives in the BiTE-format coat their tumor cell 
targets and engage effector memory T cells independent 
of their MHC : peptide specificity via the CD3ε chain of 
the T cell receptor-CD3 (TCR/CD3) complex.[7] Coupling 
between T cell and tumor cell leads to the formation of 
a cytolytic synapse and degranulation of the T cell. 
[7, 19] Moreover, the engagement of effector memory T 
cells via BiTEs leads to their proliferation and thus to an 
expansion of the effector cell population that is available for 
tumor cell lysis during the course of the treatment.[20-22] 
The CD19-specific BiTE BlinatumomabTM has shown 
impressive success in clinical studies with patients suffering 
from acute and chronic B cell malignancies.[20, 22-24] 
Other BiTEs targeting CD33 (CD33-CD3; AMG330)
[25, 26], EpCAM (MT110; EpCAM-CD3)[27-29] and 
CEA (MT111; CEA-CD3)[30, 31], respectively, have 
produced promising results in recent pre-clinical studies 
and ongoing clinical trials.
However, despite their success, these bispecific 
agents still face limitations, which are difficult to 
overcome with this molecular format, including limitations 
in tumor cell specificity and “plasma retention time” 
(“plasma half-life”).[22, 23] The drawback in specificity is 
due to the fact, that the BiTE-format is monospecific and 
monovalent for the tumor cell, recognizing only one target 
antigen. While mono-targeting has been successful in 
several applications, it may not confer sufficient specificity 
for cancer cells and sufficient discrimination between 
cancer and healthy cells in many other cases. Given that 
spontaneously arising cancer cells share many antigens 
with healthy cells, and that many of the most promising 
targets, such as growth factor receptors (e.g. EGF-
receptor) and cell adhesion molecules (e.g. EpCAM) are 
not tumor-specific, this situation will occur. Therefore, 
monospecific agents have often caused side effects that 
are difficult to manage. In addition, under therapy with 
monospecific agents, escape mutants of tumor cells can 
emerge, which have lost the surface expression of the 
corresponding target antigen and have become resistant to 
treatment.[32] Dual-targeting agents, which address two 
different target antigens on the same cancer cell, may be 
capable of overcoming some of these limitations. Also, 
most BiTEs have a molecular mass below 65 kDa and 
thus below the kidney excretion limit, which results in a 
plasma half-life in the range of approximately 1 hour.[33] 
This shortcoming can be addressed by agents with a 
higher molecular mass and by extending the half-life by 
PEGylation, by fusion to human serum albumin (HSA) 
domains carrying a binding site for the FcRn shuttling 
receptor, or antibodies and antibody fragments with 
specificity for HSA.[34]
To take advantage of these added capabilities offered 
by multispecific scFv-based agents, the molecular format 
of “single chain triplebodies” (“triplebodies”) has been 
developed by our group. A triplebody is composed of three 
scFvs connected via flexible (Gly4Ser)4 linkers, which 
results in a maximum computed distance of 20 nm between 
the two distal binding moieties[35] and a molecular mass 
of 85 to 95 kDa.[36] This mass exceeds the threshold for 
first-pass kidney excretion and consequently, triplebodies 
have a prolonged plasma half-life of approximately 4 hrs 
in mice. This corresponds to approx. 1 day in humans by 
allometric scaling.[9] Triplebodies can be designed to 
recruit different classes of effector cells via their central 
scFv, which is specific for an activating surface molecule 
such as CD16 on NK cells and macrophages[9, 10, 36], 
CD89 on polymorphonuclear granulocytes (PMNs)[37], or 
CD64 on macrophages and cytokine-stimulated PMNs.[3] 
The two distal binding moieties of the triplebody 
are capable of either monospecific bivalent targeting 
(example: 19-16-19)[9] or bispecific bivalent targeting 
(“dual-targeting”) of two different target antigens on the 
same cancer cell (examples: 123-16-33[36], 33-16-19[10] 
and HLA-DR-16-19[11]). Dual-targeting triplebodies 
have been shown to achieve preferential binding[4] and 
to mediate preferential lysis[38] of double-positive over 
single-positive target cells by cytolytic effectors in a 
mixed environment. They even permitted preferential 
effector-cell mediated lysis of the double-positive cells 
when the single-positive cells were present in an up 
to 20-fold numerical excess. For some target antigen 
combinations the dual-targeting approach may not be 
successful, because individual target affinities, antigen 
surface densities and the genetically and epigenetically 
determined susceptibility of the target cell to effector cell-
mediated lysis need to cooperate for enhanced potency.
[28] Nevertheless, dual-targeting triplebodies have been 
successful in preclinical studies for a number of different 
combinations of target antigens, and therefore this concept 
deserves further exploration.
The ability of triplebodies to recruit T cells as 
effectors is unaddressed so far and it is uncertain whether 
the fine structure of an immunological synapse mediated 
by a triplebody would be functional, as demonstrated for 
NK cells. In the present study a single chain triplebody 
was constructed and tested for the ability to recruit 
cytotoxic T cells (CTLs) as effectors for the lysis of 
CD19-positive leukemia cells. As we demonstrate in our 
current study, the new triplebody anti-CD19/anti-CD3/
anti-CD19 (19-3-19) is capable of activating resting 
T cells and of mediating redirected and serial lysis of 
tumor cells, both of established B-ALL cell lines and of 
primary cells isolated from the peripheral blood of patients 
suffering from different types of B cell malignancies. 
The successful recruitment of effector T cells via 
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19-3-19 indicates that the triplebody platform can be used 
to recruit an even broader range of effector cells. The thus 
highlighted ability of the triplebody format to choose an 
optimally suited effector cell for therapy by adjusting the 
central trigger scFv based on a patient’s specific cancer 
type and the availability of these effectors in the tumor 
tissue increases the range of therapeutic options and may 
add an additional layer to individualized cancer therapy.
RESULTS
Design and production of triplebody 19-3-19.
Triplebody 19-3-19 carries a scFv domain derived 
from the murine hybridoma antibody OKT3 (directed 
against human CD3ε) in the central position, and CD19-
specific scFv domains, targeting the B-lineage antigen 
CD19, derived from hybridoma 4G7 as previously 
described (Fig. 1).[9] In this fusion protein with an 
N-terminal Strep-tag and a C-terminal His-tag, the CD19-
specific scFv components were humanized by CDR-
grafting.[39] Triplebody 19-3-19 was expressed both 
in adherent HEK 293T cells and in suspension-adapted 
HEK 293F cells with yields between 0.9 and 5.1 mg 
protein/L culture supernatant in different experiments 
(Table 1). HEK 293F cells permitted cultivation in 
serum-free medium and efficient purification via Ni-NTA 
affinity chromatography. The N- and C-termini were 
intact and no degradation products were detected (Fig. 2). 
In addition, two new agents in the Bispecific T cell 
Engager (BiTE)-format were produced as controls. One 
carried our humanized CD19-specific scFv domain and 
was designated 19-3 (“Blinatumomab™-look-alike”), 
the other carried scFvs with specificity for Her2/NEU 
and CD3ε and was designated Her2-3. Finally, a control 
triplebody targeting Her2/NEU (designated Her2-3-Her2) 
was also produced. Expression of Her2-3-Her2 and Her2-
3 was efficient with yields of 8.5 and 9.2 mg/L of culture 
supernatant, respectively (Table 1).
Triplebody 19-3-19 binds specifically both to its 
target antigens and the trigger protein.
 Both the triplebody 19-3-19 and the BiTE 19-3 
bound to primary human T cells isolated from ex vivo 
expanded mononuclear cells (Fig. 3A; left), as well as 
to CD19-positive Nalm-6 cells (a pre-B ALL-derived 
cell line; Fig. 3A, right), but it did not bind to antigen-
negative HEK 293F cells (data not shown). The Her2-3-
Her2 specificity control bound to T cells via the trigger 
CD3ε, but not to Her2- and CD3ε-negative Nalm-6 cells. 
At the saturating concentration of 15 µg/mL both the 
control triplebody Her2-3-Her2 and the 19-3 BiTE showed 
stronger binding to T cells than triplebody 19-3-19, as 
evidenced by a stronger shift in the mean fluorescence 
intensity (MFI) of the cell-bound fusion proteins detected 
by cytofluorimetry (Fig. 3A, left panel). Thus the binding 
capacity of the CD3ε-specific scFv domain was affected 
by its molecular context within a given fusion protein. 
The difference in binding strength was also reflected in 
the equilibrium dissociation constants (KD values) of 
19-3-19 and 19-3 for CD3ε exposed on primary T cells. 
The triplebody bound less strongly with an affinity of 
53.3 ± 19 nM compared to 34.7 ± 14 nM for the BiTE 
19-3 (Fig. 3B, left panel), but the difference was not 
significant. The overall avidity of the triplebody for CD19 
an-CD3ε
C-terminal
an-CD19
N-terminal
an-CD19
VL
VH VL
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VH
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Figure 1: Domain architecture of T cell-recruiting triplebody 19-3-19. Triplebody 19-3-19 binds to the CD3ε chain of the 
TCR/CD3 complex via its central scFv and to two copies of CD19 on the surface of a malignant target cell via its two distal scFvs. 
The scFvs are connected by flexible (G4S)4-linkers (black lines), which gives the molecule a maximum computed span length (distance 
between the two distal binding sites) of 20 nm, when the flexible linkers are fully extended.
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Figure 2: N- and C-termini of triplebody 19-3-19 and control proteins 19-3, Her2-3 and Her2-3-Her2 were intact. The 
fusion proteins carried N-terminal Strep and C-terminal hexa-histidine tags. Western blot analysis with antibodies reacting with the Strep- 
and His-tags, respectively, revealed that the fusion proteins carried intact N- and C-termini and provided no indication for incomplete 
synthesis or proteolytic degradation.
Table 1.  Molecular masses and yields of T cell-engaging triplebodies and bispecific scFvs.
Proteins were expressed and purified as described in the Methods section. Buffer conditions were chosen 
to minimize protein aggregation. Proteins were concentrated to 150 - 300 ng/µL in the storage buffer 
by centrifugation, using centrifugal filters with a molecular weight cut-off (MWCO) of 50 kDa for the 
triplebodies and 10 kDa for bispecific scFvs. Theoretical molecular masses were computed from the 
known amino acid sequence composition of the molecules.
Protein
Computed Mass Yield [mg/L]
Storage Buffer
[kDa] (293F cells)
anti[CD19-CD3] 60.7 0.9 – 4.8 20mM L-Histidin
300mM NaCl
100mM D-Trehalose
5mM EDTA
10% Glycerol
pH 6.5
anti[CD19-CD3-CD19] 89.9 0.9 – 5.1
anti[Her2-CD3] 59.5 1.8 – 9.2
anti[Her2-CD3-Her2] 87.2 6.0 – 8.5
on the surface of SEM (pro-B ALL) cells was 14.7 ± 2 
nM. Thus, the binding-strength of the triplebody for CD19 
was approximately two-fold greater than the monovalent 
affinity of the CD19-specific scFv-domain carried in 
the control 19-3 with a KD value of 28.4 ± 1 nM (Fig. 
3B, right panel). These numerical values indicate that 
the two CD19-specific scFv domains of triplebody 19-
3-19 contributed to the overall avidity of this protein 
in an additive rather than a synergistic manner, which 
was previously reported for the triplebody 19-16-19.[9] 
This observation suggests that the detailed spatial 
arrangement assumed by the two CD19-specific scFvs in 
a triplebody, which mediate the association with a target 
cell, is different between an NK- and a T cell-recruiting 
agent. The increase in avidity for CD19 on living cells 
observed for the triplebody relative to the BiTE is also 
evidence that both CD19-binding sites of the triplebody 
can simultaneously bind one copy each of CD19 on the 
same target cell.
Triplebody 19-3-19 mediates specific target cell 
lysis in combination with effector T cells. 
To investigate whether the formation of a 
cytolytically productive synapse between an effector T cell 
and its tumor cell target can be mediated by triplebody 
19-3-19, redirected lysis (RDL) assays were performed. 
For this purpose, a panel of CD19-positive leukemia- and 
lymphoma-derived cell lines representing different types 
of B cell-malignancies were used as targets with a 
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T cell : target cell ratio of 6 : 1. Triplebody 19-3-19 or control 
proteins 19-3 and Her2-3-Her2 were added at different 
concentrations and after a 3 hr reaction time target cell 
death was measured by Calcein release.[11, 38] 19-3-19 
and 19-3 produced significant specific lysis of CD19-
positive target cells in a dose-dependent manner (Fig. 4a). 
However, even at the highest concentration of 10 nM, the 
specificity control triplebody Her2-3-Her2 did not produce 
any significant specific lysis (3.5 ± 5 % background). This 
result is in accordance with an earlier report[40] describing 
that the sole binding of a BiTE protein to CD3ε on the T 
cell in the absence of binding to the target cell was not 
sufficient to induce bystander lysis of target cells by the 
T cells.
Lysis of SEM cells occurred with a sigmoidal 
dose-response with a maximum specific lysis of 
89.8 ± 9 % after 3 hrs (mean of 4 experiments) and an 
EC50-value of 5.5 pM (95% CI: 3-9 pM). Dose-responses 
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Figure 3: Binding specificities of the scFv components of triplebody 19-3-19. Target specificity of the 19-3 BiTE protein 
and triplebody 19-3-19 was examined by flow cytometry as described.[53] Molecules bound to the surface of single-positive target cells 
were detected with a secondary anti-His mAb and a Phycoerythrin (PE)-conjugated tertiary goat-anti-mouse IgG mAb. (A) Shift in 
mean fluorescence intensity (MFI) produced by binding to primary T cells (left), and Nalm-6 cells (right) at a saturating concentration of 
15 µg/mL of either the BiTE or the triplebody. Black: isotype control; blue: triplebody 19-3-19; red: 19-3 BiTE; green: control triplebody 
Her2-3-Her2. MFIs are given as logarithms to the base of 10. (B) Determination of equilibrium dissociation constants KD of 19-3 and the 
triplebody 19-3-19 for CD3 on primary T cells (n = 4), and for CD19 on SEM cells (n = 7). Error bars indicate standard error of the mean 
(SEM). The dissociation constants for CD3 were 34.7 ± 14 nM and 53.3 ± 19 nM for the BiTE and the triplebody, respectively. The 
dissociation constants for CD19 were 28.4 ± 1 nM for 19-3 and 14.7 ± 2 nM for triplebody 19-3-19, where the latter value refers to the 
overall (bivalent) avidity of the entire molecule, not to the monovalent affinity of the individual CD19-specific scFvs.
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Figure 4: Specific redirected lysis of malignant target cell lines mediated by the 19-3 BiTE and triplebody 19-3-19 in 
conjunction with effector T cells. Standard Calcein Release Assays with an E : T ratio of 10 : 1 (MNCs : target cells) and a duration of 
3 hrs were performed unless indicated otherwise. Error bars indicate SEM. (A) Dose-Response-Curve for SEM cells (triangles: triplebody 
19-3-19; squares: 19-3 BiTE; cross: specificity control Her2-3-Her2; n=4). (B) Maximum specific lysis of several CD19-positive malignant 
B-lymphoid cell lines (n=4 each) induced by 19-3 (white bars), triplebody 19-3-19 (black bars) and specificity control Her2-3-Her2 (grey 
bars), respectively. (C) Serial lysis of unlabeled SEM target cells mediated by triplebody 19-3-19 at different E : T ratios. The reaction 
mixture (purified T cells and SEM target cells in RPMI1640 GlutaMAX medium containing 10% FCS) was incubated with or without 1nM 
triplebody overnight (approx. 15 hrs) (n = 3). The total number of viable cells in each reaction was determined and the fraction of CD19-
positive target cells was established by FACS analysis.
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were also recorded for Nalm-6 (pre-B ALL), Raji (Burkitt 
lymphoma), Namalwa (Burkitt lymphoma) and ARH77 
(plasma cell leukemia) cells and EC50-values were 
in the low picomolar range (Table 2). The specificity 
control triplebody Her2-3-Her2 did not induce significant 
lysis of any of the target cell lines (Fig. 4B). Different 
surface antigen densities of CD19 on these cell lines 
are an explanation for the difference in lysis measured, 
because a loose correlation was observed between 
the copy number of CD19 molecules per cell and the 
degree of maximum specific lysis (Fig. 4B and Table 2). 
Copy numbers per cell (given in the parentheses) were 
measured by calibrated cytofluorimetry and gave rise 
to the following ranking: SEM (30,000 ± 8,000) > Raji 
(23,500 ± 19,000) > Nalm-6 (17,500 ± 7,000) > Namalwa 
(7,000 ± 4,000) > ARH77 (1,500 ± 2,000). Numbers of 
CD19 copies per cell were weakly correlated with the 
degree of maximum specific lysis achieved for these 
cell lines (Table 2) with the exception of Nalm-6 cells. 
Nalm-6 cells carried intermediate numbers of CD19 copies 
per cell but responded poorly to lysis mediated by the 
triplebody plus T cells. Finally, no statistically significant 
difference between the degree of maximum lysis of these 
cell lines reached by T cells in combination with either 
the triplebody 19-3-19 or the BiTE 19-3 was observed 
(p-values > 0.05; Table 2). Thus, both agents mediated 
comparable maximum lysis of different types of malignant 
B-lymphoid cells.
Triplebody 19-3-19 induces serial tumor cell lysis. 
Cytolytic T cells alone and T cells recruited by 
BlinatumomabTM are capable of serial target cell lysis.[19] 
This is a valuable property for therapeutic efficacy, and 
therefore we sought to determine, whether T cells recruited 
by 19-3-19 were also capable of serial lysis. Redirected 
lysis experiments were performed for an extended reaction 
period of 15 hrs with a constant saturating concentration 
of 19-3-19 (1 nM), constant numbers of target cells, but 
decreasing effector-to-target cell ratios over the range 
from 10 : 1 to 1 : 10 (Fig. 4C). Even at an effector : target 
cell ratio of 1 : 10, 69 ± 13 % of the CD19-positive target 
cells were lysed, which provides clear evidence for serial 
lysis by T cells mediated by the triplebody.
Activation of resting T cells via synapse-formation 
mediated by 19-3-19.
Under physiological equilibrium conditions 
T cells in human blood are not activated unless an 
immune response is raised to a pathogen. Consequently, 
a therapeutic agent based on T cell-engagement may 
also require the activation of resting T cells to develop 
maximum efficacy. The BiTE BlinatumomabTM has already 
been shown to cause the activation of memory T cells, 
which (differing from naive T cells) do not require a 
second activation signal, and to trigger their proliferation.
[20-22] To investigate whether triplebody 19-3-19 is 
capable of activating resting T cells when it connects the 
target and effector cell via the CD3ε-specific scFv domain, 
a long-term (72 hr) RDL assay was performed using 
non-stimulated PBMCs from healthy unrelated donors as a 
source of effector cells and SEM cells as targets at an E : T 
ratio of 10 : 1 (PBMCs : targets).
The population of PBMCs from healthy donors 
includes both CD19- and CD3-positive cells and therefore, 
the frequencies of these subsets within the PBMC 
populations were measured for each donor prior to their use 
in RDL assays. For the panel of donors tested, the CD19-
positive subset ranged from 0.8 to 12.6 % and the T cell 
subset from 69.3 to 74.5 % of all PBMCs, respectively.
At the start of these experiments (time t0) the CD19-
positive cellular subset accounted for 11.6 to 19.6 % of 
all cells (PBMCs plus target SEM cells) in the reaction 
Table 2. Maximum lysis and EC50 values of 19-3 bispecific scFv and triplebody 19-3-19 for different 
malignant B-lymphoid cell lines.
Cell Line
Maximum Specific Lysis [%] EC50 [pM] (95% CI [pM])
n
19-3 19-3-19 p-value 19-3 19-3-19 p-value
pro-B ALL SEM 88.5 ± 12 89.8 ± 9 0.33 4.5 (2 - 10) 5.5 (3 - 9) 0.43 4
Nalm-6 31.9 ± 12 29.5 ± 11 0.08 12.7 (5 - 30) 22.3 (16 - 31) 0.21 4
Burkitt 
lymphoma Raji 49.6 ± 16 54.7 ± 12 0.1 1.8 (0.5 - 7) 47.4 (11 - 201) 0.053 4
Namalwa 44.6 ± 8 41.3 ± 7 0.12 6.2 (32 - 12) 19.9 (9 - 43) 0.071 4
plasma cell 
leukemia ARH77 37.0 ± 14 39.0 ± 8 0.34 5.6 (0.3 - 95) 189.6 (54 - 664) 0.003 4
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mixture. The decreasing fraction of CD19-positive cells, 
the number of memory T cells (CD3+ CD45RO+), the 
expression levels of the early T cell activation marker 
CD69 (trans-membrane C-type lectin) and of the late 
activation marker CD25 (α-subunit of the IL-2 receptor) on 
CD3-positive cells were then assessed every 24 hrs (Fig. 5).
T cell activation was induced in all donor samples 
tested, but with extensive inter-donor variability (data not 
shown). The T cell activation profile from one particular 
28-yr old male donor is shown in Fig. 5. After 24 hrs 92.5 % 
(values ranging from 86.0 to 99.4 % lysis for different 
donors) of CD19-positive target cells were depleted 
(Fig. 5A). Maximum depletion of targeted cancer cells 
was generally achieved after 48 hrs (94.2 to 99.6 % lysis). 
The control triplebody Her2-3-Her2 did not induce T cell 
activation as determined by activation marker expression 
(Fig. 5B) and Interferon-γ release (data not shown).
In all donor samples the addition of 19-3-19 or 
PHA/IL-2 (positive control) to the reaction mixture caused 
a strong increase of the early activation marker CD69 on 
the surface of the CD3-positive cells (Fig. 5B, red) within 
the first 24 hrs. At later time points the CD69 levels 
dropped progressively for the rest of the time course. 
Surface expression of CD25 was also induced, but less 
intensely and slower than CD69 and also varied greatly 
among the different donor samples. CD25 expression 
levels, induced by the triplebody, peaked between 24 to 
48 hrs and remained almost constant for the later time 
points (Figure 5B, black). In contrast, addition of the 
Her2-3-Her2 control triplebody caused no changes in 
CD69 or CD25 expression in the CD3-positive T cells. 
Addition of the triplebody 19-3-19 alone to the effector 
cells in the absence of CD19-positive target cells did not 
have any effect on the T cell population (data not shown). 
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Figure 5: Example of T cell activation induced by triplebody 19-3-19. Long-term (72 hrs) redirected lysis assay with an E : T 
ratio of 10 : 1 non-stimulated PBMCs : SEM target cells and 1 nM triplebody or 2 % PHA/100 U/mL IL-2 (pos. control) were performed 
and the expression of activation markers by the effector T cells was assessed at 0, 24, 48 and 72 hrs (n=4). Representative data from 
one 28-yr old, healthy male donor are shown. The CD3-positive cells comprised 70.4 % of the donor’s PBMC fraction and the CD19-
positive cells of the donor comprised 4.5 % of his PBMCs. At time t0 the overall content of CD19-positive cells in the reaction mixture 
(PBMCs + SEMs) was 14.6 %. (A) Depletion of CD19-positive target cells over time (white bars = triplebody Her2-3-Her2; black 
bars = triplebody 19-3-19; grey bars = 2 % PHA/100 U/mL IL-2). (B) Time course of expression of early T cell activation marker CD69 
(red) and late activation marker CD25 (black) on the cell surface. The increase in activation marker expression coincided with elevated 
IFN-γ concentrations in the supernatant (data not shown). Diamonds: no treatment; squares: treatment with triplebody Her2-3-Her2; 
triangles: treated with triplebody 19-3-19; crosses: treated with 2 % PHA/100 U/mL of IL-2. (C) Absolute number of T cells (CD3+ cells) 
and memory T cells (CD3+ CD45RO+, dark area) in the reaction mixture. (D) Fraction of memory T cells (CD3+ CD45RO+, dark area) in 
the total CD3-positive cellular compartment, which was set to 100 %.
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Therefore, the triplebody only caused activation of the 
effector T cells, when it physically connected the effector 
and the target cells in an antigen-specific manner and 
engaged them to build a productive synapse.
In the redirected lysis (RDL) experiments with 
triplebody 19-3-19 or PHA/IL-2 the overall numbers of 
living T cells dropped during the first one to two days, but 
rose again and reached the numbers present in the starting 
population after 72 hrs (shown for the 28-yr old male 
donor sample in Fig. 5C). The subset of the CD3-positive 
population defined as memory T cells (CD3+ CD45RO+) 
also followed the drop and increase over time (Fig. 5D). 
We conclude that the T cell-recruiting triplebody can 
engage and activate memory T cells and induce their 
proliferation.
Triplebody 19-3-19 mediates efficient lysis  
of CD19-positive malignant cells in primary  
patient samples.
To determine the effect of an ex vivo treatment of 
patient cells with triplebody 19-3-19 plus effector cells, 
primary patient samples were used as malignant targets. 
PBMC fractions from five patients with different types 
of B cell malignancies were isolated by density gradient 
centrifugation and then employed as targets in our Calcein 
release RDL assays. The first patient suffered from an 
unusual case of tri-phenotypic acute leukemia (expressing 
B- and T-lymphoid plus myeloid lineage markers) and 
donated blood at diagnosis. Whole blood samples were 
also collected at diagnosis from an immunocytoma 
patient and two B-CLL patients. Finally, a blood sample 
from a B-CLL patient, who had relapsed 4 years after a 
complete remission and who had received 6 courses of 
combination therapy using MabThera® plus fludarabine 
and cyclophosphamide, was collected. This patient 
still displayed low expression of approximately 1,800 
copies/cell of CD20 on its surface (Table 3, bottom). 
Patient characteristics are summarized in table 3.
Dose-responses for each patient sample were 
determined, using either our 19-3 BiTE, the triplebody 
19-3-19, or the therapeutic CD20 antibody MabThera® 
and were assessed with standard 3 hr Calcein release-
assays using allogeneic, ex vivo expanded MNC effector 
Table 3. Synopsis of patient data. Patient characteristics (top), target and effector cell content (center) 
and specific antibody binding capacity for CD3, CD19, CD20 and CD33 of malignant cells in the 
peripheral blood as determined with the QIFIKIT (Dako) (bottom).
Patient 1 
(green) Patient 2 (red)
Patient 3 
(blue) Patient 4 (yellow)
Patient 5 
(purple)
Gender Male Male Male Female Male
Age 19 years 86 years 78 years 67 years 52 years
Diagnosis
Mixed 
phenotype 
acute leukemia 
(MPAL (NOS))
CD19-positive 
NHL with 
leukemic 
progression
B-CLL Relapsed B-CLL B-CLL
Blast titer 93.4 % blasts in BM at diagnosis
58 % of 
lymphocytes 
in the PB are 
CD19-positive
29,000 B-CLL 
cells/µL
65 % lymphocytes 
in the PB (9 % 
atypical)
42 % 
lymphocytes in 
the PB
Case history newly diagnosed
newly 
diagnosed
newly 
diagnosed
4 years prior: 6x 
MabThera® plus 
fludarabine and 
cyclophosphamide 
> CR
newly 
diagnosed
% CD19+ in 
PBMCs 94.8 21 89.8 68.8 73.2
% CD3+ in 
PBMCs 0.8 56.1 6.8 16.6 8.6
Specific antibody 
binding capacity 
(SABC) of 
tumour cells in the 
peripheral blood
CD3 211 n.d. n.d. n.d. n.d.
CD19 8,400 ± 2,800 14,600 ± 7,700 9,600 ± 500 6,500 ± 1,700 7,600 ± 1,900
CD20 0 19,400 ± 2,200 4,000 ± 100 1,800 ± 300 3,900 ± 1,200
CD33 317 n.d. n.d. n.d. n.d.
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cells (expanded in the presence of IL-2) from an unrelated 
healthy donor. The E : T ratio (MNCs : targets) was 10 : 1, 
which corresponded to an actual T cell : target ratio of 
5 : 1 and an NK cell : target ratio of 2 : 1.
The maximum cytolytic response of the three 
CD20-positive B-CLL patient samples (patients 3, 4 
and 5) to both CD19-targeting antibody-derivatives was 
more pronounced than the response to the standard-of-
care reagent MabThera® (Fig. 6A). The malignant cells 
of these three patients had higher surface densities of 
CD19 than of CD20 (Table 3, bottom), which paralleled 
the higher maximum specific lysis mediated by 19-3 
and 19-3-19 than by MabThera®. The sample from the 
immunocytoma patient (patient 2) responded more 
strongly to treatment with MabThera® than to treatment 
with either 19-3-19 or 19-3 (Fig. 6A). This coincides 
with a greater surface density of CD20 than CD19 on the 
malignant target cells from this patient (Table 3, bottom). 
The mixed phenotype acute leukemia (not otherwise 
specified) (MPAL(NOS)) patient sample (patient 1) 
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Figure 6: Redirected lysis of CD19-positive malignant cells from primary patient material mediated by triplebody 
19-3-19. The ability of triplebody 19-3-19 to mediate the lysis of malignant cells isolated from the peripheral blood of patients with 
different B cell malignancies (see table 3) via allogeneic and autologous effector T cells was assessed in redirected lysis assays. Samples 
were assayed in triplicate. Error bars indicate intra-sample variation. (A) Specific lysis of malignant cells via allogeneic pre-stimulated 
effector T cells mediated at different concentrations of the 19-3 BiTE (diamonds) and triplebody 19-3-19 (circles) or the therapeutic 
antibody MabThera® (triangles) in a 3 hr assay, respectively. Patient 1 (MPAL (NOS)): blue; patient 2 (NHL): red; patient 3 (B-CLL): 
green; patient 4 (relapsed B-CLL): yellow; and patient 5 (B-CLL): purple. (B) Triplebody 19-3-19-induced depletion of CD19-positive 
cells by autologous effector T cells and expansion of memory T cells (CD3+ CD45RO+) in the PBMC fraction isolated from patient 2 (NHL) 
in a 7 d assay. 1 nM of fresh Triplebody 19-3-19 was added every 48 hrs (indicated by asterisks). A similar assay was performed with 
samples from patients 1 (MPAL (NOS)) and 3 (B-CLL) (data not shown), but no response was observed, possibly due to the relatively short 
observation time, T cell attenuation or too low initial numbers of effector T cells.
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was CD20-negative and consequently failed to display any 
response to treatment with MabThera®, but it did respond to 
treatment with both the 19-3 and 19-3-19 reagents (Fig. 6A). 
The response profile of this MPAL patient is more typical for 
patients with acute B-lymphoblastic leukemia often found in 
children and young adults, where the malignant blasts have a 
phenotype resembling early stages of B cell differentiation. 
Blasts from B cell precursor leukemias (BCP-ALLs) of 
infants, children and young adults often fail to express 
CD20, and thus these patients are more likely to benefit from 
treatment with a CD19-directed rather than a CD20-specific 
agent.[41, 42]
Triplebody 19-3-19 and our 19-3 BiTE reagent were 
effective at far lower concentrations than MabThera®. 
Although inter-patient variation was substantial, the EC50-
values for 19-3 and 19-3-19 generally were 30- to 925-fold 
lower than those determined for MabThera® for the panel 
of patient samples analyzed here (Table 4). No statistically 
significant differences between the BiTE reagent and the 
triplebody were observed with regard to the degree of 
maximum lysis and the EC50 values. Interestingly, maximum 
lysis achieved with the triplebody was marginally lower than 
the extent reached with 19-3. Maximum specific lysis and 
EC50 values are summarized in Table 4.
Triplebody 19-3-19 induces expansion of memory T 
cells in a sample from an NHL patient.
In patients with malignant hematopoietic diseases 
healthy immune effector cells are often displaced and 
suppressed. However, sufficient numbers of functioning 
effector cells are needed for a successful therapy with 
an agent critically relying on the recruitment of cytolytic 
effectors. By inducing the proliferation of memory T cells, 
the BiTE® agents BlinatumomabTM and AMG330 have caused 
an amplification of available effector cells.[20-22, 26] As the 
triplebody 19-3-19 also employs an OKT3-derived scFv-
domain to trigger its effector cells, we investigated whether 
exposure to this triplebody was also capable of stimulating 
the proliferation of memory T cells in a patient sample. To 
this effect, the triplebody was added in a 1 nM saturating 
concentration to PBMCs isolated from an immunocytoma 
patient (patient 2) every 48 hrs for 7 days. At timepoint t0, 
the sample contained 21 % CD19-positive cells and 56.1 % 
CD3-positive cells (Table 3). Approximately half of the CD3-
positive cells (53.3 %) expressed the memory T cell marker 
CD45RO on their surface. In this particular patient sample, 
the T cell population displayed the same initial drop in 
numbers during the first 24 hrs that was also observed during 
the activation of T cells in the healthy donor samples reported 
above (Fig. 5). However, after 48 hrs, the T cells started to 
expand and the numbers of memory T cells had more than 
doubled after 96 hrs in comparison to the control reaction 
without added triplebody. On day 7, the numbers of memory 
T cells were increased by more than 42-fold in the triplebody-
treated sample (Fig. 6B, right). The overall T cell population 
expanded 7-fold during the 7 d period of observation despite 
the absence of detectable numbers of CD19-positive target 
cells from 72 hrs on (Fig. 6B, left).
DISCUSSION
In the present study, the prototype T cell-recruiting 
triplebody 19-3-19 was constructed and shown to engage pre-
activated as well as non-stimulated T cells efficiently for the 
redirected and serial lysis of malignant CD19-positive target 
cells. Moreover, 19-3-19 led to the activation and induced the 
proliferation of allogeneic and autologous effector T cells. 
The key new result of the present study is the observation 
that fusion proteins in the molecular format of single chain 
triplebodies are also suited for the engagement of cytolytic 
T cells (CTLs) via CD3ε to eliminate antigen-positive cancer 
cell targets.
The concept of an “individualized therapy” usually 
refers to the selection of a specific therapeutic target 
based on a patient’s individual genotypic and phenotypic 
characteristics, as determined by molecular diagnostics. 
However, another important aspect of personalized medicine, 
especially when planning to exploit or boost the patient’s 
own immune system, is the size and activity of a suitable 
population of immune effector cells available at the cancer 
site. As a patient’s immune status varies with the type and 
stage of the disease, different effector cell populations 
may be best suited in different situations. NK cells, for 
example, recover more rapidly than T and B lymphocytes 
after chemotherapy, and they require little activation time. 
They are present in the human circulation in a pre-activated 
state and are instantaneously ready for antibody-mediated 
cytolysis. Thus NK cells may be a suitable choice of effector 
cells to combat minimal residual disease after an induction 
Table 4. Synopsis of maximum lysis and EC50 values for patient samples.
Maximum Specific Lysis [%] EC50 [pM] (95% CI [pM])
19-3 19-3-19 MabThera® 19-3 19-3-19 MabThera®
Patient 1 79.3 70.8 n.d. 1.2 (0.3 - 5) 48.1 (9 - 270) n.d.
Patient 2 61.5 59.2 72.8 6.1 (4 - 10) 4.8 (3 - 9) 185.7 (135 - 255)
Patient 3 98 100 44.5 2.8 (1 - 8) 6.4 (4 - 11) 1,300 (426 – 4,224)
Patient 4 49.4 44.7 8.4 10.7 (1 - 177) 13.9 (2 - 84) 9,900 (0.1 - 568 nM)
Patient 5 51.3 48.8 43.9 6.7 (1 - 36) 7.1 (2 - 29) 247.5 (89 - 688)
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chemotherapy.[3] CD8+ T cells, however, are frequently 
present in cancer tissues in abundance, have a greater 
intrinsic cytotoxic potential than NK cells, and are capable 
of more prolonged serial lysis.[43, 44] CTLs are therefore 
a particularly desirable class of cytolytic effectors for 
cancer therapy.
Ideally, for a fully individualized approach and to 
avoid successful immune evasion by the tumor cells, both 
the therapeutic target and the effector population should 
be chosen corresponding to the patient’s individual disease 
properties. The molecular format of triplebodies may help 
to reach this goal, because triplebodies were found suited 
in this study to recruit not only NK cells but also T cells 
as cytolytic effectors.
Both the protein 19-3 in the BiTE-format and the 
newly constructed triplebody 19-3-19 were produced 
with similar expression yields and had similar cytolytic 
potential. Triplebody 19-3-19 led to efficient in vitro 
lysis of CD19-positive targets from both established 
malignant B-lymphoid cell lines and primary patient 
material at picomolar concentrations. Cell surface density 
of target antigens was a major, but not the only important 
determinant of cytolytic efficacy of the agent. A CD19-
positive cell line with high antigen surface expression 
(SEM) showed a greater degree of maximum lysis in a 
standard 3 hr reaction interval in our redirected lysis 
experiments than cell lines with lower surface expression 
of the target antigen (Raji, Namalwa and ARH77).
The difference between maximum lysis of SEM 
cells (89.8 %) and Raji cells (54.7 %) was significant, 
even though CD19 copy numbers per cell differed by 
only 6,500 copies between these two cell lines. However, 
the determination of antigen copy numbers per cell by 
calibrated cytofluorimetry does not take the actual cell 
size into account and therefore produces copy numbers 
per cell, but not antigen density values. We have observed 
that Raji cells (Burkitt’s lymphoma-derived) are much 
larger than SEM cells (pro-B ALL-derived), and therefore, 
the antigen density per surface unit may be lower for Raji 
cells than for SEMs. However, this argumentation does 
not fully explain the low specific lysis achieved for Nalm-
6 cells. Nalm-6 cells have a relatively small cell volume 
that is comparable to SEMs and carried 17,500 copies of 
CD19/cell, but resulted in only 31.9 and 29.5 % specific 
lysis mediated by 19-3 and 19-3-19, respectively, which 
were the lowest values observed. Additional parameters 
other than antigen surface density appear to play important 
roles in determining the sensitivity of a target cell to T cell-
mediated lysis, probably linked to the specific oncogenic 
genomic and epigenetic alterations of the particular target 
and their tumor-type specific susceptibilities to apoptosis.
The triplebody 19-3-19 induced a similar T cell 
response profile as BlinatumomabTM. Activation of the 
T cell by this triplebody only occurred when the T cells 
were connected to the target cells by the triplebody in an 
antigen-specific manner, but was independent of specific 
MHC : peptide recognition. Furthermore, memory T cells 
rather than naïve T cells were engaged and induced 
to proliferate. Whether the triplebody also affects the 
activation state of naïve T cells, i.e. whether naïve T 
cells remain resting or are forced into anergy due to the 
interaction of 19-3-19 with CD3 in the absence of any 
“second signal” (co-stimulus), remains to be determined.
Interestingly, the CD3ε-specific scFv of 19-3-
19 bound less efficiently to primary T cells than when 
this domain was embedded in our 19-3 BiTE protein or 
the Her2-3-Her2 control protein, when each was used 
at saturating concentrations. Together with the lower 
affinity of 19-3-19 for CD3ε in comparison to 19-3, these 
observations indicate that CD3ε on the surface of the T cells 
is less available for binding by the triplebody 19-3-19 than 
by triplebody Her2-3-Her2 and by the 19-3 protein. We 
cannot yet offer a definitive explanation for this observation, 
but the precise conformation of the CD3ε-specific scFv is 
likely different, when it is flanked at both sides by CD19-
specific scFvs or Her2-specific scFvs, or only at one side by 
a single CD19-specific scFv. One possibility may be partial 
sterical hindrance of the CD3ε-specific scFv by the two 
distal CD19 scFvs, which may impact affinity.
A sensitivity of CD3ε-specific scFvs to their precise 
molecular surroundings has been previously reported by 
other authors. In the hands of M. Arndt and colleagues 
the CD3ε-specific scFv required optimization for every 
different BiTE construct, which led to the development 
of a new modular targeting system by these authors.[13] 
Further development of previously reported trispecific 
T cell-engaging antibody-derivatives, which employed 
an N-terminal tumor-associated antigen (TAA)-specific 
scFv, a central CD3ε-specific scFv or VH domain, and a 
C-terminal CD28-specific VH domain in one polypeptide 
chain,[45, 46] was discontinued. The question, whether 
the CD3ε-specific scFv domain in the central position of 
these fusion proteins was stable and functional, remained 
unanswered.
The value of triplebodies recruiting effector T cells 
can most likely be further increased by taking advantage 
of the unique capability of triplebodies for “dual-
targeting”. Dual-targeting has been reported to enhance the 
selectivity of triplebodies recruiting NK cells as cytolytic 
effectors,[38] but it needs to be determined whether a 
preferential lysis of antigen double-positive cells over 
simultaneously present antigen single-positive cells can 
also be achieved by dual-targeting triplebodies, which 
recruit T cells as effectors. This may not be a foregone 
conclusion, because results recently reported by Harms 
and colleagues about the cross-arm binding efficiencies 
of monoclonal antibodies and different multispecific 
antibody-derived formats[47] suggest, that not every 
target combination leads to an improved antibody-activity 
in spite of the higher combined target antigen density. 
This may be explained in part by the “protein island”-
model of the cell membrane, which is currently one of the 
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most potent models for the surface architecture of human 
leukocytes.[48, 49] This model proposes that the surface 
of human leukocytes is composed of “protein islands” of 
approximately 200-300 nm in diameter. Particular groups 
of proteins are segregated in separate islands. They are 
anchored to the cytoskeleton by protein contacts, and the 
lipid composition within the islands is different from the 
areas outside of the islands. The islands have a degree 
of freedom for lateral movement on the surface, and 
specific events can cause the relocation of one island into 
the immediate vicinity of another to facilitate protein 
interaction. This has been reported for example for the T 
cell antigen receptor (TCR) and its co-factor Lat.[49] On 
the surface of resting T cells these two proteins were found 
in different protein islands, which concatenated upon T 
cell activation. If we assume this model to be valid, and 
if two antigens, which are targeted by a multispecific 
antibody-derivative such as our triplebody, reside in 
separate protein islands, and if the intrinsic cross-arm 
binding property of the employed molecule is unsuited 
for simultaneous binding, and if none of the two antigens 
can relocate to the other island, then there is no benefit in 
multispecificity. However, if two different antigens can be 
bound simultaneously on the same cell, then cancer cell 
selectivity may be possible and several immunotherapeutic 
mechanisms of action, such as growth factor receptor 
inhibition, neutralization of immune evasion mechanisms, 
or induction of apoptosis and ADCC (or RDL), can 
potentially be combined.
In this proof-of-principle study, we have 
demonstrated that triplebodies which are bivalent, but 
monospecific for the target antigen, can recruit one of the 
most desirable effector cell populations, the cytolytic T 
cells, for cancer cell lysis. It remains to be investigated 
in future studies, whether it is possible to further enhance 
the value of T cell-recruiting triplebodies as potential 
therapeutic agents by endowing them with the dual-
targeting option, based on the rational choice of a pair of 
target antigens on the cancer cell, which is more abundant 
and/or more accessible on the surface of the cancer cell 
than on the corresponding healthy cells. It also remains 
to be seen, whether the triplebodies have the improved 
plasma half-life relative to the BiTE agents in humans, 
which has been demonstrated for them in mice. However, 
we anticipate that both of these goals are within reach, 
and therefore, that triplebodies have significant therapeutic 
potential for the treatment of cancer and other diseases.
METHODS
Bacterial strains and cell lines
DNA plasmids for the eukaryotic expression of 
antibody-derived fusion proteins were amplified in 
Escherichia coli strain XL-1. The mammalian production 
cell line 293F was purchased from Life Technologies™ 
and cultured in serum-free FreeStyle™ medium (Life 
Technologies™). The pro B-ALL cell line SEM has 
been continuously propagated in our laboratory since its 
establishment in 1995,[50] the CD19-positive pre-B cell 
line Nalm-6, the Burkitt lymphoma cell lines Raji and 
Namalwa and the plasma cell leukemia cell line ARH77 
were purchased from the Leibniz Institute DSMZ (German 
Collection of Microorganisms and Cell Cultures).[51] 
All cell lines were cultured in RPMI 1640, GlutaMAX™ 
supplemented with 10 % fetal calf serum (FCS) and 
Penicillin (100 U/mL)/Streptomycin (100 µg/mL) 
(Gibco®, Life Technologies™). The medium for the 
Namalwa cell line was additionally supplemented with 
1 mM sodium pyruvate.
Construction, expression and purification of 
triplebody 19-3-19 and control proteins
All antibody derivatives employed in this study 
were cloned into the mammalian expression vector 
pSecTag2-HygroC (Life Technologies™). The scFv 
building blocks for the bispecific scFv proteins 19-3 and 
the Her2-3, and for the triplebodies 19-3-19 and Her2-
3-Her2 were developed by our team at the University of 
Erlangen (CD19-specific scFv) or provided by M. Peipp 
(University of Schleswig-Holstein, Kiel; CD3ε- and Her2-
specific scFvs), respectively. The sequences coding for 
the disulfide-stabilized CD16-specific scFv in the gene 
encoding the triplebody 19-16-19 (derived from Kellner 
et al. 2008, but with humanized scFv sequences) were 
replaced with the murine CD3ε-specific scFv sequence 
amplified by polymerase chain reaction (PCR) from 
the sequence coding for Her2-3 by standard molecular 
cloning methods. Similarly, the sequences coding for 
the Her2-specific scFv in the Her2-3 construct were 
replaced with the sequences coding for the humanized 
CD19-specific scFv to produce the coding sequences 
for 19-3. The sequences coding for the CD19-specific 
scFvs in the coding construct for triplebody 19-3-19 were 
replaced with coding sequences for the Her2-specific 
scFv amplified by PCR from the construct coding for 
Her2-3 to produce the coding sequences for triplebody 
Her2-3-Her2. (Details of the construction scheme are 
listed in Supplementary Table S1). 293F cells were 
transfected with the respective expression vectors using 
the TransIT®-LT1 transfection reagent (Mirus® Bio LLC) 
following manufacturer’s instructions. Antibody-derived 
fusion proteins were purified by affinity chromatography 
from cell culture supernatants that were harvested 7 days 
post transfection. A Nickel-nitrilo triacetic acid (Ni-NTA) 
matrix was used. Protein concentrations were determined 
by measurement of their absorbance at 280 nm. Protein 
identity was confirmed and purity assessed by SDS-
polyacrylamide gel electrophoresis and Western Blotting 
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(N-terminal integrity confirmed with anti-Strep- and 
C-terminal integrity confirmed with anti-His antibodies).
Preparation of peripheral blood mononuclear 
cells (PBMCs) from whole blood
10 - 60 mL of peripheral blood was drawn into 
EDTA monovettes (Sarstedt) from healthy unrelated 
donors and patients suffering from different types of B cell 
neoplasias, after informed written consent was obtained. 
This study is in accordance with the declaration of 
Helsinki and was approved by the ethics committee of the 
Medical Faculty of the Ludwig-Maximilians-Universität 
München (project no. 173-13). PBMCs were separated 
by density gradient centrifugation using Lymphoprep™ 
(Axis Shield PoC) medium, and residual erythrocytes were 
lysed by incubation with Ery-Lysis-Buffer (University 
Pharmacy, Munich) for 5 min. To generate effector cells 
for standard 3 hr cytotoxicity assays, an ex vivo expansion 
and stimulation of mononuclear cells (MNCs) was carried 
out for 20 d in the presence of IL-2 as described.[52] For 
T cell activation assays freshly isolated, non-stimulated 
PBMCs were used.
Enrichment of a pan T cell population by 
preparative magnetic cell separation
Pan T cells were isolated from ex vivo expanded 
MNCs or freshly isolated, non-stimulated PBMCs by 
negative selection using a commercial Pan T cell isolation 
kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer’s instructions. The enriched 
T cells are referred to as “untouched cells” because they 
have no residual antibody bound to their surface and have 
been maintained under mild buffer/medium conditions. T 
cell purity was assessed by flow cytometry and the purified 
T cells were used for binding and T cell activation studies.
Flow cytometry
An Accuri C6 flow cytometer (BD Biosciences, 
Heidelberg, Germany) was used for flow cytometric 
analysis of the binding behavior of the antibody-derived 
fusion proteins and for the differential analysis of 
leukocyte/tumor cell subpopulations. In the Accuri C6 
instrument the laser and optical alignments have been pre-
set and locked. In this instrument the detector voltages are 
not adjustable as opposed to other machines. Equilibrium 
binding constants (affinity constants, KD) for CD19 and 
CD3 were determined by calibrated cytofluorimetry.
[53] The maximum mean fluorescence value was set to 
100 % and all data points were normalized accordingly. 
Experiments were repeated 4 to 7 times and KD values 
were calculated with the GraphPad Prism Software 
(GraphPad Software Inc., San Diego, CA, USA) 
using a nonlinear regression curve fit. Cell-bound 
antibody-derivatives were detected using a Penta-His™ 
AlexaFluor488-conjugated antibody (QIAGEN, Hilden, 
Germany). The CD3-, CD4-, CD8-, CD19-, CD25-, 
CD33-, CD45RA-, CD45RO-, CD56- and CD69-specific 
monoclonal antibodies (mAbs) used for the analysis of 
lymphocyte and myeloid cell content and for the detailed 
analysis of relevant T cell subpopulations as well as the 
respective isotype control mAbs were from Immunotech 
(Marseille, France). Specific antibody binding capacity of 
cells from established B-ALL lines and primary leukemia 
blasts for CD3 (unconjugated mAb from ebioscience, 
Frankfurt, Germany), CD19 (unconjugated mAb from 
DAKO, Hamburg, Germany), and CD33 (unconjugated 
mAbs from BD Pharmingen, Heidelberg, Germany) was 
determined with a commercial calibrated cytofluorimetric 
assay (QIFIKIT®, DAKO, Hamburg, Germany) as 
described.[54, 55]
Cytotoxicity assay
To quantitate cell-mediated cytolysis (referred to as 
redirected lysis, RDL) induced by the BiTE or triplebody 
proteins, target cells were pre-labelled with Calcein AM 
(Life Technologies) and mixed with effector cells in RPMI 
1640 GlutaMAX medium supplemented with 10 % fetal 
calf serum at an E : T ratio of 10 : 1 unless otherwise 
stated. Either MNCs expanded ex vivo for 20 days and 
pre-stimulated with anti-CD3 mAb OKT3 and IL-2,[11, 
56] or untouched T cells isolated via magnetic separation, 
were used as effector cells. After addition of different 
antibody-derived proteins to 200 µL reaction volume in 
round-bottom 96-well plates, the reactions were incubated 
at 37 °C with 5 % CO2. Calcein release was determined by 
measuring the fluorescence intensity (relative light units, 
RLU) in the supernatant with a Berthold Mithras plate 
reader (Berthold technologies, Bad Wildbad, Germany). 
Maximum lysis was achieved by addition of 50 µL of a 
solution containing 10 % Triton X-100 in RPMI 1640 
GlutaMAX medium supplemented with 10 % fetal calf 
serum and 1 % Penicillin/Streptomycin. Specific lysis was 
calculated as follows:
% specific Lysis = 100*[RLU (sample) 
−  RLU (background)] / [RLU (maximal lysis) 
− RLU (background)]
T cell activation assay
Activation of resting T cells was determined by 
measurement of IFN-γ release and the expression of 
the early activation surface marker CD69 and the late 
activation marker CD25, the alpha-subunit of the high-
affinity receptor for interleukin-2 (IL-2R). Freshly 
isolated PBMCs from healthy unrelated donors remained 
either untouched, were depleted of CD19-positive cells 
by magnetic separation, or were mixed with SEM cells 
at an E : T ratio of 10 : 1. Triplebody was added at a 
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concentration of 1 nM to a 280 µL reaction mixture 
containing 1,4*10^5 PBMCs with or without 1.4*10^4 
SEMs in RPMI 1640 + GlutaMAX™ medium with 10 % 
FCS and 1 % Pen/Strep (Gibco®, Life Technologies™). 
After incubation for 0, 24, 48 and 72 hrs the total 
number of living cells in the reaction mixture was 
determined with a hemocytometer (Marienfeld Superior, 
Lauda-Königshofen, Germany) using Trypan Blue 
staining (Gibco®, Life Technologies™). The surviving 
cells were stained for CD3/CD19, CD3/CD25, CD3/
CD69 and CD3/CD45RO and the fraction of the relevant 
cell populations (CD19-positive targets, CD3-positive 
effectors, activated CD3-positive effectors and CD3 
CD45RO double-positive memory T cells) was assessed 
by flow cytometry. The fraction of depleted B cells, i.e. 
the differential removed by the depletion, was computed 
with the help of the following formula:
% depleted B cells = 100% *  (CD19+ cells control − 
CD19+ cells sample) / (CD19+ cells control)
Measurement of IFN-γ release into peripheral 
blood samples
Induction of cytokine release by immune effector 
cells due to the presence of the triplebody or BiTE 
control molecule was determined in whole blood assays. 
Triplebodies 19-3-19 or Her2-3-Her2 or the protein 19-3 
were added to 200 µL of peripheral blood in a round-
bottom Nunc™ 96-Microwell plate (ThermoFisher 
Scientific, MA, USA) at different concentrations and were 
incubated for 6 hrs at 37 °C with 5 % CO2. The samples 
were then diluted 1 : 1 with PBS and concentrations of 
IFN-γ were determined using commercial Ready-Set-Go 
ELISA kits (ebioscience, Frankfurt, Germany). Depending 
on sample availability, samples were run in duplicates or 
triplicates.
Statistical analysis
All statistical analyses were performed by GraphPad 
Prism Software (GraphPad Software Inc., San Diego, 
CA, USA) using Student’s t-test for the determination of 
significance, defined by p < 0.05.
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SUPPLEMENTARY TABLE
Supplementary Table S1. Computed protein characteristics of the T cell-engaging bispecific scFv 
molecules and triplebodies. Protein parameters calculated from the primary sequences of the engineered 
T cell-engaging BiTEs and triplebodies with the ProtParam (http://web.expasy.org/protparam/) and 
PeptideCutter (http://web.expasy.org/peptide_cutter/) tools[41].
Protein Length [aa]
MW 
[kDa]
ε
[M-1 
cm-1]
computed 
pI Construct
Relevant 
Proteinases
19-3 572 60.747 117,620 8.52
Chymotrypsin, 
Clostripain, 
Pepsin, Proline 
endopeptidase 
(4 sites), 
Trypsin
19-3-19 854 89.94 168,180 8.53
Chymotrypsin, 
Clostripain, 
Pepsin, Proline 
endopeptidase 
(5 sites), 
Trypsin
Her2-3 563 59.503 117,160 8.66
Chymotrypsin, 
Clostripain, 
Pepsin, Proline 
endopeptidase 
(4 sites), 
Trypsin
Her2-3-
Her2 834 87.249 167,260 8.71
Chymotrypsin, 
Clostripain, 
Pepsin, Proline 
endopeptidase 
(5 sites), 
Trypsin
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2.3.1 Summary 
 
In cancer patients, the leukocyte population is often functionally impaired or greatly reduced. It is 
difficult to take this parameter into account, when trying to predict whether an individual patient will 
benefit from an immunotherapeutic approach that relies on his autologous immune effector cells. 
Currently there are few methods available to monitor the cytolytic capacity of a patient’s NK or CTL 
population in conjunction with therapeutic agents: on the one hand chromium and calcein release 
assays have a limited reaction period and provide average cytolysis values at single time points, but 
no details on the cellular interactions. On the other hand imaging techniques provide a more detailed 
insight into the cytolytic reaction, but have a low throughput. Therefore a single-cell cytometry (SCC) 
assay, which allows the observer to follow the cellular lysis of individual targets at high throughput 
for at least 15 hours, was developed and is introduced in this publication. 
 
Active adhesion site arrays were prepared on microstructured hydrophobic surfaces of ibidi® channel 
slides and coated either with fibronectin for the adhesion of HEK 293.123 cells or with an anti-CD15 
IgM antibody (SSEA-1) to immobilize MOLM-13 target cells. Ex vivo expanded NK cells from a healthy 
donor and triplebody SPM-2 were then added at different concentrations and time-lapse imaging 
was performed at 12 minute intervals for a period of 16 hours. Target cell lysis was assessed by 
uptake of propidium iodide (PI) and the time of cell death was determined to be the time at which 
the slope of the increasing PI signal reached its maximum. 
 
The SCC method was compared to standard calcein release cytolysis assays with HEK 293.123 cells as 
targets. At an E : T ratio of 2 : 1 an isometric dose-response to increasing concentrations of SPM-2 
was observed in both methods. The EC50-values were comparable with 12.2 ± 0.1 pM in SCC and 
10.2 ± 8 pM in the calcein release assay, respectively. The maximum specific lysis observed via SCC 
(25 ± 1%) was lower than that observed via calcein release (48 ± 2%), which was attributed to the 
lower target cell density and cell surface accessibility in SCC. In addition to its dose-dependence on 
SPM-2, the extent of NK cell-mediated lysis also increased with increasing E : T ratios. Moreover, 
more than one NK cell attacked a single target cell at an E : T ratio of 5 : 1 as observed by SCC. 
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For the dynamic analysis of NK cell-cytolysis, a killing rate was defined, which is the number of lytic 
events (lysed/total target cells) in an hour. Interestingly, a massive killing rate was generally observed 
in the first hour that dropped significantly in the second hour. Then the killing rate displayed a slow 
increase over the next 5 to 10 hours and a subsequent gradual decrease. Presumably the initial high 
killing rate was due to previous stimulation of NK cells and the resultant high stores of lytic granules. 
After the first attack, the depleted stores had to be replenished for further lytic events to occur. This 
resulted in the steady increase of the killing rate during the replenishment phase. At later time points 
medium exhaustion, accumulation of cell debris and partial apoptosis of NK cells was responsible for 
the gradual decrease in killing rate. The magnitude and speed of increase of the killing rate were 
affected by the concentration of SPM-2. At the example of AML-M5a cell line MOLM-13 it was shown 
that SCC can also be adapted to suspension cells as targets. They were immobilized with a 
CD15-specific IgM antibody and a natural NK cell-mediated lysis of 2.6% was observed. 
 
In summary, the single-cell cytometry approach is reliable and suitable for the study of the dynamics 
and timing of cell-cell interactions and the influence of therapeutic agents. Therefore it may become 
a helpful technique to decide on optimal dosing and administration schedules for therapeutic agents 
and may be extended to biomarker assessment. SCC already has a low requirement for cellular 
material and may be further miniaturized and automated. Lastly, SCC is a suitable method to 
investigate the effect of therapeutic agents on cellular subset, for example the sensitivity of AML 
stem cells towards treatment with SPM-2 plus NK cells. 
 
 
2.3.2 Contribution 
 
I expanded peripheral blood mononuclear cells and isolated NK cells for single-cell cytometry. 
Furthermore, I performed the bulk assays (4 hour calcein release assay) for comparison with the SCC 
assays. I also helped with the interpretation of the results and reviewed the paper prior to 
submission. 
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Chip-based platform for dynamic analysis of NK
cell cytolysis mediated by a triplebody†
Elisavet I. Chatzopoulou,a Claudia C. Roskopf,b Farzad Sekhavati,a Todd A. Braciak,b
Nadja C. Fenn,c Karl-Peter Hopfner,c Fuat S. Oduncu,b Georg H. Feyd and
Joachim O. Rädler*a
Cancer therapy via redirected lysis mediated by antibodies and antibody-derived agents relies on the
availability of substantial numbers of sufficiently active immune effector cells. To monitor antitumor
responses before and during therapy, sensitive methods are needed, capable of quantitating specific lysis
of target cells. Here we present a chip-based single-cell cytometric assay, which uses adherent human
target cells arrayed in structured micro-fields. Using a fluorescent indicator of cell death and time-lapse
microscopy in an automated high-throughput mode, we measured specific target cell lysis by activated
human NK cells, mediated by the therapeutic single chain triplebody SPM-2 (33-16-123). This antibody-
derived tri-specific fusion protein carries binding sites for the myeloid antigens CD33 and CD123 and
recruits NK cells via a binding site for the Fc-receptor CD16. Specific lysis increased with increasing triple-
body concentration, and the single-cell assay was validated by direct comparison with a standard calcein-
release assay. The chip-based approach allowed measurement of lysis events over 16 hours (compared to
4 hours for the calcein assay) and required far smaller numbers of primary cells. In addition, dynamic pro-
perties inaccessible to conventional methods provide new details about the activation of cytolytic
effector cells by antibody-derived agents. Thus, the killing rate exhibited a dose-dependent maximum
during the reaction interval. In clinical applications ex vivo monitoring of NK activity of patient’s endogen-
ous cells will likely help to choose appropriate therapy, to detect impaired or recovered NK function, and
possibly to identify rare subsets of cancer cells with particular sensitivity to effector-cell mediated lysis.
Introduction
Several antibody-derived proteins used in cancer therapy func-
tion in conjunction with cytolytic effector cells, such as NK-
cells and cytotoxic T-cells (T-CTLs). Examples are the CD20
antibody Rituximab (Rituxan™) and the CD19-directed bi-
specific agent Blinatumomab (Blincyto™), as well as the bispecific
proteins AMG330 and MGD006, developed for the treatment of
Acute Myeloid Leukemia (AML;1–7). The cytolytic activity of
several therapeutic antibodies in the classic IgG format largely
depends on the Fcγ RIII-receptor CD16 present on NK-cells,
monocytes and macrophages,8–12 while the activity of the men-
tioned bispecific agents depends on T-CTLs. Therapeutic use
of these agents requires that the patient harbors the respective
effector cells in substantial numbers and in a sufficiently
active state. For AML originating in the bone marrow (BM),
this requirement is often not met during the early stages of
treatment. At diagnosis and during the first cycle of induction
therapy of AML patients, NK- and T- cells are usually reduced
by about 10- to 20-fold in numbers relative to a healthy BM,
and the remaining cells are functionally impaired.13–16 To
determine a suitable therapeutic agent and time point for the
start of treatment, it would therefore help, if investigators
could monitor the capacity of a patient’s NK- and/or T-cells to
mediate cancer cell lysis in conjunction with the therapeutic
agent. This requires the availability of reliable functional
assays permitting a quantitative assessment of the cytolytic
potential of a patient’s NK- and/or T-cells by using only small
numbers of these cells, which are available in limited supply.
Chromium-51 and Calcein-release assays have been used
extensively to measure cytotoxicity induced by therapeutic
agents.17,18 However, they cannot be used for reaction periods
in excess of approximately 4 hours due to increasing spon-
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5an02585k
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taneous release of the label from target cells.19 They also do
not provide further information regarding the intrinsic aspects
of the investigated cellular interaction. On the other hand,
imaging techniques traditionally offered a more detailed
insight into the interrogated phenomenon, however at low-
throughput. This led to the concomitant use of microscopy to
visualize processes that have previously been hypothesized
based on data averaged over large cell populations and
produced with the standard assays.20 Nevertheless, time-lapse
microscopy has evolved significantly over the past decade and
now permits us to follow the death of individual cells at high
throughput and for observation periods of up to 15 hours and
beyond.21 These newly developed microscopy-based approaches
have uncovered detailed features of NK physiology and their
innate ability to direct lysis of tumor cells, the “natural killing
mode of NK cells”. Furthermore, different types of NK cells have
been used in these studies, including both NK-cell lines and
primary NK cells activated by IL-2 as well as unstimulated NK
cells isolated from healthy donors. As a result, many different
approaches have been implemented to uncover new aspects of
the complex physiology of NK cells, such as the kinetics of their
natural killing mode22 and their “kinetic boosting” by Fc-engin-
eered antibodies.23 Moreover, the NK population was classified
based on migratory behavior and cytotoxic response of individ-
ual cells.24,25 Finally, altered NK cell cytotoxicity, migratory be-
havior and contact dynamics have been reported between IL-2
stimulated and non-stimulated NK cells.26
In oncology Antibody Dependent Cellular Cytotoxicity (ADCC)
makes use of antibodies to enhance the natural killing mode of
NK cells.27,28 This process more generally is called “redirected
lysis; RDL” when the mediator protein is not an antibody, but
an antibody-derived agent. Although unmodified antibodies in
the classic immunoglobulin (IgG) format have been successful
in the treatment of selected types of cancer, in particular of
hematologic malignancies, their broader use for the treatment
of solid tumors is limited. Antibody engineering has led to the
development of more broadly applicable derived proteins.29–32
Some of these new molecular formats no longer carry the full
antigen-binding-domains of classic IgGs (Fv-domains) but
employ antibody fragments, termed “single-chain Fragment vari-
ables (scFvs)”, as recognition domains. Bispecific tandem diabo-
dies are a class of recombinant fusion proteins based on scFv-
recognition domains, and Blinatumomab, the prototype of this
class of agents, is approved for the treatment of certain types of
lymphomas and leukemias.3,4 An extension of the molecular
format of tandem diabodies are the “single-chain tandem triple-
bodies” (“triplebodies” for simplicity), which carry two scFv reco-
gnition domains for target antigens on the cancer cell plus an
scFv module specific for a trigger molecule on an effector cell,
arranged in tandem in a single polypypeptide chain.33–35 They
can be designed to bind either two copies of the same target
antigen or one copy each of two different antigens on the
surface of the same cancer cell. The latter “dual-targeting” mode
of binding leads to an increased selectivity of cancer cells
bearing both antigens in high combined density.18,36 Triplebody
SPM-2 (33-16-123) was designed for the elimination of AML
cells. It carries one binding site for CD16 and two binding sites
for the tumor-antigens CD123 and CD33, present on AML
cells.16,34 Triplebodies can bind their target cells either mono-
valently with only one of the two target binding modules,
leaving the other module non-engaged, or bi-valently, employing
both target binding modules simultaneously.
Here we use single-cell cytometry (SCC) to assess the
efficiency of SPM-2-mediated killing of malignant target cells
by NK cells in a time-lapse mode. We use a design where
target cells are arranged in arrays of microstructured adhesion
sites, allowing for a facilitated assessment of the fraction of
cells specifically lysed by NK cells, which are added to the
assay. We recorded time-lapse movies over a period of
16 hours and followed the action of SPM-2 by the apoptosis
marker propidium iodide (PI). Our main objective was to
implement a single-cell assay for time-resolved studies of the
triplebody and NK cell-mediated lysis in accordance with exist-
ing standard assays. The platform presented herein facilitated
a dynamic analysis of the cytotoxic response of the NK cell
population triggered by the triplebody. As model target cells,
HEK293.123 cells were used. Our results open the possibility
for future use of the assay to study not only the quality of
primary effector cells from human donors, but also to study
mechanistic details of the mode of action of the therapeutic
agent on different subsets of target cells.
Results and discussion
To quantitate the extent of re-directed lysis of tumor cells by
NK cells mediated by the triplebody SPM-2, we developed a
single-cell assay based on fluorescence microscopy and micro-
structured arrays. Arrays of adhesion sites spaced by 60 µm
were fabricated as previously reported37,38 and further
described in the Methods section. The 60 μm spacing of the
adhesion sites was found to be the optimal distance for gener-
ating a single-cell array of the adherent HEK293.123 cells, after
having tested smaller and larger distances in preliminary tests
(data not shown). Triplebody SPM-2 (33-16-123) was syn-
thesized as previously described,16 following rearrangement,
humanization, and stabilization of the DNA sequences of an
earlier prototype of this agent.34 Target cells (the established
human cell line HEK293.123) were seeded on the microstruc-
tured topas surfaces using ibidi® channel slides. Fig. 1
illustrates the basic experimental imaging platform (Fig. 1A)
and a typical image of a HEK-cell array after addition of NK
cells (Fig. 1B). NK cells were derived from a healthy donor and
activated as previously described.18,39 Image acquisition
started immediately after NK cell addition. Images were
acquired in 12 min intervals over a time course of 16 hours.
The time-lapse sequences were analyzed using custom-made
image-analysis software integrating the fluorescence intensi-
ties from each individual adhesion site at each time-point.
We determined the fraction of specifically lysed cells
(% specific lysis), representing the incremental lysis mediated
by NK cells in the presence of the triplebody SPM-2 over the
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background of natural killing by NK cells alone according to
the formula given in Methods section. Lysed cells were
accounted for based on a threshold in the PI fluorescence
signal. Fig. 2 shows the percentage of lysed cells as a function
of triplebody dose. For clarity the percentage of total lysed
cells and the percentage of natural killing by NK-cells are
shown together with the calculated extent of specific lysis.
Dose-dependence measurements and comparison with calcein
release assay
Dose-dependence measurements were also performed with the
established calcein release assay (Fig. 2B). For these measure-
ments the effector-to-target cell (E : T) ratio was kept constant
at 2 : 1 and the concentration of the SPM-2 triplebody varied
from 0–100 nM for the SCC assay and from 0–10 nM for the
calcein release assay. As effector cells immunomagnetically
(MACS) purified pre-stimulated NK cells from the same
healthy donor were used. The average percentage of NK cells
(CD56brightCD16bright) after the MACS purification was 83.3% ±
4.6%. This percentage was taken into account in order to
achieve an actual NK-to-target ratio of 2 : 1 as mentioned
above. The total number of target cells analyzed in this set of
measurements is given in Table 1. Over a 16 hour measure-
ment period, a maximum of about 35% of the cells analyzed
were lysed in the SSC assay in the presence of triplebody
SPM-2 (Fig. 2A, red open bars). The fraction of specifically
Fig. 1 Experimental set-up of the single-cell cytometry (SCC) assay.
Chemically modified patterned surfaces (arrays) were prepared on
6-channel microscope slides (A). Protein-coated arrays were generated
by plasma-induced patterning. (B): Squares with a side-length of 30 μm
were coated with fibronectin (here fibronectin labeled with Alexa Fluor
488) and the backfilling (black) area with PLL(20k)-g(3.5)-PEG(2k) (PEG
(2)). Each channel on the carrier surface, shown in (A), contained 4400
adhesive squares for cell attachment. In (B) a part of an overview micro-
scopic scan of one coated channel of the slide is shown. (C): Arrays of
adherent HEK293.123 target cells were prepared on the chemically
modified surfaces (surfaces seeded with cells have adhesive squares
with unlabeled fibronectin). NK cells were added and squares occupied
by single target cells (framed in blue) were selected and tracked in a
time-lapse mode. NK cells were identified cinematographically by their
size and motility. The distance between the squares was 60 μm in our
experiments, but arrays with different spacing can be produced. (D): The
cell-impermeable red fluorescent marker PI (propidium iodide) was
used to identify dead cells. Overlay of brightfield and PI emission is pre-
sented for the first and last frame of a measurement. (E): The mean fluo-
rescence intensity of 40 cells over time is plotted (in the presence of 10
nM SPM-2 triplebody). Each track (“fate plot”) represents the fluo-
rescence intensity of one cell in the PI channel. Tracks exceeding an
intensity threshold (defined by a supervised selection process as
described under Methods) represent lysed cells. Two exemplary time-
courses of two target cells that were lysed are highlighted in red.
Fig. 2 Validation of the SCC assay by direct comparison with the bulk
assay. A: Data obtained with the SCC assay. Red open bars: percentage
of dead target cells relative to the total number of target cells analyzed
(“overall lysis”). Red filled bars: percentage of specific lysis induced by
SPM-2 after subtraction of natural killing by NK cells alone (the numbers
shown for 0 nM concentration). Black open bars: overall lysis produced
by addition of control triplebody SPM-1 (19-16-19), a triplebody in the
same molecular format as SPM-2, but recognizing the target antigen
CD19, which is absent from HEK293.123 cells. This control was not per-
formed for 50 and 100 nM concentrations of the control protein.
Medium control: without added NK cells and triplebodies; this control
measures the extent of spontaneous death of target cells over the
measurement interval. The averaged value of all the dose-dependent
measurements is shown. (B) Comparison of data obtained with the SCC
assay (red circles) over a 16 hour measurement and the bulk assay
(calcein release assay; blue circles) over a 4 hour period. Data points of
the calcein assay represent the mean value of the percentage of specific
lysis averaged over triplicate reaction wells on the same microtiter plate,
and error bars represent the SEM (standard error of the mean). Effector
cells were MACS-purified NK cells from a healthy donor, pre-stimulated
with IL-2 (LAK cells), and seeded at an E : T ratio of 2 : 1.
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lysed cells (% specific lysis) steadily increased with triplebody
concentration and reached a plateau at about 25% for concen-
trations from 1 nM upwards (Fig. 2A, red bars). As a negative
control the triplebody SPM-1 (19-16-19) was used, a protein in
the same molecular format as SPM-2 and carrying the same
scFv binding site for CD16, but with specificity for the target
antigen CD19, which is absent from the surface of
HEK293.123 cells. In separate experiments with CD19-positive
target cells this control triplebody mediated cytolysis by NK
cells,33 but it did not produce specific lysis of HEK293.123
targets in the SCC assay (Fig. 2A, black open bars). The fraction
of specific lysis induced by SPM-2 showed comparable dose-
dependence in the SSC and the calcein-release assays (Fig. 2B).
In both cases specific lysis reached plateau values for concen-
trations from 1 nM upwards, and the shape of the curves was
similar (isometric). The EC50 values (half-maximum effector
concentrations; the concentrations, at which half of the
maximum lysis was reached) derived from both curves were
(10.2 ± 8.0) and (12.2 ± 0.1) pM for the calcein and the SCC
assays, respectively. The errors represent the standard devi-
ation computed by statistical modeling of the two assays (see
Methods section). While the EC50 values derived from both
data sets were very similar, the maximum fractions of specifi-
cally lysed cells were (48 ± 2)% for the calcein assay and (25 ±
1)% for the SCC assay. This difference most likely is explained
by the fact that in the calcein assay both effector and target
cells were present in the fluid phase, whereas in the SSC assay
the targets were anchored to the substrate and were therefore
less accessible to the effector cells. In addition, in the SCC
assay the density of cells per unit volume was less than half of
the density reached in the calcein assay. However, this quanti-
tative difference in the maximum levels of specific lysis
recorded with both assays does not affect the key conclusion
that the SSC assay is validated by this comparison, as it cap-
tured the dose-dependence of the triplebody’s lytic potential
in the same qualitative manner as the calcein assay.
Dependence of the extent of cytolysis on the E : T ratio
Next we measured the efficiency of lysis as a function of the
effector-to-target cell (E : T) ratio (Fig. 3). For measurements of
the dependence of this variable on the E : T ratio, the concen-
tration of the SPM-2 triplebody was kept constant at 1 nM,
while the E : T ratios tested were 0.2 : 1, 1 : 1, 2 : 1 and 5 : 1. The
total number of target cells analyzed in this set of measure-
ments is given in Table 2. The effector cells used were MACS-
purified NK cells. The mean final percentage of the NK cells
(CD56brightCD16bright) after the enrichment was 90.2% ± 3.0%.
This percentage was taken into account in order to reach the
actual NK to target cell ratio for each of the conditions men-
tioned above. The specifically lysed fraction increased as a func-
tion of the E : T ratio (Fig. 3). When the number of effector cells
increased the probability for cell encounters increased too,
explaining the increase in lytic events. Furthermore, in the case
of the E : T = 5 : 1 the number of effector cells attacking one
single target cell was also increased. In this case, we observed
that more than one effector cells were able to form a synapse
with one specific target cell at the same time. The maximum
extent of specific lysis was achieved at the E : T = 5 : 1 condition.
Dynamic analysis of the lytic events
The automated SCC assay allowed us to monitor cellular lysis
over a long period of time with high numeric precision. Focus-
ing on the target cells enabled us to track the activity of the NK
cell population, regarding their cytotoxic activity and how the
SPM-2 agent affected it. In the following, we quantified the
killing rate i.e. the number of lytic events that occurred per
hour. This percentage corresponds to the number of lysed
cells versus the total number of target cells analyzed. In
Table 1 Total number of target cells analyzed in dose-dependence
measurements
nM SPM-2 Control triplebody
0 3099 465
0.01 1648 303
0.1 1888 507
1 3482 524
10 3254 344
50 1528 —
100 1364 —
Medium 3075 489
Fig. 3 Dependence of specific lysis measured with the SCC assay on
the E : T ratio. Lysis induced over a range of different Effector to Target
(E : T) cell ratios by SPM-2 at a 1 nM saturating concentration. Data
points are fitted to an exponential curve. Effector cells were MACS-
purified NK cells from a healthy donor, pre-stimulated with IL-2 (LAK
cells).
Table 2 Total number of target cells analyzed in measurements of the
dependence on the E : T ratio
E : T 1 nM 0 nM
0.2 : 1 1061 1300
1 : 1 992 815
2 : 1 3482 744
5 : 1 1309 867
Medium 1909 1909
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Fig. 4B, the mean fluorescence intensity of 3 arbitrary single
target cells is illustrated, while for one of these cells the corres-
ponding time-lapse frames of selected time points are pre-
sented (Fig. 4A). We determined the individual time points of
target cell lysis using the maximum slope of the fluorescence
signal increase as an indicator. From such data, the cumulat-
ive percentage of lysed cells was computed and plotted for 3
different concentrations of SPM-2: 0, 1 and 100 nM (Fig. 4C).
The variation of the killing rate over the course of 16 hours for
various SPM-2 concentrations and for constant numbers of NK
cells is plotted in Fig. 4D. For comparison, the first plot shows
the rate of background lysis rate in the absence of NK cells and
the SPM-2 agent (labeled “medium”). When the SPM-2 agent
was absent or present in low concentration, the killing rate of
the NK cells was almost constant, 0.5 ± 0.2 target cells were
killed per hour at 0 nM and 1.3 ± 0.5 at 0.01 nM (Fig. 4D, 2nd
and 3rd panel from the left). The killing rate increased until a
maximum was reached after several hours into the measure-
ment and then gradually decreased. The maximum rate was
greater for higher concentrations of SPM-2 (50 and 100 nM;
last 2 panels to the right in Fig. 4D) than for intermediate con-
centrations (0.1 to 10 nM; central panels in Fig. 4D), and there-
fore, the agent clearly influenced the maximum killing rate of
the NK cells. The maximum rate also occurred earlier at high
concentrations of the agent than at lower concentrations
(Fig. 4D; 2 panels at right). Importantly, the rates of lysis were
elevated in the 1st hour of the reaction (highlighted in yellow
in Fig. 4D) and dropped strongly in the 2nd hour for all tested
Fig. 4 Dynamic analysis of lytic events with the SCC assay. (A) Time-lapse images of an exemplary target cell being killed by an NK cell (arrow). The
progressively increased PI fluorescence intensity reflects progressive nuclear membrane disintegration (irreversible apoptosis). (B) PI fluorescence
intensity of 3 exemplary target cells over the course of 16 hours, including the cell shown in (A) (red curve). Raw intensities were fitted with the Hill
Equation. (C) Cumulative percentage of lysed target cells for 3 different concentrations of SPM-2: 0, 1 and 100 nM. Data points were fitted with the
sigmoid function. (D) Killing rate as a function of time for increasing concentrations of SPM-2 by a constant number of NK cells. The left panel
(“medium”) shows the dynamic of spontaneous cell death events, in the absence of NK cells. Data points were fitted with a log normal distribution
curve. Data points for the first hour of the reaction (highlighted in yellow) represent natural killing by the NK cells but not specific lysis mediated by
the triplebody. These events also occurred in the absence of added triplebody (2nd panel from the left), and were therefore excluded from the
fitting.
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concentrations of the mediator protein, even without added
mediator protein (Fig. 4D, 2nd panel from the left). Thereafter
the rates increased until maximum rates were reached between
5–10 hours into the reaction, and then the rates declined
again. The log normal distribution was fitted to the data
points. In all cases, the first data point, indicated in the yellow
region (Fig. 4D) was excluded from the fitting, because it con-
sistently was an outlier. We explain this excessively high lytic
rate as being probably owed to the previous stimulation of the
NK cells by long-term culture in the presence of IL-2.
NK cells are “ready-to-kill” cells and the most common way
to kill is through perforin/granzyme granule-mediated exocyto-
sis.40 In this study, LAK (Lymphokine Activated Killer cells) NK
cells, pre-stimulated with IL-2 from a healthy donor, were
used. These cells exhibit greater cytotoxicity due to increased
intracellular concentrations of effector molecules such as per-
forin and granzymes.41 They form a synapse with the target
cell and then degranulation occurs which leads to apoptotic
death of the target. At the beginning of the measurement the
cytosol of the NK cells is full of granzymes, which then degra-
nulate to lyse the large number of target cells at the beginning
of the measurement. These distinctly large killing rates during
the first hour of the measurement were further boosted by the
triplebody in a dose-dependent manner. Subsequently, the NK
cells were exhausted and gradually resumed their cytotoxic
activity by producing again new granzymes. The triplebody
played a role in the early hours of the reaction interval, either
in the replenishment process or the subsequent lytic events or
both, because the maximum rates of lysis were clearly augmen-
ted by the triplebody in a dose-dependent manner (Fig. 4D).
The observed increase in lytic rates with time suggests an
influence of the triplebody on the speed of replenishment or
on other metabolic processes preparing the NK cell for the
next degranulation event and on an acceleration of the
cadence of lytic bursts. Furthermore, the initial increases in
the rate during the first few hours of the reaction may also be a
consequence of the lytic events themselves; either the NK cells
or the targets or both may have released soluble mediators (e.g.
cytokines and others) which favored the lytic process in a posi-
tive feedback manner (a paracrine loop). At the same time, the
medium was progressively exhausted and cellular debris from
dead target and effector cells accumulated, which must have
inhibited the lytic activity. The system was a closed system in
our set-up and the medium was not renewed. Therefore, these
inhibitory influences eventually may have outpaced the positive
feedback mechanisms, an optimum was passed, and beyond
this point the reaction rates began to decline. Moreover, it has
been previously shown42 that NK cells isolated from healthy
donors and stimulated with IL-2 do not have a uniform cyto-
toxic activity. In essence a small subset of the NK cells are
responsible for the majority of kills. Finally, taking into con-
sideration that tumor cells can also induce the apoptosis of IL-2
activated NK cells43,44 we propose that the decrease of the reac-
tion rates after a certain time point most likely was due to a
partial apoptosis of the active cytotoxic subpopulation in combi-
nation with the exhaustion of the medium.
Natural killing dynamic analysis against non-adherent AML
target cells
Many samples of primary cancer cells, especially those derived
from hematologic malignacies, consist of non-adherent cells. To
address this matter and to render the proposed assay suitable
for non-adherent cells we developed a second version of the
chip, in which the patterns of squares covered with fibronectin
were replaced by squares covered with an antibody of IgM
isotype. To test this variant of our assay, we measured the
natural killing potency of primary NK cells from another healthy
donor for the human AML-derived target cell line MOLM-13.
A suitable antibody candidate for anchoring MOLM-13 cells
to the micro-patterns, without interfering with the NK cells, is
a CD15-specific antibody. The myeloid marker CD15 is present
on the surface of the MOLM-13 cells45 but not on the primary
NK cells (Fig. S1†). Both IgG1- and IgM-types were tested and
MOLM-13 cell arrays of greater occupancy and greater stability
for longer periods of time (up to 24 h) were achieved with the
IgM antibody, probably due to more favorable stereochemical
properties of the IgM relative to the IgG1 isotype. Patterns of
squares with 25 μm side-length were used for the MOLM-13
cell line, because these cells were smaller than the adherent
HEK-cells used so far. As a result, smaller square patterns led to
a greater percentage of single-cell occupied patterns. Even
though we could have chosen smaller distances between the
squares for the non-adherent MOLM-13 cells, we chose to main-
tain the 60 μm for better comparability with the measurements
of the adherent target cells and to avoid introducing a new vari-
able into the experimental setup. An array of MOLM-13 cells in
the presence of NK cells is shown in Fig. 5A. Size and mor-
phology of MOLM-13 and NK cells are very similar, therefore
MOLM-13 cells were stained with fluorescent tracker dye Green
CMFDA to permit the distinction from the NK cells.
To test this version of the assay for non-adherent cells we
measured the natural killing of MOLM-13 targets by NK cells
alone without addition of a mediating protein. For the measure-
ments with the non-adherent cells, NK cells were derived from
a second healthy donor and activated by long-term culture in
the presence of IL-2 as previously described.18,39 Preparation of
the samples, image acquisition and analysis were performed as
described for the measurements with the adherent HEK293.123
cells. The E : T ratio was 2 : 1 and after a 16 hour measurements
period 2.6% of the cells analyzed (Table 3) were lysed (Fig. 5C).
This percentage was lower than the average natural killing
observed for the NK cells from the first donor at the same E : T
ratio (8.4%) (Fig. 2A), which probably reflects donor-to-donor
variability and the different types of target cells used. Time-
lapse frames of an NK cell progressively killing a MOLM-13 cell
are presented in Fig. 5B. The variation of the killing rate over
Table 3 Total number of target cells analyzed in measurements with
the non-adherent cells
E : T = 2 : 1 Medium
1775 2276
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the course of 16 hours for the natural killing of the NK cells
measured is presented in Fig. 5D. A slightly greater killing rate
during the 1st hour was also observed in this case and probably
reflects the preceding stimulation of the NK cells with IL-2 as
was discussed above.
Compared with existing methods, single-cell cytometry
allows for time-resolved studies of NK cell activity. Chromium-
51 and calcein release assays offer a statistically valid measure-
ment of cytotoxity, but they are restricted in duration due to
spontaneous release of the label, and they produce time- and
population-averaged data. Flow cytometry and ELISPOT assays
offer single-cell data for large number of cells, but also only
for at a single time point. Moreover, they measure cytotoxicity
in an indirect manner, as with flow cytometry usually target
cells that have survived are counted, while in ELISPOT assays
usually IFN-γ secretion or degranulation of the effector cells is
measured.46,47 The SCC assay presented here fills the gap
between these two different approaches of measuring cytotoxi-
city. SCC is capable of following the progression of NK cyto-
toxic activity over an extended duration of 16 hours. Due to
spatial ordering of the target cells, image analysis is feasible
with limited computational means generating data that
contain full information on the time course of killing events
relevant to therapeutic applications.
To better understand the mode of action of novel therapeutics
based on the recruitment of effector cells and the functional pro-
perties of the effector cells involved, it is essential to have the
ability to study also the dynamics of these processes. Additional
studies will likely produce suggestions for optimal dosing and
administration schedules in clinical applications. Time-lapse
methods are promising in this regard, since meta-analysis can be
extended to the use of additional markers including biomarkers
of therapy success, disease progression and impending relapse,
and because they lend themselves to further automatization.
An additional advantage of single cell assays is that they
generate reliable data with substantially smaller numbers of
effector cells. For an SCC assay typically only 2 × 104 NK cells
are needed per measurement point, 5-times fewer than the
>105 cells needed for each measurement point in a calcein
release assay. Patient-derived NK cells are a scarce resource, in
particular to monitor disease status and therapy outcome for
AML patients. Further miniaturization of the new method is
Fig. 5 Variation of the SCC assay adapted to non-adherent target cells. Arrays of antibody coated square patterns were generated with the same
procedure as the fibronectin arrays, by substituting fibronectin with an anti-human CD15 antibody. Arrays of stained MOLM-13 cells (CellTracker™
Green CMFDA) were prepared on the chemically modified surfaces and then NK cells (unstained) were added (A). (B) Time-lapse images of an
exemplary MOLM-13 target cell (green) being killed by an NK cell (unstained). The progressively increased PI fluorescence intensity reflects progress-
ive nuclear membrane disintegration (irreversible apoptosis). (C) Data obtained with the SCC assay showing the natural killing potency of NK cells
against MOLM-13 cells. The bars represent the percentage of dead target cells relative to the total number of target cells analyzed. (D) Dynamic ana-
lysis of the natural killing mode of NK cells against the MOLM-13 target cells. The right panel (“medium”) shows the dynamic of spontaneous cell
death events, in the absence of NK cells.
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possible, so that reliable measurements will likely become
possible with as few as 5000–10 000 NK cells. Furthermore, pat-
terned arrays provide uniform micro-environments and
spacing of target cells and hence potentially improve the stan-
dardization of cell–cell encounters. Hence, chip-based single
cell assays are potentially valuable for clinical monitoring of
the patients NK response and for the choice of personalized
treatment for individual AML patients. They can also be
applied to T-CTL as effector cells in combination with corres-
ponding triplebodies and with other antibody-derived proteins
recruiting T-cells as cytolytic effectors.4–7,48
Assays employing spatially arrayed target cells can also be
useful to study questions regarding the timing in cell–cell reco-
gnition and immune response, such as for example the
“memory” effect described for NK cells.22 In the experiments
presented here the full potential of the dual-targeting triple-
body SPM-2 has not yet been analyzed. Here we have so far only
used the CD123-binding site of this agent. In the future the
effect of simultaneous engagement of both binding sites by
one copy each of CD33 and CD123 on the lytic activity of NK
cells can be studied. Dual-targeting renders the SPM-2 agent
particularly promising for the therapy of AML because virtually
all patients expressed either one or the other of the two anti-
gens.49 Indeed, in cell culture cytolysis assays with primary
cells from a broad range of AML patients with different sub-
types of AML and with a standard batch of NK cells from an
unrelated healthy donor, all samples showed very effective
lysis.50 This is an unusually high degree of responsiveness, con-
sidering that the response rate to the best antibody-derived
agent available so far for the treatment of AML (Mylotarg™ 51)
was in the range of 40% for blasts from patients with different
subtypes of AML.52 Even blasts from patients with AML sub-
types that typically show a poor response to conventional
chemotherapy were lysed efficiently by SPM-2 plus NK cells.50
Moreover, the pair of CD33 plus CD123 is highly expressed on
AML leukemia stem cells (AML-LSCs) but far less on normal
hematopoietic stem cells (HSCs;52–54). Therefore, a therapeutic
window appears to exist, which may permit a preferential elim-
ination of the AML-LSCs over the normal HSCs of the patient
and a reconstitution of the patient’s hematopoietic system after
the end of therapy from the patient’s own HSCs, without the
need for an allogeneic or autologous stem cell transplantation.
If this could be achieved in the future, then this result would
constitute major progress in the therapy of AML. Therefore, in
the future it is important to study in detail not only how a
patient’s autologous NK cells in conjunction with this agent
lyse the patient’s bulk AML blasts, but also whether and how
they lyse subsets of blasts progressively closer and closer to the
leukemia initiating cells (LICs) and relapse initiating MRD
cells, which are likely to be encompassed in the CD34posCD38-
negCD123high compartment of BM and peripheral blood cells,
which comprises between 0.01 and 67% of all malignant cells
for different AML patients.55 To this end cytolysis assays with
rare subsets of patient-derived AML cells and NK- or T cells are
required, which will be available in small numbers only.
Finally, agents targeting the same pair of antigens, but recruit-
ing T-cells as cytolytic effectors are also under development,56
and similar experiments as those outlined above will also need
to be performed with the corresponding T-cell-recruiting
agents in order to find the best suited agent for individual
patients in the sense of a personalized medicine. Develop-
ments are well under way that personalized medicine will
clearly become more prevalent in the future. Time-resolved
SSC assays are promising means to further investigate the
capabilities of Fc engineered antibodies and other bi- and tri-
specific antibody-derived agents such as the triplebodies
described here for enhanced target cell lysis. They therefore
offer the potential to assist treatment decisions and monitor-
ing of treatment success in cancer therapy.
Experimental
Cell culture
Human Embryonic Kindey 293 cells (HEK 293), obtained from
the American Type Cell Culture Collection (ATCC, Manassas,
VA, USA), were transfected with cDNA expression constructs for
human CD123 and sublines were selected, which stably
expressed CD123 over many passages in culture. The subline
employed here has been in culture for several years and stably
expresses approx. 360 000 copies of CD123 per cell on the
surface.57 It was cultured in RPMI 1640 medium (Biochrom;
Merck Millipore, Berlin, Germany) supplemented with 10%
(vol/vol) Fetal Bovine Serum (FBS; Gibco®, Life Technologies
GmbH, Darmstadt, Germany) and 400 μg ml−1 Geneticin Selec-
tive Antibiotic G418 Sulfate (Roth, Karlsruhe, Germany).
MOLM-13 cells were cultured in RPMI 1640 medium sup-
plemented with 10% (vol/vol) FBS.
Ex vivo expansion of MNCs from healthy donors in the
presence of IL-2 and immunomagnetic enrichment of NK cells
Mononuclear cells (MNCs) from peripheral blood (PBMCs)
were expanded ex vivo in RPMI medium containing Inter-
leukin-2 (IL-2) plus 5% (vol/vol) human serum (Life Technologies)
for 20 days as described18,39 and were then frozen in aliquots
for subsequent use. Prior to use in cytolysis experiments, the
cells were thawed and cultured overnight in RPMI medium con-
taining 5% (vol/vol) human serum plus 50 units per ml of peni-
cillin and 50 μg ml−1 of streptomycin (PS; Life Technologies)
respectively, but no additional IL-2. NK cells were then enriched
by negative selection using the human NK Cell Isolation Kit
(Miltenyi Biotec; Cat. No. 130-092-657; Bergisch Gladbach,
Germany) according to the provider’s instructions. The enriched
batches contained 83–90% of CD56bright CD16bright NK cells.
Surface patterning
Protein-coated arrays were prepared on polymer coverslips for
6-channel sticky slides (ibidi GmbH, Munich, Germany). First,
coverslips were treated selectively with oxygen plasma (40 W
for 3 min; Femto, Diener Electronic GmbH+Co. KG, Ebhausen,
Germany). Selectivity was achieved using a polydimethyl-
siloxane (PDMS) stamp (cast from a master produced by photo-
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lithography) as a mask. The area exposed to plasma was passi-
vated with PLL(20k)-g(3.5)-PEG(2k) (SuSoS AG; Dübendorf,
Switzerland) at 1 mg ml−1 in aqueous buffer (10 mM HEPES
pH 7.4 and 150 mM NaCl). Then the PDMS stamp was
removed and the remaining hydrophobic areas (squares 30 ×
30 μm) were exposed to fibronectin (50 μg ml−1; YO Proteins
AB, Huddinge, Sweden) for 1 hour. Finally, channels were
rinsed thoroughly with PBS and the slides were stored at 4 °C
for a maximum of 5 days. Before cell seeding, PBS was
exchanged with culture medium (RPMI with 10% (vol/vol) FBS)
and kept for 1 hour at 37 °C.
The same procedure was followed for the antibody-coated
arrays with the following alterations: arrays were prepared on
uncoated 8-well μ-slides (ibidi GmbH, Munich, Germany). After
treatment with plasma, the PDMS stamp was removed and the
remaining hydrophobic areas (squares 25 × 25 μm) were exposed
to purified anti-human CD15 (SSEA-1) antibody (15 μg ml−1; Bio-
Legend®, San Diego, CA USA) for 1 hour at room temperature.
Time-resolved fluorescence microscopy
Sample preparation. For the fluorescence microscopy
measurements 6-channel/8-well slides were used (ibidi GmbH)
with protein-coated arrays. HEK293.123 cells were added to the
channels (10 000 cells per channel) and incubated at 37 °C, in
culture medium for approx. 4 hours, until the cells were de-
posited in an array. MOLM-13 cells were stained in 1 μM Cell-
Tracker™ Green CMFDA dye (Thermo Fischer Scientific,
Waltham, MA USA) for 15 min in serum-free media in 37 °C,
followed by 1 h of recovery in complete media. Then stained
cells were seeded into the wells (10 000 cells per well), and
after 2 hours the culture medium was exchanged to Leibovitz’s
L15 medium with GlutaMAX (Gibco®, Life Technologies) sup-
plemented with 10% (vol/vol) FBS. Meanwhile, final solutions
with the appropriate number of MACS enriched NK cells and
the desired concentration of the SPM-2 triplebody or control
agents were prepared and added to the channels/wells. A
trypan blue exclusion test of the NK cells was performed
immediately before the preparation of the final solutions.
Imaging was performed under an inverted Nikon Ti eclipse
microscope with a motorized stage, a Plan Apochromat 4×/0.2
N.A. objective, an Andor Clara-E camera, and a Lumencor
SOLA LED lamp. For detection of PI fluorescence a filter cube
with 540/25 nm (excitation) and 630/60 nm (emission) filters
was used. For the stained MOLM-13 cells a filter cube with
470/40 nm (excitation) and 525/50 nm (emission) filters was
used. Images were taken with constant exposure times of 10
and 300 ms in the brightfield and the PI/Green CMFDA chan-
nels respectively at 12 min intervals for 16 hours. A pre-deter-
mined X–Y position list was used for the automated time-lapse
recording of 84 positions for each measurement. During the
recording samples were kept at a constant temperature of
37 °C using an ibidi heating system (ibidi GmbH).
Image and data analysis
Raw images were pre-processed with ImageJ (http://imagej.nih.
gov/ij/). Using an in-house plugin, Microwell Analysis, an
orthogonal grid was aligned over cells and single-cell occupied
grid positions were selected. The mean intensities over the
selected positions of the grid were extracted and exported to a
data file. Custom Matlab scripts (MATLAB version R2014b
Natick, Massachusetts: The MathWorks Inc., 2014) were
employed to quantify the number of dead target cells and to
find their lysis time-points based on the maximum slope of
the signal increase in the PI channel. In the representative set
of data, a threshold was chosen as a maximum value that can
separate the weakest signal of a dead target cell from the back-
ground signals e.g. from healthy cells. Further analysis con-
firmed that the threshold was at least 4 times higher than the
background fluorescence intensity of the healthy cells in the PI
channel. Specific lysis was calculated as:
Redirected lysis (RDL) assays using calcein release
Target cells HEK293.123 were pre-labeled with Calcein AM
(Life Technologies) and mixed with MACS-purified NK cells in
RPMI 1640 GlutaMAX medium supplemented with 10% (vol/
vol) FBS at E : T = 2 : 1. SPM-2 triplebody was added at the
desired concentration to a 200 μL reaction volume in round-
bottom 96-well plates. Reactions were incubated at 37 °C with
5% CO2 for 4 hours. Calcein release was quantitated by
measuring the fluorescence intensity (relative light units, RLU)
in the supernatant using a fluorimeter/ELISA plate reader at
485/535 nm. Maximum lysis was achieved by addition of 50 μL
of a solution containing 10% Triton X-100 in RPMI 1640 Gluta-
MAX medium supplemented with 10% (vol/vol) FBS and 1%
(vol/vol) PS. Specific cellular cytotoxicity was expressed as
overall lysis minus the background of spontaneous lysis
mediated by the NK cells alone, in the absence of added anti-
body-reagents. Specific lysis was evaluated by the formula:
specific lysis% ¼ RLUðsampleÞ  RLUðbackgroundÞ
RLUðmaximum lysisÞ  RLUðbackgroundÞ
 
 100%
Statistical analysis
In the case of the single-cell cytometry (SCC) assay we
hypothesized that data follow the binomial distribution and
error bars were calculated with a confidence level of 95%.
Statistical modeling of the calcein assay and single cell assay
results
Statistical modeling of the single cell assay. Five different
conditions were interrogated (0, 0.01, 0.1, 1, and 10 nM). For
every condition we considered the number of dead cells and
specific lysis% ¼ fraction lysedwith SPM2 fraction lysedwithout SPM2
total cells spontaneous cell deaths
 
 100%
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the number of cells in total. The problem at hand was to calcu-
late the EC50 and its confidence interval of the dose response
curve with measurements in these 5 conditions/concen-
trations. The concentrations correspond to the independent
variable, and the ratio of dead cells/total cells corresponds to
the response variable of the model (curve). From here on the
log10 of the concentrations was used.
We hypothesized that the killing events in every condition
can be modeled using a binomial distribution. The metrics of
the binomial distributions were calculated using the binofit()
function in Matlab. Then, these binomial distributions were
sampled with replacement to generate 1000 random measure-
ments (in terms of dead cells) per condition (concentration).
From this random sampled number of dead cells we sub-
tracted the number of dead cells observed for the 0 nM con-
dition and divided by the corresponding number of total cells,
having subtracted the number of spontaneous cell death
events. This number corresponds to the specific killing ratio.
Dose response curves in the form of a sigmoid curve were
fitted for every set of random killing ratios, yielding 1000
random sampled dose response curves. The fit of the sigmoid
curves was performed using the nlinfit() function in Matlab.
From the sigmoid curves the parameters corresponding to the
EC50 values were extracted and averaged across all 1000
random samplings yielding a mean value and a standard
deviation.
Statistical modeling of the calcein assay. Here, we con-
sidered the specific lysis ratio measured directly using the
calcein assay. The mean specific lysis ratios and corresponding
standard deviations for the 5 conditions discussed above were
used as an input to this analysis. We hypothesized that the
lysis ratios in every condition can be modeled by using a
normal distribution. We used these distributions in similar
fashion as above to generate random measurements in terms
of lysis ratios for every condition and to fit sigmoid curves to
model dose response. From the sigmoid curves the terms
corresponding to the EC50 were extracted and averaged across
all random samplings to yield a mean and a standard
deviation.
Conclusions
Single cell arrays combined with time-resolved fluorescence
microscopy were used to study the interaction of primary
human NK cells with human target cells mediated by triple-
body SPM-2, an antibody-derived protein, which recruits NK
cells for target cell lysis. The arrayed pattern of target cells
allowed for highly efficient and automated counting of lytic
events under standardized conditions. Lysis depended on the
dose of the agent and the E : T ratio in a manner typical for
standard cytolysis assays, and therefore this new assay was vali-
dated relative to existing standard procedures (calcein release
assay). Use of the new SCC assay revealed so far unreported
changes in the killing rate over long-term reaction periods
(16 hours). Finally, a variation of the assay employing surface-
coated antibodies demonstrated the feasibility to array non-
adherent target cells in the chip-based single-cell cytometric
assay. The proposed platform facilitates testing the suscepti-
bility of many tumor-derived cell types to lysis by NK cells with
or without an added mediator protein and can become a
useful tool for the design of personalized therapies.
Disclosure of potential conflict of
interest
The authors declare no conflict of interest.
Acknowledgements
Financial support by the Deutsche Forschungsgemeinschaft
within the Excellence Graduate School Quantitative Bio-
Sciences (QBM) and the program project grant (Sonder-
forschungsbereich) SFB 1032 (project B01) is gratefully
acknowledged. Drs. Oduncu, Hopfner and Fey were funded by
an M4 Excellence Award for Personalized Medicine from the
Bavarian Ministry for Trade and the Economy. We thank Dr.
Christoph Stein, Fraunhofer Institute, Aachen, Germany, for
the kind gift of the HEK293.123 cell line. We are grateful to
Max Albert for wafer and chip fabrication, and to Peter J. Rött-
germann for microscopic pictures of the fibronectin-coated
arrays.
References
1 L. Weiner, J. Murray and C. Shuptrine, Cell, 2012, 148,
1081–1084.
2 P. McLaughlin, A. J. Grillo-López, B. K. Link, R. Levy,
M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-
Bruckler, C. A. White, F. Cabanillas, V. Jain, A. D. Ho,
J. Lister, K. Wey, D. Shen and B. K. Dallaire, J. Clin. Oncol.,
1998, 16, 2825–2833.
3 T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann,
U. Syring, F. Hanakam, P. Kufer, G. Riethmuller, R. Bargou
and P. A. Baeuerle, Int. J. Cancer, 2002, 100, 690–697.
4 R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler,
S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler,
H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers,
M. Schmidt, G. Riethmüller, C. Reinhardt, P. Baeuerle and
P. Kufer, Science, 2008, 321, 974–977.
5 M. Aigner, J. Feulner, S. Schaffer, R. Kischel, P. Kufer,
K. Schneider, A. Henn, B. Rattel, M. Friedrich,
P. A. Baeuerle, A. Mackensen and S. W. Krause, Leukemia,
2013, 27, 1107–1115.
6 M. Friedrich, A. Henn, T. Raum, M. Bajtus, K. Matthes,
L. Hendrich, J. Wahl, P. Hoffmann, R. Kischel, M. Kvesic,
J. W. Slootstra, P. A. Baeuerle, P. Kufer and B. Rattel, Mol.
Cancer Ther., 2014, 13, 1549–1557.
7 C. go. identifier NCT02152956.
Paper Analyst
Analyst This journal is © The Royal Society of Chemistry 2016
Pu
bl
is
he
d 
on
 0
9 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
by
 L
ud
w
ig
 M
ax
im
ili
an
s 
U
ni
ve
rs
ita
et
 M
ue
nc
he
n 
on
 1
4/
03
/2
01
6 
09
:1
9:
59
. 
View Article Online
8 T. Takai, M. Li, D. Sylvestre, R. Clynes and J. V. Ravetch,
Cell, 1994, 76, 519–529.
9 G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny,
P. Bardos, P. Colombat and H. Watier, Blood, 2002, 99, 754–
758.
10 W.-K. K. Weng and R. Levy, J. Clin. Oncol., 2003, 21, 3940–
3947.
11 M. Albanesi, D. A. Mancardi, L. E. Macdonald,
B. Iannascoli, L. Zitvogel, A. J. Murphy, M. Daëron,
J. H. Leusen and P. Bruhns, J. Immunol., 2012, 189, 5513–
5517.
12 F. Nimmerjahn and J. V. Ravetch, Nat. Rev. Immunol., 2008,
8, 34–47.
13 R. T. T. Costello, S. Sivori, E. Marcenaro, M. Lafage-Pochi-
taloff, M.-J. J. Mozziconacci, D. Reviron, J.-A. A. Gastaut,
D. Pende, D. Olive and A. Moretta, Blood, 2002, 99, 3661–
3667.
14 C. Fauriat, S. Just-Landi, F. Mallet, C. Arnoulet, D. Sainty,
D. Olive and R. T. Costello, Blood, 2007, 109, 323–330.
15 E. Lion, Y. Willemen, Z. N. Berneman, V. F. Van Tendeloo
and E. L. Smits, Leukemia, 2012, 26, 2019–2026.
16 T. Braciak, S. Wildenhain, C. Roskopf, I. Schubert, G. Fey,
U. Jacob, K.-P. Hopfner and F. Oduncu, J. Transl. Med.,
2013, 11, 289.
17 K. T. Brunner, J. Mauel, J. C. Cerottini and B. Chapuis,
Immunology, 1968, 14, 181–196.
18 I. Schubert, D. Saul, S. Nowecki, A. Mackensen, G. H. Fey
and F. S. Oduncu, mAbs, 2014, 6, 286–296.
19 D. L. Nelson, C. C. Kurman and D. E. Serbousek, Curr.
Protoc. Immunol., 2001, Ch. 7, Unit 7.27.
20 R. Bhat and C. Watzl, PLoS One, 2007, 2, e326.
21 J. Albeck, J. Burke, B. Aldridge, M. Zhang, D. Lauffenburger
and P. Sorger, Mol. Cell., 2008, 30, 11–25.
22 P. Choi and T. Mitchison, Proc. Natl. Acad. Sci. U. S. A.,
2013, 110, 6488–6493.
23 G. Romain, V. Senyukov, N. Rey-Villamizar, A. Merouane,
W. Kelton, I. Liadi, A. Mahendra, W. Charab, G. Georgiou,
B. Roysam, D. A. Lee and N. Varadarajan, Blood, 2014, 124,
3241–3249.
24 E. Forslund, K. Guldevall, P. E. Olofsson, T. Frisk,
A. E. Christakou, M. Wiklund and B. Onfelt, Front.
Immunol., 2012, 3, 300.
25 Unknown.
26 P. E. Olofsson, E. Forslund, B. Vanherberghen, K. Chechet,
O. Mickelin, A. R. Ahlin, T. Everhorn and B. Onfelt, Front.
Immunol., 2014, 5, 80.
27 C. Shuptrine, R. Surana and L. Weiner, Semin. Cancer Biol.,
2012, 22, 3–13.
28 A. Scott, J. Wolchok and L. Old, Nat. Rev. Cancer, 2012, 12,
278–287.
29 P. J. Carter, Nat. Rev. Immunol., 2006, 6, 343–357.
30 R. E. Kontermann, mAbs, 2012, 4, 182–197.
31 R. Kontermann and U. Brinkmann, Drug Discovery Today,
2015, 838–847.
32 C. Spiess, Q. Zhai and P. J. Carter, Mol. Immunol., 2015, 95–
106.
33 C. Kellner, J. Bruenke, J. Stieglmaier, M. Schwemmlein,
M. Schwenkert, H. Singer, K. Mentz, M. Peipp, P. Lang,
F. Oduncu, B. Stockmeyer and G. H. Fey, J. Immunother.,
2008, 31, 871–884.
34 M. Kügler, C. Stein, C. Kellner, K. Mentz, D. Saul,
M. Schwenkert, I. Schubert, H. Singer, F. Oduncu,
B. Stockmeyer, A. Mackensen and G. H. Fey, Br. J. Haematol.,
2010, 150, 574–586.
35 H. Singer, C. Kellner, H. Lanig, M. Aigner, B. Stockmeyer,
F. Oduncu, M. Schwemmlein, C. Stein, K. Mentz,
A. Mackensen and G. H. Fey, J. Immunother., 2010, 33, 599–
608.
36 J. M. Rowe and B. Löwenberg, Blood, 2013, 121, 4838–
4841.
37 P. J. Röttgermann, A. P. Alberola and J. O. Rädler, Soft
Matter, 2014, 10, 2397–2404.
38 M. Ferizi, C. Leonhardt, C. Meggle, M. Aneja, C. Rudolph,
C. Plank and J. Rädler, Lab on a Chip, 2015, 15, 3561–
3571.
39 E. Alici, T. Sutlu, B. Björkstrand, M. Gilljam, B. Stellan,
H. Nahi, H. C. Quezada, G. Gahrton, H.-G. G. Ljunggren
and M. S. Dilber, Blood, 2008, 111, 3155–3162.
40 M. J. Smyth, E. Cretney, J. M. Kelly, J. A. Westwood,
S. E. Street, H. Yagita, K. Takeda, S. L. van Dommelen,
M. A. Degli-Esposti and Y. Hayakawa, Mol. Immunol., 2005,
42, 501–510.
41 M. Cheng, Y. Chen, W. Xiao, R. Sun and Z. Tian, Cell. Mol.
Immunol., 2013, 10, 230–252.
42 B. Vanherberghen, P. E. Olofsson, E. Forslund,
M. Sternberg-Simon, M. A. Khorshidi, S. Pacouret,
K. Guldevall, M. Enqvist, K.-J. J. Malmberg, R. Mehr and
B. Önfelt, Blood, 2013, 121, 1326–1334.
43 A. Poggi, A.-M. Massaro, S. Negrini, P. Contini and
M. Zocchi, J. Immunol., 2005, 174, 2653–2660.
44 G. M. Spaggiari, P. Contini, A. Dondero, R. Carosio,
F. Puppo, F. Indiveri, M. R. Zocchi and A. Poggi, Blood,
2002, 100, 4098–4107.
45 Y. Matsuo, R. A. MacLeod, C. C. Uphoff, H. G. Drexler,
C. Nishizaki, Y. Katayama, G. Kimura, N. Fujii, E. Omoto,
M. Harada and K. Orita, Leukemia, 1997, 11, 1469–1477.
46 A. Malyguine, S. Strobl, K. Dunham, M. Shurin and
T. Sayers, Cells, 2012, 1, 111–126.
47 E. Ranieri, I. Popescu and M. Gigante, Methods Mol. Biol.,
2014, 1186, 75–86.
48 C. C. Roskopf, C. B. Schiller, T. A. Braciak, S. Kobold,
I. A. Schubert, G. H. Fey, K.-P. P. Hopfner and F. S. Oduncu,
OncoTargets Ther., 2014, 5, 6466–6483.
49 A. Ehninger, M. Kramer, C. Röllig, C. Thiede,
M. Bornhäuser, M. von Bonin, M. Wermke, A. Feldmann,
M. Bachmann, G. Ehninger and U. Oelschlägel, Blood
Cancer J., 2014, 4, e218.
50 T. A. Braciak, C. C. Roskopf, S. Wildenhain, N. Fenn,
C. Schiller, I. A. Schubert, U. Jacob, A. Honegger,
C. Krupka, M. Subklewe, K. Spiekermann, K.-P. Hopfner,
G. H. Fey, M. Aigner, S. Krause, A. Machensen and
F. S. Oduncu, OncoTargets Ther., in press.
Analyst Paper
This journal is © The Royal Society of Chemistry 2016 Analyst
Pu
bl
is
he
d 
on
 0
9 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
by
 L
ud
w
ig
 M
ax
im
ili
an
s 
U
ni
ve
rs
ita
et
 M
ue
nc
he
n 
on
 1
4/
03
/2
01
6 
09
:1
9:
59
. 
View Article Online
51 A. Burnett, M. Wetzler and B. Löwenberg, J. Clin. Oncol.,
2011, 29, 487–494.
52 C. T. Jordan, D. Upchurch, S. J. Szilvassy, M. L. Guzman,
D. S. Howard, A. L. Pettigrew, T. Meyerrose, R. Rossi,
B. Grimes, D. A. Rizzieri, S. M. Luger and G. L. Phillips,
Leukemia, 2000, 14, 1777–1784.
53 A. W. Hauswirth, S. Florian, D. Printz, K. Sotlar, M.-T.
T. Krauth, G. Fritsch, G.-H. H. Schernthaner, V. Wacheck,
E. Selzer, W. R. Sperr and P. Valent, Eur. J. Clin. Invest.,
2007, 37, 73–82.
54 R. B. Walter, F. R. Appelbaum, E. H. Estey and
I. D. Bernstein, Blood, 2012, 119, 6198–6208.
55 F. Vergez, A. S. Green, J. Tamburini, J.-E. E. Sarry,
B. Gaillard, P. Cornillet-Lefebvre, M. Pannetier, A. Neyret,
N. Chapuis, N. Ifrah, F. Dreyfus, S. Manenti, C. Demur,
E. Delabesse, C. Lacombe, P. Mayeux, D. Bouscary, C. Recher
and V. Bardet, Haematologica, 2011, 96, 1792–1798.
56 C. Arndt, A. Feldmann, M. von Bonin, M. Cartellieri, E.-M.
M. Ewen, S. Koristka, I. Michalk, S. Stamova, N. Berndt,
A. Gocht, M. Bornhäuser, G. Ehninger, M. Schmitz and
M. Bachmann, Leukemia, 2014, 28, 59–69.
57 C. Stein, C. Kellner, M. Kügler, N. Reiff, K. Mentz,
M. Schwenkert, B. Stockmeyer, A. Mackensen and G. Fey,
Br. J. Haematol., 2010, 148, 879–889.
Paper Analyst
Analyst This journal is © The Royal Society of Chemistry 2016
Pu
bl
is
he
d 
on
 0
9 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
by
 L
ud
w
ig
 M
ax
im
ili
an
s 
U
ni
ve
rs
ita
et
 M
ue
nc
he
n 
on
 1
4/
03
/2
01
6 
09
:1
9:
59
. 
View Article Online
Expression profile of the cd15 myeloid expression marker on molm-13 and nk cells.
Electronic Supplementary Material (ESI) for Analyst.
This journal is © The Royal Society of Chemistry 2016
Results 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  96 
 
Results 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  97 
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2.4.1 Summary 
 
Targeted immunotherapy is limited by the lack of tumor-specific antigens. However, cancer cells can 
sometimes be distinguished immunophenotypically by the co-expression of two or more TAA. Such 
cases offer an intriguing opportunity for selective and individualized immunotherapy with multi-
specific antibody derivatives such as single-chain triplebodies. The blasts in mixed phenotype acute 
leukemia, for instance biphenotypic B/myeloid leukemia cells, are an example for co-expression-
dependent immunophenotypic distinction. In the present study, the T cell-engaging triplebody 
33-3-19 was constructed and found to lyse biphenotypic CD19+ CD33+ leukemia cells preferentially 
over CD19 single-positive cells. 
 
Triplebody 33-3-19 was generated by replacing the N-terminal CD19 scFv from the previously 
characterized 19-3-19248 construct with a humanized CD33-specific scFv. It was produced in stably 
transfected FreeStyle™ 293F production cell pools and purified by Ni-NTA affinity and size exclusion 
chromatography to yield 0.5 to 1.5 mg monomeric protein per liter supernatant. The triplebody 
displayed a marked aggregation tendency and had two melting points at 58.5°C (CD19 and CD3ε 
scFv) and 70°C (CD33 scFv). Stabilization attempts by targeted mutagenesis and disulfide-stabilization 
failed. 
 
33-3-19 bound specifically to its three target antigens and had a strong biological activity, which 
decreased after two months of storage at -80°C. Similar to prototype 19-3-19, triplebody 33-3-19 
activated freshly isolated, non-stimulated T cells in cytolysis assays. T cell activation dynamics were 
donor-dependent, but maximum target cell depletion (94.2 to 99.6%) was generally achieved after 
48 hours. For the induction of redirected lysis (RDL) the presence of either CD19 or CD33 on the 
target cell surface was sufficient, but no activation occurred in the absence of both targets. 
B lymphoid and myeloid cancer cell lines responded in a dose-dependent manner to 33-3-19 
treatment with EC50-values for the B lymphoid targets ranging from 3 to 460 pM and ranging from 0.1 
to 2.4 nM for the myeloid targets. Higher maximum lysis and lower EC50-values correlated with 
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higher target antigen densities. In addition to depletion of the bulk leukemia cells, 33-3-19 also led to 
the lysis of more than 97% of colony forming cells (CFC) from the BV173 and MOLM-13 cell lines. 
33-3-19 in combination with T cells also depleted primary blasts from patients with MPAL, B-ALL and 
B-CLL in a dose-dependent manner. 
 
Finally, the selectivity of lysis that is mediated by dual-targeting triplebody 33-3-19 was assessed in 
cytolysis assays with mixed CD19 single-positive (sp; SEM) and CD19 and CD33 double-positive (dp; 
BV173) target cell populations with comparable target antigen densities: In a flow cytometric 
approach three times more sp SEM target cells survived cytolysis than dp BV173 target cells. The 
ratio of surviving cells (BV173/SEM) was 0.13, whereas the ratios of survivors upon treatment with 
monospecific triplebody 19-3-19 or the bispecific scFv (19-3 plus 33-3) were 0.68 and 0.66, 
respectively. Similarly, in a complementary calcein release-based cytolysis assay, the dp BV173 target 
cells displayed a 145-fold higher sensitivity towards 33-3-19 than the sp SEM cells, when both target 
cell populations were present in the reaction volume simultaneously. EC50-values were 4.6 pM for 
BV173 and 667.7 pM for SEM cells. The dose-response of both cell lines was identical when the 
combination of bispecific scFv (19-3 plus 33-3) was used. EC50-values were 6.1 pM (BV173) and 
5.9 pM (SEM), respectively. 
 
In conclusion, although the presence of one target antigen is sufficient to induce redirected lysis of 
cancer cells by T cell-engaging triplebody 33-3-19, the dual-targeting of CD19 and CD33 achieves 
target cell selectivity. A therapeutic window for this “selectivity effect” exists provided that sub-
saturating triplebody concentrations are used. The therapeutic window as well as the limiting 
proteinchemical characteristics of 33-3-19 may be improved via affinity and stability engineering to 
provide a potentially useful therapeutic agent for the treatment of B/myeloid leukemias. 
 
 
2.4.2 Contribution 
 
I designed, purified and characterized triplebody 33-3-19 and control molecules, performed 
activation studies on T cells and investigated the cytolytic potential of triplebody 33-3-19 with 
respect to ALL and AML cell line targets, including their colony forming cells, and with respect to 
primary target cells from patients with different hematologic malignancies. Furthermore, I 
established two different approaches to determine selective lysis of CD19+ CD33+ biphenotypic 
leukemia cells by 33-3-19 plus T cells in a reaction environment with mixed target cell populations. I 
am also the author of the manuscript, which was edited by Prof. Fey and reviewed by all co-authors. 
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ABSTRACT
Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer 
immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune 
escape.
The combination of B lymphoid marker CD19 and myeloid marker CD33 is 
exclusively present on biphenotypic B/myeloid leukemia cells. Triplebody 33-3-19 
binds specifically to both of these TAAs and activates T cells as immune effectors. 
Thereby it induces specific lysis of established myeloid (MOLM13, THP-1) and 
B-lymphoid cell lines (BV173, SEM, Raji, ARH77) as well as of primary patient cells. 
EC50 values range from 3 pM to 2.4 nM. In accordance with our hypothesis, 33-3-19 is 
able to induce preferential lysis of double- rather than single-positive leukemia cells 
in a target cell mixture: CD19/CD33 double-positive BV173 cells were eliminated to 
a significantly greater extent than CD19 single-positive SEM cells (36.6% vs. 20.9% 
in 3 hours, p = 0.0048) in the presence of both cell lines. In contrast, equivalent 
elimination efficiencies were observed for both cell lines, when control triplebody 
19-3-19 or a mixture of the bispecific single chain variable fragments 19-3 and 33-3 
were used. This result highlights the potential of dual-targeting agents for efficient 
and selective immune-intervention in leukemia patients.
INTRODUCTION
In acute leukemia of ambiguous origin with B/
myeloid or trilineage phenotype (ca. 2 – 3% of all acute 
leukemias) and B-ALL or AML with aberrant antigen 
expression, the B lymphoid lineage marker CD19 and 
myeloid lineage marker CD33 are simultaneously 
displayed on the blast cell surface [1, 2]. Acute leukemias 
with co-expression of CD19 and CD33 usually have a 
poor prognosis [1, 3, 4]. In addition, there is no consensus 
regarding treatment protocols for mixed phenotype 
acute leukemias (MPAL) due to the rarity of these 
hematopoietic neoplasms and lack of clinical studies in 
this specific patient population [3, 5–7]. However, both 
CD19 and CD33 are validated therapeutic targets. The 
co-expression of these two lineage markers may offer 
unique opportunities for selective, individualized 
immunotherapy with novel antibody-derived agents, 
because the leukemia cells are immunophenotypically 
distinct from the corresponding healthy cells. By targeting 
both tumor-associated antigens, i.e. CD19 and CD33, at 
the same time, selectivity of elimination may be achieved 
and immune escape will likely be reduced, because antigen 
double-negative leukemia cell clones are less likely to be 
selected than single-negative ones [8, 9].
A number of multi-specific antibody-derived 
molecular formats have emerged over the past 25 years 
[8, 10] including the single chain triplebody platform. 
Single chain triplebodies are polypeptides that are 
composed of three single chain variable fragments 
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(scFvs) connected by flexible linkers. They are 
bi-specific for the target cell and mono-specific for the 
effector cell [11, 12]. In the classical triplebody format 
immune effector cells are engaged and activated via the 
central scFv, which binds to a trigger antigen such as 
FcγRIII (CD16) on NK cells and macrophages, CD64 or 
CD89 on neutrophilic granulocytes or the CD3-epsilon 
chain on T cells. The two distal scFvs in dual-targeting 
triplebodies bind to two different TAAs on the cancer 
cell surface. By coupling the recruited immune effector 
cell to the targeted cancer cell in an Fc receptor- and 
MHC:peptide-complex-independent manner, the 
immune effectors are activated and redirected against the 
target cells [11, 12]. This mode of action - referred to as 
redirected lysis (RDL) - is also employed by Bispecific 
T cell Engagers (BiTE®s), including Blinatumomab 
(BlinCyto™) and AMG330, which target CD19 and 
CD33, respectively [13–15]. Blinatumomab is the first-
in-class of a new group of biotherapeutics after its FDA-
approval for the treatment of relapsed and refractory 
adult B-ALL in December 2014. However, BiTE®s have 
a number of limitations including their low molecular 
weight (55 – 60 kD), which results in a serum half-
life of only 1.5 to 2 hours [14, 15], and targeting of a 
single tumor-associated antigen (TAA). Since the latter 
is not tumor-specific, it does not allow for a very strong 
discrimination between malignant and normal antigen-
positive target cells.
Triplebodies have a molecular mass of 80 to 90 
kDa, which is above the threshold of immediate renal 
clearance. This is reflected in their extended serum half-
life of 4 hours in mice in comparison to 2 hours for 
bispecific single chain Fvs (bsscFvs) [16]. Based on the 
slower clearance rate compared to bsscFvs, the smaller 
size compared to monoclonal antibodies and their capacity 
for multivalent tumor targeting, triplebodies are expected 
to achieve an efficient penetration of solid tissues [10, 
11, 17]. A number of different triplebodies have been 
developed, which are capable of recruiting NK cells, γδ T 
cells and T cells as immune effector cell populations for 
RDL and of targeting a variety of different TAAs that are 
relevant in hematopoietic malignancies [16, 18–23].
In the present study, we constructed a T cell-
recruiting triplebody 33-3-19 to explore the question 
whether preferential lysis of B/myeloid cancer cells 
relative to cells expressing only one lineage marker 
is also possible with the help of T cells as cytolytic 
effectors. Triplebody 33-3-19 was able to activate 
resting T cells to induce their proliferation and effector 
cell activity. Moreover, it enhanced the selective lysis 
of CD19/CD33 double-positive leukemia cells relative 
to CD19 single-positive targets with comparable target 
antigen density, which were present in the same reaction 
environment. These results lend further support to the 
concept of enhanced selectivity of lysis mediated by 
dual-targeting.
RESULTS
Construction and properties of dual-targeting T 
cell-engaging triplebody 33-3-19
To clone the triplebody 33-3-19 (Figure 1A), the 
N-terminal anti-CD19 single chain variable fragment 
(scFv), which was encoded at the 5’-end of the 19-3-
19 gene in a pSecTag2-HygroC mammalian expression 
vector [21], was replaced by a humanized anti-CD33 scFv. 
Triplebody 33-3-19 and control proteins were purified 
from the supernatant of stably transfected Freestyle 
293F cell pools by Ni-NTA affinity (Figure S1A) and 
size exclusion (Figure S1B) chromatography. Between 
0.5 to 1.5 mg monomeric triplebody were obtained 
on average from 1 L of culture supernatant. As can be 
inferred from the size exclusion chromatogram (Figure 
S1B), triplebody 33-3-19 displayed a marked aggregation 
tendency. The protein’s thermostability was measured by 
thermal shift assays and two melting points at 58.5 °C 
(CD19 and CD3 scFvs) and at 70 °C (CD33 scFv) were 
recorded. The biological activity of 33-3-19, which was 
determined from its EC50-value in a standard redirected 
lysis (RDL) experiment against SEM target cells at 
different time points post production (data not shown), 
weakened over time, in spite of stabilization attempts via 
a variety of formulation-buffers, disulfide stabilization 
and site-directed mutagenesis (data not shown). However, 
triplebody 33-3-19 was suitable for proof-of-concept 
studies as it bound specifically to its three target antigens 
CD33, CD3-epsilon and CD19 (Figure 1B) and displayed 
a strong biological activity when used within one to two 
months after production.
Activation of resting T cells by triplebody  
33-3-19
We first tested the ability of 33-3-19 to activate 
resting T cells. 33-3-19 was added to cytolysis reactions 
of unstimulated mononuclear cells (MNCs) from healthy 
donors, which were mixed with SEM (CD19-positive 
pre-B ALL cell line) target cells at an effector-to-target 
(E : T) ratio of 1 : 2. Within 24 to 48 hours after treatment 
with 33-3-19, the expression of early activation marker 
CD69 on the surface of the CD3+ cell population was 
strongly increased (Figure 1C). Expression of CD25, the 
alpha-chain of the IL-2 receptor, on the T cell surface 
was also increased (Figure 1C) with different kinetics 
than CD69. The response patterns for the expression of 
activation markers varied considerably between different 
blood donors, but upon reaching peak cytolysis levels of 
94.2 - 99.6 % of target cells after 48 hours, the levels of 
both CD69 and CD25 on the T cell surface began to drop 
again in each case. Addition of triplebody 33-3-19 to T 
cells without antigen-positive target cells did not lead to 
the elevation of activation marker levels (data not shown), 
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nor did the addition of a Her2-3-Her2 control triplebody 
to a reaction mixture containing T lymphocytes and 
leukemia cells (Figure 1C). This result suggests that T cell 
activation was not due to HLA-mismatch between donor 
and leukemia cells. Further, the presence of target antigen, 
which was physically linked to the surface of the T cell via 
the mediator protein, was thus an essential requirement for 
triplebody-mediated activation of T lymphocytes.
In parallel to the elevation of activation markers 
on the T cell surface, a donor-dependent elevation of the 
concentration of cytokines IL-2, IL-6, IL-10, TNFα and 
IFN-γ in the supernatant was detected (Figure S2A). To 
further analyze the impact of 33-3-19 on T cell proliferation, 
MNCs were fluorescently labelled with the cell proliferation 
dye CellTrace™ CFSE prior to the cytolysis reaction. More 
than 60 % of CD3+ cells had already run through 1 to 3 cell 
cycles after 72 hours (Figure 1D). After 120 hours more than 
97 % of T cells had proliferated (Figure S2B). No cytokine 
release or T cell proliferation was observed in control 
reactions without triplebody or with the specificity-control 
triplebody Her2-3-Her2.
Efficient redirected lysis of ALL and AML target 
cell lines
To determine the efficiency of 33-3-19-induced, T 
cell-mediated cytolysis of target antigen-positive cells, 
redirected lysis assays were performed with different AML 
and B cell lines as targets and with ex vivo expanded, pre-
stimulated, allogeneic MNCs as effectors. An effector-to-
target-cell ratio of 10 : 1 and an incubation time of 3 hours 
were employed. The expression of either CD19 or CD33 on 
the cancer cell surface was sufficient to induce cytolysis via 
33-3-19 plus T cells (Figure 2A). However, cytolysis was 
not induced in the absence of target antigen on the cancer 
cells as determined with the specificity control Her2-3-Her2 
(data not shown). The extent of cytolysis was concentration-
dependent and a trend towards higher maximum lysis and 
Figure 1: Specific binding and T cell-activation induced by dual-targeting triplebody 33-3-19. A. Design principle of 
33-3-19. B. Specific binding of 33-3-19 to its target antigens as determined by cytofluorimetry. The antigen-positive targets used were 
the MOLM-13 (CD33) and SEM (CD19) cell lines and primary T cells (CD3) isolated from a healthy donor. No binding was observed to 
antigen-negative cells (HEK 293, data not shown). C. Non-stimulated PBMCs were incubated at an E : T ratio of 1 : 2 with SEM target 
cells and 1 nM triplebody or 2% PHA/100 U/mL IL-2 (pos. control) for 72 hours. The expression of activation markers CD69 and CD25 by 
effector T cells was assessed (n = 4). Representative data from one 28-yr old, healthy, male donor (70.4% CD3+, 4.5% CD19+) are shown. 
At time t0 the overall content of CD19-positive cells in the reaction mixture (PBMCs + SEMs) was 14.6%. D. Non-stimulated PBMCs were 
labelled with 5 μM CFSE prior to incubation with SEM target cells at an E : T ratio of 1 : 2 and a cell density of 3 * 105 / mL at t0. T cell 
proliferation was assessed based on dilution of the CFSE cell proliferation dye (n = 3). Black = reaction without triplebody; blue = reaction 
with 1 nM 33-3-19.
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Figure 2: 33-3-19-mediated lysis of B and AML cell lines including their colony forming cells (CFCs), as well as of 
primary patient material. A. Dose-response of several B-lymphoid (left) and AML cell lines (right) representing different types of 
hematologic malignancies. No cytolytic response was observed, when the specificity-control triplebody Her2-3-Her2 was employed (data 
not shown). B + C. Cells were harvested post cytolysis and used in a human colony-forming cell (CFC) assay. 5.5 * 104 (MOLM-13 targets) 
or 1.1 * 105 cells (BV173 targets) were seeded into each well, respectively, which corresponds to 5,000 seeded MOLM-13 and 10,000 
seeded BV173 cells (the remaining cells are the MNC effector cells). After 7 days, cells were stained with 1 mg/mL iodonitrotetrazolium-
chloride solution overnight. Images were taken on the following day and colonies counted manually (n = 3 for each cell line). D. Dose-
response of primary patient material (PBMCs) to treatment with triplebody 33-3-19 plus allogeneic PBMCs. All patient samples were 
collected at first diagnosis. The MPAL (NOS) patient displayed a trilineage phenotype (B lineage: CD19high, CD79ahigh; T lineage: cyCD3+, 
CD2+, CD5high, CD7high; myeloid lineage: MPO detectable, CD33+, CD117high).
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lower EC50-values was observed with higher target antigen 
density on the cell surface (Table 1). EC50-values for the B 
lymphoid cell lines were in the low picomolar range (3 – 
460 pM). The tested AML-cell lines responded at higher 
triplebody concentrations with EC50-values of 0.1 nM 
(MOLM-13) and 2.4 nM (THP-1), respectively (Table 1).
Elimination of potential leukemia-initiating cells
To achieve long-lasting remissions, it is necessary 
to eliminate those cancer cells that are capable of 
repopulating the cancer tissue, i.e. the leukemia-initiating 
cells (LICs) and especially the leukemia stem cells (LSCs). 
One hallmark of LICs is their colony-forming capacity. 
To investigate whether treatment with 33-3-19 leads to 
the eradication of LICs as well as bulk cancer cells, we 
performed colony forming cell (CFC) assays with the cells 
that had survived a 4 hour redirected lysis assay with or 
without triplebody. The addition of 33-3-19 resulted in the 
elimination of more than 97% of CFCs from a biphenotypic 
Philadelphia chromosome-positive B-precursor ALL 
cell line (BV173) as well as a CD33+ AML M5a cell 
line (MOLM-13) (Figure 2B and 2C). This result points 
towards the capacity of triplebodies to eradicate potential 
LICs and warrants further careful examination in the future 
with primary patient cells as targets.
Redirected lysis of primary material from 
patients with different disease entities
To determine, whether triplebody 33-3-19 was 
also effective against primary cancer cells, redirected 
lysis assays were performed with primary cells from 
three patients, diagnosed with B-CLL, B-ALL and 
mixed phenotype acute leukemia (no other specification) 
(MPAL (NOS)), respectively. Each leukemia cell sample 
responded to treatment with 33-3-19 plus allogeneic 
effector cells in a dose-dependent manner, and maximum 
specific lysis values of 46.6% (MPAL (NOS)), 72.9% 
(B-ALL) and 99.2% (B-CLL) were achieved within 3 
hours (Figure 2D, Table 1). EC50-values ranged from 40 
to 100 pM. The blasts from the patient with MPAL (NOS) 
displayed a combined (CD19 plus CD33) target antigen 
density of approximately 9,000 molecules/cell (Table 1). 
This - together with its maximum lysis and EC50-value - 
supports the notion that combined target antigen density 
correlates with higher maximum specific lysis/lower EC50-
value. In the samples from the B-CLL and B-ALL patient 
a higher degree of specific lysis was achieved with 1 nM 
than with 10 nM triplebody (Figure 2D).
Enhanced selectivity of lysis for biphenotypic 
CD19+ CD33+ target cells
To assess whether the dual-targeting of CD19 
and CD33 with a single molecule actually enhanced the 
selectivity of target cell lysis in a mixed environment, 
cytolysis experiments with mixed target cell populations 
were performed. The target cell population was composed 
of a mixture of CD19 single-positive SEM cells and CD19/
CD33 double-positive BV173 cells. The SEM cell line 
was chosen, because of its comparably high target antigen 
density: SEM cells carried approximately 50,000 CD19 
molecules and no detectable CD33 molecules on their 
surface, BV173 cells carried approximately 60,000 copies of 
CD19 and 4,500 copies of CD33 on their surface (Table 1).
Table 1: EC50-values, maximum specific lysis and antigen density for 33-3-19-sensitive cell lines and patient samples
  
Disease EC50 (95% CI) [pM] 
Max. spec. 
lysis [%] 
Antigen Density 
 [molecules/cell] 
  CD19 CD33
B cell lines SEM Pre-B ALL 12 (8 – 18) 58.7 50,000 ± 17,000 < 100
 BV173 Pre-B ALL 3 (1 – 6) 61.0 60,000 ± 11,000 4,500 ± 800
 Raji Burkitt’s lymphoma 42 (18 – 98) 60.8 31,000 ± 19,000 650 ± 100
 ARH77 Plasma cell  leukemia 460 (179 – 1,177) 39.4 3,000 ± 2,000 < 100
AML cell lines MOLM-13 AML-M5a 100 (58 – 173) 42.3 0 32,000 ± 6,500
 THP-1 AML-M5 2,442 (1,105 – 5,311) 14.6 0 17,000 ± 4,000
Patient samples  ALL 39 (9 – 165) 72.9 n.d n.d.
  MPAL(NOS) 72 (63 – 84) 46.6 8,500 ± 3,000 300
  B-CLL 101 (1 – 44,550) 99.2 n.d. n.d.
EC50-values and maximum specific lysis were determined from the sigmoidal dose-response in 3 hour Calcein release 
cytolysis assays with an E : T Ratio of 10 : 1. Antigen density was determined by calibrated cytofluorimetry using the 
QifiKit (Dako) [28]. N.d. = not determined.
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In a first approach, the target cell populations were 
labelled with different concentrations of a permanent 
fluorescent dye and mixed with pre-stimulated MNCs at 
an E : T ratio of 1 : 6. After 12 hours the surviving target 
cells were enumerated cytofluorimetrically. Upon addition 
of 1 nM dual-targeting triplebody 33-3-19, the double-
positive BV173 target cells were lysed preferentially over 
the single-positive SEM target cells, as demonstrated by a 
three-fold higher viability of the SEM cells (Figure 3A). 
In contrast, the monospecific bivalent triplebody 19-3-
19 or a mixture of the bsscFvs (19-3 plus 33-3) reduced 
both populations to a similar extent: treatment with 33-
3-19 resulted in a ratio of 0.13 for surviving BV173-to-
SEM target cells (Figure 3B), while treatment with the 
bsscFv mixture (19-3 plus 33-3) resulted in a significantly 
different ratio of 0.66 (t-test, p = 0.007). Treatment with 
19-3-19 resulted in a ratio of 0.68 for surviving BV173-to-
SEM target cells (t-test, p = 0.067).
To confirm these results by a complementary 
method, we now labeled each cell type independently with 
Figure 3: Selective lysis of CD19/CD33 double-positive target cells induced by dual-targeting triplebody 33-3-19 plus 
allogeneic T cells. Cytolysis assays with mixed CD19 single-positive (sp) and CD19/CD33 double-positive (dp) target cell populations 
were performed to investigate whether dual-targeting triplebody 33-3-19 achieved selectivity of lysis. A. PBMCs were labelled with 2 
μM CellTracker™ Deep Red and sp SEM and dp BV173 target cells were labelled with 2 μM and 20 nM CellTracker™ Green CMFDA, 
respectively, and mixed at an E : sp T : dp T ratio of 1 : 3 : 3. After incubation for 12 hours cells were stained with 7-AAD to exclude dead/
dying cells and the number of surviving sp and dp target cells was assessed by flow cytometry (n = 5). Figure 3A shows an example of the 
histograms for surviving CMFDA+ 7-AAD- Deep Red- target cells from each reaction. B. The ratio of surviving dp BV173 to sp SEM target 
cells was calculated from absolute cell numbers in a set sample volume (250 μL). The box plot in Figure 3B is based on five independent 
measurements. On average, three-times more sp SEM target cells survived treatment with 1 nM dual-targeting triplebody 33-3-19 than 
dp BV173 target cells. Treatment with 1 nM mono-targeting triplebody 19-3-19 or an equimolar concentration of bsscFvs (19-3 plus 33-
3) reduced both target cell lines to a similar extent. C. sp SEM target cells were Calcein-labelled in one and dp BV173 target cells were 
labelled in the other arm of a 3 hour Calcein release cytolysis assay with mixed target cell populations (E : sp T : dp T is 2 : 1 : 1). The 
concentrations of dual-targeting triplebody 33-3-19 and an equimolar mixture of the CD3 bsscFvs (19-3 plus 33-3) were titrated. The ratio 
of killed sp-to-dp target cells was determined from the ratio of specific lysis achieved in each arm of the experiment, respectively (n = 4). 
While both cell lines were equally sensitive towards treatment with the bsscFv mixture (EC50-values are 6.1 pM for BV173 and 5.9 pM for 
SEM), the double-positive cell line BV173 was 145-times more sensitive towards treatment with 33-3-19 (EC50-value = 4.6 pM) than the 
single-positive cell line SEM (EC50-value = 667.7 pM), when both target cell lines were present in the same reaction volume.
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Calcein green in a cytolysis test to determine specific lysis 
of each target cell population individually (Figure S3A). 
Again, the BV173 population was lysed to a significantly 
greater extent than the SEM population upon treatment 
with 33-3-19, but not after treatment with 19-3-19 or an 
equimolar mixture of (19-3 plus 33-3) (Figure S3B). Dose-
response curves were established for each population in 
the target cell mixture treated with either 33-3-19 or the 
bsscFv mixture (19-3 plus 33-3). The concentration of the 
CD3-epsilon scFv was equimolar between the treatment 
groups, i.e. 1 nM 33-3-19 corresponded to (0.5 nM 19-3 
plus 0.5 nM 33-3). CD19+ CD33+ BV173 target cells 
responded to far lower doses of dual-targeting triplebody 
33-3-19 than the CD19+ SEM target cells, when both were 
simultaneously present in the reaction mixture (Figure 3C, 
left panel). The EC50-values of 33-3-19 for the double- 
and single-positive cell lines were 4.6 pM and 667.7 pM, 
respectively. This is a significant 145-fold difference in 
sensitivity (Mann-Whitney u-test, p = 0.029) towards 33-
3-19 treatment between the two target cell populations. 
In contrast both, the double- and the single-positive cell 
lines, displayed equal sensitivity towards treatment with 
the mixture of bsscFvs (19-3 plus 33-3) with EC50-values 
of 6.1 and 5.9 pM, respectively (Figure 3C, right panel).
DISCUSSION
In the present study, we characterized a dual-
targeting T cell-recruiting triplebody 33-3-19 that was 
designed for the selective lysis of CD19/CD33 double-
positive B/myeloid leukemia cells over CD19 single-
positive normal cells. The results emphasize that dual-
targeting agents have the capacity to achieve better target 
cell selectivity and reduced off-target toxicity.
To activate CTLs, to redirect their effector 
cell functions, and to induce T cell proliferation, the 
simultaneous binding of the CD3-epsilon trigger antigen 
on the T lymphocytes and tumor-associated antigen 
(TAA) on the cancer cell surface by triplebody 33-3-19 
was required. This observation as well as our previous 
experiences with the mono-targeting triplebody 19-3-19 
[21] suggest that the mode of action of T cell-recruiting 
triplebodies is very similar to that postulated for BiTE®s 
[24–26]: the higher affinity of these antibody derivatives 
for the TAAs rather than the effector cell antigen leads to 
a preferential coating of the cancer cells. Once a T cell 
has come into proximity of the target cell, multiple specific 
binding events to the triplebodies coating the cancer cell 
result in CD3-receptor cross-linking and subsequent T 
cell activation. However, in contrast to BiTE®s, antibody 
derivatives with multiple targeting domains such as 33-
3-19 bind bi-(or multi-)valently to the target cell and can 
thus profit from a cooperativity or avidity effect, which has 
previously been demonstrated for several triplebodies [16, 
19–21]. Therefore the difference in affinity for the TAA 
and trigger antigens may not need to be as pronounced as 
for BiTE® molecules [25]. This may also give rise to lower 
off-target toxicity, because the affinity for single-positive 
non-target cells may be too low to induce a prolonged 
contact with CTLs or other immune effector cells.
Since the mode of action of BiTE®s and T 
cell-recruiting triplebodies appears to have common 
components, it is not surprising that the release of 
cytokines IL-2, IL-6, IL-10, TNFα and IFN-γ was 
observed after treatment of target cells in vitro with 33-3-
19 and effector T cells. This result leads to the prediction 
that T cell-engaging triplebodies may also induce a 
cytokine release syndrome (CRS) similar to the one 
described clinically for Blinatumomab [14, 15]. However, 
the clinical experience with this T cell-activating agent and 
with the use of (CAR) T cells for therapy have helped to 
implement CRS treatment strategies, which are effective 
in most cases [27].
In this study, we also provided clear evidence 
suggesting that dual-targeting of (CD19 plus CD33) 
improved target cell selectivity, in particular at sub-saturating 
concentrations. The presence of only one of the TAAs on the 
target cell surface was sufficient to redirect T cell function; 
however, CD19/CD33 double-positive target cells displayed 
a 145-fold greater sensitivity towards treatment with 33-3-
19 than CD19 single-positive cells, when both populations 
were present in the same reaction environment. This 
observation points to a possible concentration-dependent 
therapeutic window for the selectivity of dual-targeting 
agents: at concentrations of the agent, which fall into this 
window, double-positive cancer cells are largely eradicated, 
but single-positive cells are mostly spared. It may be 
possible to maximize this “selectivity window” by affinity 
engineering of the individual arms of dual-targeting agents 
as was recently shown by Mazor et al. for an anti-CD4/
CD70 DuetMab® [9].
Another important parameter is the combined and 
individual target antigen density on the target and non-
target tissues. The antigen density limits the number of 
triplebody molecules that can be bound to the cancer cell 
surface. We frequently observe - for example in the case 
of the B-CLL and B-ALL patient samples in this study 
- that target cells display a higher specific lysis at 1 nM 
triplebody than at 10 nM triplebody. This pattern might be 
attributed to an “oversaturation” effect: when the amount 
of triplebody exceeds the number of available binding 
sites on the cancer cells, the effector cells may be coated 
in addition to the targets and a successful interaction 
between effectors and targets to form a cytolytic synapse 
is mediated less frequently or less efficiently. Thus, the 
most effective concentration of a dual-targeting agent such 
as 33-3-19 may depend on the combined target antigen 
density of an individual patient’s target cells. This may 
pose a challenge for the determination of an appropriate 
dosing regimen: target antigen densities vary significantly 
between individuals [28] and can even vary between the 
bulk of leukemia cells and the leukemia-initiating stem- or 
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progenitor cells (as is the case for the combined density 
of CD33 and CD123 on AML LSCs [29], for example). 
Thus, the suitable concentration to achieve a selective 
eradication of target cells may also vary between patients.
Triplebody 33-3-19 has not yet undergone late-stage 
preclinical development. Most of the limiting protein-
chemical properties described above and in particular the 
tendency to form aggregates can probably be attributed to 
intra- and intermolecular shuffling of V-chain subdomains, 
because the individual scFvs used here were stable in other 
triplebody constructs. However, recent advances in antibody 
engineering [30] offer the opportunity to improve the 
intrinsic stability of antibody derivatives such as 33-3-19. 
If such stability engineering were combined with affinity 
engineering to further increase the “selectivity window”, 
then later-stage versions of 33-3-19 may become potent and 
clinically useful therapeutic agents for a selective targeting 
of CD19+ CD33+ B/myeloid leukemia cells.
MATERIALS AND METHODS
Cloning, production and purification
Triplebody 33-3-19 and bsscFv 33-3 were 
constructed using standard molecular biology techniques. 
Briefly, the 5’ (i.e. N-terminal) CD19-scFv in our previously 
described 19-3-19 and 19-3 constructs [21] were replaced 
with the humanized CD33-specific scFv, which was isolated 
by polymerase chain reaction (PCR) from the SPM-2 
gene cassette [22]. All triplebody- and bsscFv-encoding 
genes were cloned into the pSecTag2-HygroC vector 
for mammalian expression. Freestyle 293F cells were 
transfected with TransIT-LT1 transfection reagent and a 
stable production cell pool was generated by Hygromycin B 
selection for 8 weeks. The recombinant protein was purified 
from the supernatant via Ni-NTA affinity chromatography 
followed by analytical size exclusion chromatography. 
Protein aliquots were stored at -80 °C.
Thermal shift assay
SYPRO Orange (Thermo Fisher Scientific, 
Darmstadt), which only fluoresces upon binding to 
denatured protein, was added to 45 μL aliquots of a 
0.1 mg/mL protein solution at a dilution of 1 : 5,000. 
Fluorescence emitted by the labeled denatured triplebody 
was monitored on a Biorad CFX 96 instrument during 
a temperature increase from 10 °C to 95 °C at 0.5 °C 
intervals (10 sec/interval).
Cell culture methods
Cell lines BV173, Raji, ARH77, THP-1 and 
MOLM-13 were purchased from the German Collection of 
Microorganisms and Cell Lines (Leibniz-Institut DSMZ, 
Braunschweig). The SEM cell line was purchased from the 
American Type Culture Collection (ATCC). SEM, Raji, 
ARH77 and THP-1 were cultured in RPMI 1640 (Gibco, 
Thermo Fisher Scientific, Darmstadt) supplemented with 
10% fetal bovine serum (FBS) and Penicillin (100 U/mL) 
/ Streptomycin (100 μg/mL). Medium for BV173 and 
MOLM-13 was supplemented with 20% FBS. Freestyle 
293F cells were purchased from Life Technologies and 
grown in FreeStyle™ medium in a shaking incubator.
Blood samples from healthy donors and patients 
with hematologic malignancies were drawn into EDTA-
monovettes (Sarstedt) after informed written consent 
had been obtained. This study is in compliance with 
the declaration of Helsinki and was approved by the 
ethics committee of the Medical Faculty of the Ludwig-
Maximilians-Universität München (project no. 173-13). 
PBMCs were separated by density gradient centrifugation 
using Lymphoprep™ (Axis Shield PoC) medium, and 
residual erythrocytes were lysed by incubation with 
erythrocyte-lysis-buffer (University Pharmacy, Munich) 
for 5 minutes. To generate effector cells for standard 
3 hours cytotoxicity assays an ex vivo expansion and 
stimulation of mononuclear cells (MNCs) was carried 
out for 20 days in the presence of IL-2 as described [23, 
31]. For T cell activation and proliferation assays freshly 
isolated, non-stimulated PBMCs were used.
Flow cytometry
Flow cytometric analyses were carried out on a BD 
Accuri C6 or a Millipore Guava instrument. For binding 
studies target antigen-positive cells were incubated with 15 
μg/mL antibody derivatives and washed. Bound antibody 
derivatives were then detected with an AlexaFluor488-
conjugated anti-His5 antibody (1 : 200 dilution, Qiagen). 
CD3, CD4, CD8, CD16, CD19, CD25, CD33, CD56, 
CD69 and isotype control antibodies conjugated with 
different fluorophores were purchased from Immunotech 
(Beckmann-Coulter, Marseille). For cell-surface marker 
analysis, target cells were fixed in 3.7 % paraformaldehyde 
(PFA) solution at room temperature for 15 minutes, 
subsequently stained with the required antibody cocktail 
at 4 °C for 30 minutes, washed with phosphate buffered 
saline (PBS) and analyzed. The viability dye 7-AAD and 
the Cytometric Bead Array™ Human Th1/Th2 Cytokine 
Kit II were purchased from BD Biosciences (San Diego, 
CA) and used according to the manufacturer’s instructions. 
The CellTrace™ CFSE proliferation dye (Molecular 
Probes, Darmstadt) and the QifiKit (Dako, Eching) for the 
quantification of surface antigens were used according to 
the manufacturer’s instructions.
Calcein release assay/redirected lysis 
assay (RDL)
Target cells were labelled with 15 μM Calcein 
Green AM (Molecular Probes, Darmstadt), washed, and 
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mixed with ex vivo expanded and stimulated PBMCs from 
healthy unrelated donors in RPMI 1640 GlutaMAX™ 
supplemented with 10 % FBS and Penicillin (100 U/
mL)/Streptomycin (100 μg/mL) (Gibco, Thermo Fisher 
Scientific, Darmstadt) at an E : T ratio of 10 : 1. Antibody 
derivatives were diluted to the desired concentration with 
medium and added to 200 μL reaction volumes in a 96-
well round bottom tissue culture plate (CellStar, Greiner 
bio-one). After a 3 hour incubation period at 37 °C, 5 
% CO2, 100 μL supernatant was transferred to a black 
96-well flat bottom plate (Nunc) and fluorescence was 
determined on a Berthold Mithras plate reader (Berthold 
Technologies, Bad Wildbad). Maximum lysis was 
achieved by addition of 2.5 % Triton X-100. Specific lysis 
was calculated as follows:
% Specific Lysis = 100 * [( RLU (sample) – RLU 
(background)) / (RLU (max. lysis) – RLU (background))]
, where RLU = relative light units and the 
background is the degree of lysis obtained with effector 
cells alone in the absence of added triplebody.
Selective lysis studied by flow cytometry
To investigate whether 33-3-19 induces a selective 
lysis of target antigen double-positive (dp) cells, single-
positive (sp) CD19+ SEM cells and dp CD19+ CD33+ 
BV173 cells were differentially labeled with CellTracker™ 
Green CMFDA (i.e. 2 μM and 20 nM, respectively) 
and mixed with ex vivo expanded and stimulated, 
CellTracker™ Deep Red (2 μM)-labelled PBMCs at an E 
: sp T : dp T Ratio of 1 : 3 : 3. Triplebodies 19-3-19, 33-3-
19, Her2-3-Her2 or a mixture of the bsscFvs (19-3 plus 33-
3) were added to give 1 nM concentration. After a 12 hour 
incubation period at 37 °C/5 % CO2 cells were harvested, 
stained with the viability dye 7-AAD and resuspended in 
500 μL PBS. 250 μL of each sample were analyzed by 
flow cytometry. Surviving target cells were identified by 
gating on CMFDA+, Deep Red-, 7-AAD- cells.
Selective lysis studied by Calcein release
In an alternative approach to investigate the 
hypothesized target cell selectivity of 33-3-19, cell 
death of sp and dp target cells in a mixed population 
was measured by Calcein release in parallel reactions. In 
one reaction mixture sp SEM cells were labeled and in 
the parallel reaction dp BV173 cells were labeled with 
15 μM Calcein Green AM. Cell death was determined 
by fluorescence from released Calcein Green in the 
supernatant after an incubation period of 3 hours with pre-
stimulated PBMCs from healthy unrelated donors at an E : 
sp T : dp T ratio of 2 : 1 : 1. Triplebodies Her2-3-Her2, 19-
3-19, 33-3-19 and the mixture of bsscFvs (19-3 plus 33-
3) were adjusted to the desired concentrations. Maximum 
lysis was achieved by addition of 2.5 % Triton X-100 and 
specific lysis was calculated as described above.
Colony formation assays
Colony formation assays in MethoCult™ were 
performed after a 4 hour cytolysis reaction with an E : T 
ratio of 10 : 1 PBMCs to target cells and 1 nM triplebody 
Her2-3-Her2 or 33-3-19. Colony Forming Cells (CFCs) 
were detected and counted using the MethoCult™ H4434 
Classic medium (Stem Cell Technologies, Munich). 
Briefly, cells were harvested and washed with Iscove’s 
Modified Dulbecco’s Medium after the cytolysis reaction. 
5,000 to 10,000 target cells were seeded to 1 mL of 
rigorously vortexed MethoCult™ medium and transferred 
to a 24-well tissue culture plate. The sample well was 
surrounded with water-containing wells and the dish was 
incubated at 37 °C/5 % CO2 for 7 days. On day seven, 
100 μL of a 1 mg/mL iodonitrotetrazolium chloride 
(INT) solution in PBS was added and after an overnight 
incubation at 37 °C/5 % CO2 the number of colonies was 
counted.
Statistical analysis
All statistical analyses were performed by GraphPad 
Prism Software (GraphPad Software Inc., San Diego, 
CA, USA) using Student’s t-test for the determination of 
significance in normally distributed, and using the Mann-
Whitney u test in samples with unknown distribution. 
Statistical significance was defined as p < 0.05.
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SUPPLEMENTARY FIGURES
Supplementary Figure S1: Protein-chemical properties of dual-targeting T cell-engaging triplebody 33-3-19. A. SDS-
polyacrylamide gel electrophoresis of protein fractions post Ni-NTA enrichment of triplebody 33-3-19 from the supernatant of a stable 
Freestyle 293F production cell pool (yield = 0.5 – 1.5 mg/L supernatant). M = protein marker, SN = supernatant, FT = flow through, W 
= wash fraction, E = elution fraction. B. Size exclusion chromatogram of triplebody 33-3-19. The monomer fraction (main peak) was 
collected and concentrated. Aliquots were flash-frozen in liquid nitrogen and stored at -80 °C until use (max. 2 months). C. Melting curve 
of 33-3-19 monomer as determined by a thermal shift assay. Melting point 1 (CD19 and CD3 scFvs) = 58.5°C; melting point 2 (CD33 scFv) 
= 70°C. Identification of the peaks from comparison of similar experiments performed earlier by our team with the triplebodies 33-16-123 
(SPM-2) (N.C. Fenn, unpublished data) permitting identification of the transition caused by the CD33-specific scFv component and 19-3-19 
(C.C. Roskopf, unpublished data) permitting identification of the transitions attributed to the CD19- and CD3-specific scFv components.
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Supplementary Figure S2: T cell-activation induced by triplebody 33-3-19 and targets. Non-stimulated PBMCs from 
healthy unrelated donors were labelled with 5 μM CFSE and incubated with SEM target cells at an E : T ratio of 1 : 2 and a cell density of 
3 * 105/ mL at t0 (n = 3). A. After 0, 4, 12, 24, 48, 72 and 96 hours, cytokine levels in the medium were determined using the BD CBA™ 
Human Th1/Th2 Cytokine Kit II. Cytokine secretion profiles from 2 donors are shown. Both donors displayed complete target cell depletion 
and T cell proliferation was induced. Probably due to the very low cell numbers, cytokine concentrations increased slightly only, but IL-2, 
IL-6, IL-10, TNFα and IFN-γ were detectable, a similar profile to the one seen after treatment with the BiTE®s Blinatumomab and AMG330 
[14, 15]. B. After 72, 96 and 120 hours T cell proliferation was assessed based on the dilution of the CellTrace™ CFSE proliferation dye.
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Supplementary Figure S3: Selective lysis of CD19+ CD33+ target cells at 1 nM 33-3-19. CD19 single-positive (sp) SEM 
target cells were Calcein-labelled in one and CD19/CD33 double-positive (dp) BV173 target cells were labelled in the other arm of a 3 hour 
Calcein release cytolysis assay with mixed target cell populations (E : sp T : dp T is 2 : 1 : 1; n = 11). A. Specific lysis of individual target 
cell populations in parallel reactions. In the presence of 1 nM dual-targeting triplebody 33-3-19, roughly twice as many BV173 target cells 
were lysed as SEM target cells (p = 0.0048). B. Box plot of the ratio of lysed dp-to-sp target cells, which was determined from the ratio of 
specific lysis achieved in each arm of the experiment, respectively.
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2.5.1 Summary 
 
CD16 (FcγRIIIa) is not only expressed by NK cells, but also by γδ T cells. Both of these immune effector 
populations already have natural roles in fighting cancer and thus engaging them via 
immunotherapeutic agents appears to be a promising approach to boost anti-cancer responses. 
Aside from the interaction of IgG Fc-domains with CD16, antibody-derived molecules with a scFv 
directed against CD16 have been shown to successfully engage NK cells for the redirected lysis of 
cancer cells. However, many antibody derivatives have been difficult to produce in large scale or 
under conditions that reflect the industrial standard. In this publication, humanized triplebody SPM-1 
with dual specificity for CD19 and CD16 is presented, whose manufacturing protocols follow industry 
standard. Furthermore, SPM-1 is capable of engaging both NK and γδ T cells for the redirected lysis of 
malignant B lymphoid cells with the same efficiency as an Fc-optimized antibody. 
 
The binding moieties of triplebody SPM-1 derive from the previously described triplebody 
ds[19-16-19]211 and were humanized by CDR-grafting.249 Homologous recombination was minimized 
by codon optimization. Using a three-step chromatographic procedure that reflects industrial 
purification procedures highly pure, monomeric protein was obtained at a yield of 1.7 to 5.5 mg/L 
supernatant. With a KD value of (12 ± 1.5 nM), the disulfide-stabilized humanized CD16 binding head 
displayed a higher affinity for the FcγRIIIa than its murine predecessor. The avidity of the two CD19 
scFv for CD19 was comparable to the parental molecule with a KD value of (17.5 ± 0.4 nM). In 
redirected lysis assays with either B lymphoid cell lines or primary patient material as targets and ex 
vivo expanded, prestimulated NK cells from healthy donors as effectors, highly efficient cytolysis was 
achieved with EC50-values in the picomolar range. In patient samples, the EC50-values were 5 to 
430-fold lower than those achieved with the commercially available anti-CD20 antibody rituximab 
(MabThera®). In fact, the triplebody displayed the same cytolytic efficiency as a CD19-specific 
Results 
 
CC Roskopf: Selective CD19+ leukemia cell lysis mediated by T cell-engaging triplebodies  │  114 
 
Fc-optimized antibody (i. e. 4G7SDIE) and minibody, while a minibody with an unmodified IgG1 
Fc-domain was ineffective. 
 
To investigate the activation potential of SPM-1 for γδ T cells, which were present at an average of 
(2.3 ± 12%) in the PBMC fraction of healthy donors, the level of degranulation marker CD107a on the 
γδ T cell surface and the levels of intracellular TNF-α and IFN-γ were examined by FACS after cytolysis 
assays. All levels were elevated upon exposure to SPM-1 plus target cells. Moreover, SPM-1 
mediated 100% lysis of immobilized CD19-transfected MCF7 cells (i. e. MCF7-CD19 tm250) by freshly 
isolated and ex vivo expanded γδ T cells at E : T ratios of 10 : 1 and 20 : 1 in an impedance-based 
cytotoxicity assay (xCELLigence technology) within 12 hours. In this assay, the triplebody displayed 
biphasic killing kinetics with a faster initial rise in killing rate than monoclonal antibody 4G7SDIE. This 
suggests a faster on-rate of the triplebody compared to the mAb. 
 
In conclusion, triplebody SPM-1 was sufficiently optimized biochemically to be a candidate for future 
clinical studies. It has highly efficient cytolytic properties in conjunction with NK cells and γδ T cells 
that match those of Fc-engineered antibodies and may thus be suitable for the treatment of B cell 
malignancies or B cell-mediated autoimmune disorders. 
 
 
2.5.2 Contribution 
 
I prepared the patient samples and performed the corresponding redirected lysis assays with SPM-1, 
provided by Dr. Schiller, and rituximab. Furthermore I determined the antigen densities of CD19 and 
CD20 on the surface of different B cell lines and of primary leukemia blasts. I also constructed control 
triplebody Her2-16-Her2. Finally, I wrote the first draft of the manuscript, which was edited by 
Prof. Fey, and implemented the changes requested by the co-authors. 
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ABSTRACT
Triplebodies are antibody-derived recombinant proteins carrying 3 antigen-
binding domains in a single polypeptide chain. Triplebody SPM-1 was designed for 
lysis of CD19-bearing malignant B-lymphoid cells through the engagement of CD16-
expressing cytolytic effectors, including NK and gd T cells.
SPM-1 is an optimized version of triplebody ds(19-16-19) and includes 
humanization, disulfide stabilization and the removal of potentially immunogenic 
sequences. A three-step chromatographic procedure yielded 1.7 - 5.5 mg of purified, 
monomeric protein per liter of culture medium. In cytolysis assays with NK cell 
effectors, SPM-1 mediated potent lysis of cancer-derived B cell lines and primary 
cells from patients with various B-lymphoid malignancies, which surpassed the ADCC 
activity of the therapeutic antibody Rituximab. EC50-values ranged from 3 to 86 pM. 
Finally, in an impedance-based assay, SPM-1 mediated a particularly rapid lysis of 
CD19-bearing target cells by engaging and activating both primary and expanded 
human gd T cells from healthy donors as effectors.
These data establish SPM-1 as a useful tool for a kinetic analysis of the cytolytic 
reactions mediated by gd T and NK cells and as an agent deserving further development 
towards clinical use for the treatment of B-lymphoid malignancies.
INTRODUCTION
CD19 is a type I transmembrane glycoprotein and 
a signaling receptor of the immunoglobulin superfamily. 
It is a component of the B cell receptor (BCR) co-
complex, and is expressed from early to late stages of 
B cell development. Signaling through CD19 promotes 
proliferation and differentiation [1–4]. The antigen is 
particularly promising for targeted immunotherapy of 
B-lymphoid malignancies, because of its relatively high 
and lineage-specific expression on B cells of different 
maturation stages and its presence on the surface of cancer 
progenitor cells [5–7]. However, the results of initial 
clinical trials with CD19-antibodies were disappointing [5, 
8], presumably due at least in part to a far lower surface 
density of CD19 on the malignant cells than of CD20 
on lymphoma cells, the target antigen for the clinically 
successful antibody Rituximab.
A second generation of improved CD19-targeting 
proteins and cellular agents has been developed, which 
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includes Fc- and glyco-engineered immunoglobulins, 
such as the antibodies XmAb5574 (MOR208) and 
MEDI-551 [9, 10], the bispecific T cell engager (BiTE®) 
Blinatumomab (Blincyto®) [11, 12], and the adoptive 
transfer of genetically modified T cells, obtained by 
stable transfection with chimeric antigen receptors 
(CARs). Genetically modified CAR-T cells (CAR-
Ts) have been remarkably successful in the treatment 
of various B-lymphoid malignancies, in particular of 
Acute Lymphoblastic Leukemia (ALL) in children 
and young adults with poor prognosis [13–16]. CD19 
therefore clearly is a useful target for antigen-specific 
immunotherapy, provided an appropriate molecular format 
of the therapeutic agent is chosen.
BiTE and CAR-T cell approaches rely on cytotoxic 
T lymphocytes (CTLs) for the elimination of cancer 
cells [11, 13–16]. Although highly effective in many 
cases, these approaches still leave room for future 
improvements. In rare cases, undesirable adverse events 
have been reported after treatment of patients with CD19-
directed BiTEs and CD19-directed CAR-Ts. These include 
cytokine release syndromes and involvement of the central 
nervous system [17] as well as tumor lysis syndrome 
and the occasional outgrowth of target antigen-negative 
tumor cell clones (“antigen-loss” or “escape” variants) 
[12, 17, 18]. A short serum half-life in the case of BiTEs, 
potentially durable lymphopenia in the case of CARTs and 
finally, the associated high costs limit the availability of 
these therapies for a significant segment of patients.
The use of antibodies for therapeutic purposes, on 
the other hand, is well-established and effective, and is 
generally less expensive, but also suffers from certain 
limitations. These agents rely on the presence of Fc-
receptor-bearing effector cells, which can be activated 
by the mediator protein to assemble a productive synapse 
with the target cell. In some cases, the needed effector 
cells are not available in sufficient quantity and quality 
at certain stages of disease development. An example are 
limiting numbers of functionally active NK cells in the 
bone marrow of AML patients at diagnosis, which limit 
the use of IgGs as front-line therapeutic agents [19–22]. 
Immunoglobulins further suffer from limited penetration 
into solid tumor tissues, owed to their large mass [23–25].
To address some of these limitations of mono-
targeting IgGs, our team has developed the molecular 
format of single chain triplebodies. These proteins consist 
of 3 single chain variable antibody fragments (scFvs) 
connected by flexible (G4S)n linkers [26–31]. Triplebodies 
are anticipated to have improved pharmacokinetic 
properties due to their smaller size of approximately 90 
kD. Based on experimental and theoretical data from other 
groups, this is expected to result in a faster equilibration of 
these molecules in the mammalian blood circulation and in 
an easier penetration into solid tumor tissues compared to 
full-length antibodies [23, 32, 33]. Furthermore, triplebody 
SPM-2 was shown to mediate an efficient elimination 
of AML blasts from an AML patient in remission by 
autologous NK cells [34].
Triplebodies developed so far were designed 
for bivalent binding of a tumor cell via their two distal 
scFvs, and for monovalent binding to a trigger molecule 
on a cytolytic effector cell through their central scFv. 
Effector cells engaged by triplebodies to date include NK 
cells, CTLs, and neutrophilic granulocytes, which were 
activated for cytolysis via the triggers CD16, CD3ε, and 
CD64, respectively [35]. CD16, the human Fcγ-receptor 
III (FcγRIII), is expressed by NK cells, macrophages, γδ 
T cells and a subset of cytokine-stimulated dendritic cells 
(DCs). Upon cross-linking, signaling via CD16, which 
associates with the FcR γ-chain or CD3ζ, elicits potent 
effector functions including ADCC and phagocytosis [36].
NK cells and γδ T cells are capable of recognizing 
and eliminating malignant cells in a natural killing mode 
in the absence of mediator proteins such as antibodies. NK 
cells respond to the absence of MHC class I proteins on 
cancer cells (“missing self”). γδ T cells are independent of 
MHC : peptide recognition, but can react to non-peptidic 
phosphoantigens, which are preferentially displayed on the 
surface of cancer cells. Therefore, both of these effector 
cell classes can bypass immune evasion of cancer cells 
by downregulation of MHC class I [37, 38]. In addition, 
NK cells and γδ T cells are major anti-viral effectors after 
transplantation of hematopoietic stem cells (HSCT), but 
do not cause graft-versus-host-disease (GvHD) [37]. 
Enhancing the cytolytic activity of NK cells and γδ T 
cells via CD16-triggering therapeutic agents therefore is 
a promising strategy for cancer treatment, which may also 
lead to a systemic cellular immune response following an 
initial lysis of cancer cells by ADCC, in the sense of a 
tumor-vaccination effect.
The capacity to recruit γδ T cells as cytolytic 
effectors has not yet been established for triplebodies 
triggering through CD16, although it had been reported 
for other agents in related molecular formats, including the 
Fc-engineered CD19-antibody 4G7SDIE and the bispecific 
CD19-targeting fusion protein N19-C16 [39–41]. 
Therefore, we anticipated that a similar result may also be 
obtained for corresponding triplebodies, but experimental 
verification of this hypothesis was still needed. These 
agents have different sizes and space-filling properties, 
and may therefore differ in their steric access to CD16 
epitopes on NK and γδ T cells. To test this hypothesis, the 
previously described triplebody ds(19-16-19) [26], with 2 
binding sites for CD19 and one for CD16, was humanized 
and stabilized, and the new agent was named SPM-1. The 
protein was purified, characterized and compared here 
in NK cell-based ADCC assays to other CD19-specific 
agents in related molecular formats. In support of the 
hypothesis, SPM-1 was found capable indeed of mediating 
lysis of CD19-bearing target cells in combination 
with human γδ T cells as effectors in ADCC assays. In 
these studies we also observed that SPM-1 mediated a 
particularly rapid lysis of substrate-bound CD19-bearing 
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target cells in a time-resolved, impedance-based assay, 
the XCelligence® assay [41, 42]. This stimulating finding 
calls for additional future studies of the kinetics of the 
ADCC process mediated by antibody-derived agents with 
different molecular architecture, which will likely lead 
to a better understanding of the unusually high cytolytic 
potential of triplebodies compared to some of the related 
bi-specific agents [26].
RESULTS
Design and production of triplebody SPM-1
Triplebody SPM-1 was constructed based on the 
published parental triplebody ds(19-16-19) [26]. The scFv 
domains of the parental protein were derived from the 
murine monoclonal antibodies 4G7 and 3G8. To minimize 
immunogenicity, the CD16- and CD19-directed scFv 
sequences were humanized by CDR grafting [43, 44] plus 
subsequent adjustment of the framework. The humanized 
CD16 scFv was then disulfide-stabilized, whereas the 2 
humanized CD19-binding domains were used without 
further stabilization, because this protein was sufficiently 
stable compared with disulfide-stabilized variants, which 
have also been studied (Figure 1A and additional data not 
shown). The cDNA coding sequences for the 2 CD19-
specific scFvs were adjusted by mutations in the wobble 
bases to minimize homologous recombination in the 
producer cells, and thus to improve production yields of 
the desired protein. This procedure reduced the occurrence 
of truncated variants, which had been observed prior to 
this optimization.
SPM-1 was expressed in Freestyle™ 293-F cells 
(Life Technologies) and was purified in a 3-step procedure, 
which included capture from culture supernatants by zinc 
ion affinity chromatography followed by anion and cation 
exchange chromatography. This capture step and the ion 
exchange chromatography protocol followed industry 
standard procedures, and the downstream purification 
process is scalable and suitable for commercial production. 
Yields ranged from 1.7 - 5.5 mg of purified protein/L of 
culture supernatant in different production runs (Table 1). 
Purified SPM-1 eluted as a single monomeric peak in size 
exclusion chromatography profiles and was highly pure 
as evidenced by SDS-polyacrylamide gel electrophoresis 
(Figure 1B, 1C).
Figure 1: Structural characteristics and purification of triplebody SPM-1. A. CD19-specific scFv domains shown in light 
grey; CD16-specific scFv domain in dark grey. B. After purification with the 3-step chromatographic procedure described in Methods, 
SPM-1 eluted in size exclusion chromatography profiles (SEC) as a single monodisperse peak corresponding to the molecular mass of an 
SPM-1 monomer. Species of higher molecular mass (aggregates) were absent/below detection limit. C. Fractions from the SEC elution 
profile (eluting between the dashed lines in B) were analyzed by SDS-PAGE and stained with Coomassie blue. The preparation was of high 
purity; higher and lower molecular mass species were absent or only very minor contaminants.
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Binding characteristics of SPM-1
Specificity of SPM-1 binding to CD19 and CD16 
was established by cytofluorimetry with suitable control 
antibodies and control cells (unpublished data). The 
monovalent affinity of SPM-1 for CD16 and the bivalent 
avidity for CD19 were measured by determining the 
equilibrium binding constants (KD) by flow cytometry 
with CD16- or CD19-bearing human cells as previously 
described [45, 46]. The KD value of SPM-1 for CD16 was 
12.0 ± 1.5 nM, which was lower than the value of 58.6 
± 4 nM reported for the parental triplebody ds(19-16-
19). Therefore, the humanized plus disulfide-stabilized 
CD16 binding domain carried in SPM-1 displayed 4- to 
5-fold stronger binding to human CD16 on living cells 
than the corresponding domain of the parental protein. 
The KD value of SPM-1 for CD19 (17.5 ± 0.4 nM) 
was comparable to the value measured for the parental 
protein (13.0 ± 1.2 nM; Table 1) [26], and therefore, the 
humanization procedure has not significantly altered the 
binding avidity of the second-generation triplebody for 
CD19.
Cytolytic activity of SPM-1 in combination with 
human NK cells
The ability of SPM-1 to mediate cytolysis of human 
cancer cells by NK cells from unrelated healthy donors 
was tested in standardized redirected lysis (RDL) assays 
against malignant human B-lymphoid cell lines at an 
effector-to-target cell (E : T) ratio of 2 : 1. The target 
cell lines represented different classes of B-lymphoid 
neoplasias and carried different mean surface densities 
of CD19 (Table 2). All tested cell lines displayed a dose-
dependent cytolytic response to treatment with SPM-1 
plus NK cells (Figure 2). The potential of these cell lines 
for specific lysis was weakly correlated with their mean 
target antigen density: the SEM line with the highest CD19 
density displayed the strongest cytolytic response, whereas 
the ARH-77 line with the lowest density displayed the 
weakest response. No specific lysis was observed, when 
the specificity control triplebody Her2-16-Her2 was used 
(Figure 2), as expected, because Her2 is not expressed on 
these target cells. The measured EC50-values of 5.6 pM 
for the SEM line and 79.4 pM for ARH-77 cells (Table 1) 
were in the same range as the values previously reported 
for the non-humanized parental triplebody, which were 4.1 
and 29 pM, respectively [26]. Therefore, in combination 
with NK cells from an unrelated healthy donor, SPM-1 
displayed overall similar cytolytic potential for malignant 
B-lymphoid cell lines as the parental triplebody.
SPM-1 mediates stronger lysis of some primary 
cancer cell samples by NK cells than the 
therapeutic antibody Rituximab (MabThera®)
The ability of SPM-1 to mediate cytolysis of a panel 
of primary B-lymphoid cancer cell samples in conjunction 
with NK cells was compared with the corresponding ability 
of the clinically successful CD20 antibody Rituximab 
(MabThera®). Peripheral blood samples from 2 newly 
diagnosed B-CLL patients, from a relapsed B-CLL patient 
4 years after treatment with Rituximab, from a Non-
Hodgkin lymphoma patient with leukemic progression, 
and from an adolescent patient with a mixed phenotype 
acute leukemia (not otherwise specified) (MPAL (NOS)) 
were collected. Mean target antigen densities on the blast 
surfaces were determined by calibrated cytofluorimetry, 
and all blast populations with exception of the MPAL 
(NOS) sample were double-positive for CD19 and CD20 
at varying mean densities (Table 3). The MPAL (NOS) 
sample was CD20-negative. The newly diagnosed B-CLL 
and NHL samples displayed dose-dependent responses to 
both SPM-1 and Rituximab, whereas the MPAL (NOS) 
sample responded only to treatment with SPM-1 (Figure 
3). Blasts from the relapsed B-CLL patient did not respond 
to treatment with Rituximab under these conditions, 
although they expressed CD20 on their surface, and these 
cells were therefore not antigen-loss escape variants. They 
displayed a weak, but clearly measurable dose-dependent 
response to treatment with SPM-1. Therefore, they still 
were capable of responding to NK-mediated lysis, and 
thus their failure to respond to treatment with Rituximab 
must have been due to other causes. The EC50-values for 
SPM-1 were 5- to 430-fold lower than those for Rituximab 
under these experimental conditions (Table 3).
SPM-1 mediates comparable cytotolytic activity 
by NK cells as related Fc-engineered antibody-
derived agents
After having established that triplebody SPM-1 was 
capable of mediating effective lysis of cancer cells via the 
CD16-specific scFv domain in ADCC experiments with 
Table 1: Biological activity and antigen affinity of triplebody SPM-1
Construct Yield [mg/L cell culture]
Biol. Activity (SEM) 
EC50 [pM]
Affinity CD16 [nM] Avidity CD19 [nM]
SPM-1 1.7 - 5.5 11 ± 3 12.0 ±1.5 17.5 ± 0.4
The affinity is the equilibrium binding constant KD for monovalent binding to CD16 on stably transfected CHO-CD16 cells; 
the avidity is the KD value of the molecule for bivalent binding to CD19-bearing SEM target cells.
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human NK cells, we asked how strong this activity was 
compared with related molecular formats of antibody-
derived proteins, which carry an Fc portion optimized 
for ADCC activity by suitable point mutations. To this 
effect we employed 2 CD19-specific minibodies, one with 
an engineered Fc-domain, mutated for optimized ADCC 
activity, the other with the non-mutated Fc-portion from 
the parental human IgG1 antibody. In addition, we had 
access to the Fc-engineered CD19-antibody 4G7SDIE 
[39, 41] for comparative cytotoxicity studies, which 
carried some of the same mutations in its Fc-portion as 
the optimized minibody (Figure 4A). Standardized 3 hr 
cytolysis assays were performed with NK cells from a 
healthy donor at an E : T ratio of 2 : 1 against SEM (pro-B 
ALL) and Namalwa (Burkitt lymphoma) target cells. No 
difference was observed between the dose-response of the 
target cells to treatment with SPM-1 or the Fc-engineered 
CD19 antibody 4G7SDIE and the Fc-engineered 
minibody, while treatment with the non-Fc-engineered 
minibody was  ineffective (Figure 4B). Remarkably, SPM-
1 and the Fc-engineered 4G7SDIE antibody produced a 
similar degree of maximum specific lysis in this endpoint 
assay, and both were active with similar EC50-values, 
while clear differences in the kinetics of their action in 
ADCC experiments with γδ T cells as effectors were 
observed in the impedance-based, time-resolved assays 
described below (Figure 6; Supplementary Figure S1). 
Therefore, release assays measuring only the endpoint 
of cytotoxicity integrated over an entire measurement 
interval, typically of 3 - 4 hrs, fail to reveal kinetic details 
of the reaction, which however are likely to be important 
for an understanding of the in vivo activity of these agents 
in animal models and human recipients.
Activation of non-pre-stimulated γδ T cells from 
peripheral blood of healthy donors by SPM-1 
plus target cells
Human γδ T cells express CD16 and are capable of 
mediating ADCC of malignant targets in combination with 
CD19-antibodies and the antibody-derived bispecific agent 
N19-C16 [39–41]. Therefore here we asked, whether 
primary human γδ T cells from healthy donors, not pre-
stimulated by other means, can be activated for cytolysis 
by exposure to SPM-1 plus target cells. Peripheral blood 
mononuclear cells (PBMCs) were isolated from platelet-
pheresis products from healthy donors and the fraction of 
γδ T cells in this population was (2.3 ± 1.2) % on average. 
These low frequencies necessitated an indirect detection 
method for the activation of primary untreated γδ T cells. 
To this effect, CD19-bearing pro-B (SEM) and pre-B 
ALL (NALM-6) cells were first incubated overnight with 
primary samples of γδ T cells, and subsequently SPM-
1 or control agents were added and ADCC activity was 
indirectly monitored by measuring the appearance of the 
degranulation marker CD107a on the surface of the γδ T 
cells. In addition, intracellular concentrations of TNFα 
and IFN-γ were measured by cytofluorimetry as markers 
for activation towards cytolysis. In the absence of CD19-
bearing targets, γδ T cells of only a few sensitive donors 
displayed a weak elevation of CD107a on their surface 
and a small increase in intracellular TNFα after addition of 
SPM-1. However, after overnight incubation with CD19-
bearing target cells, γδ T cells from several donors showed 
a clear increase in cell surface CD107a and intracellular 
TNFα and IFN-γ after addition of SPM-1, and thus 
showed clear evidence for activation towards cytolysis by 
SPM-1 plus target cells (Figure 5).
SPM-1 mediates target cell lysis by both primary 
non-expanded and ex vivo expanded γδ T cells 
from healthy donors
To assess whether γδ T cells are capable of lysing 
CD19-bearing target cells by ADCC in combination with 
SPM-1 or control agents, and to observe the progress of 
this reaction in real time, viability of CD19-expressing, 
adherent MCF7-CD19 tm cells was monitored with the 
xCelligence assay system [41, 42]. This assay was initially 
used here with freshly isolated, non-expanded γδ T cells 
from 2 healthy donors. The γδ T cells were enriched in 
one case by positive selection with immunomagnetic 
(MACS) beads and reached a purity of 97 %, but the 
absolute number of cells collected in this manner was 
low. Specific lysis was obtained in combination with both 
SPM-1 and the CD19 antibody 4G7SDIE, in particular at 
Table 2: Surface expression of CD19 and EC50 values for RDL by SPM-1 with different malignant B lymphoid cell 
lines as targets
Cell Line Subtype of malignancy CD19 density [#] EC50 (range) [pM]
SEM Pro-B (mixed lineage) 42,600 ± 10,700 5.6 (2.5 – 10)
NALM-6 Pre-B 26,700 ± 11,400 6.1 (1.8 – 17.3)
RAJI Burkitt’s Lymphoma 31,900 ± 22,800 16.5 (5.4 – 38.5)
ARH-77 Mature B (myeloma) 2,400 ± 1,200 79.4 (38 – 645.3)
Antigen densities are given in copy numbers per cell.
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high E : T ratios of 10 : 1 and 20 : 1, but not with the 
control triplebody SPM-2 (data not shown). These results 
are consistent with earlier reports, in which specific lysis 
of MCF7-CD19 tm cells with similarly enriched non-
expanded γδ T cells from healthy donors mediated by the 
4G7SDIE antibody had been reported [41]. In conclusion, 
SPM-1 was capable of mediating ADCC of these adherent 
target cells by non-expanded γδ T cells from a healthy 
donor, but the available cell numbers were too low to 
permit a systematic study. Therefore, the experiments, 
which are described below (Figure 6; Supplementary 
Figure S1), were performed with ex vivo expanded γδ T 
cells.
For this purpose PBMCs from healthy volunteers 
obtained by leukapheresis were first expanded ex vivo 
in the presence of rhIL-2 and zolendronate as described 
previously [41]. After 12 -14 d in culture the total number 
of expanded cells was increased only marginally (by about 
30 %), but the fraction of γδ T cells within the expanded 
population was increased by about 20 - 30-fold from 
typically 2 - 3 % to 35.9 – 60.6 %. The fraction of CD16-
bearing γδ T cells in the expanded cell population was 
around 36 % for the sample from Donor 2. γδ T cells were 
then isolated from this population with immunomagnetic 
beads, which resulted in highly pure γδ T cells in sufficient 
numbers. The batch derived from Donor 2 was 98 % pure 
at this stage and was incubated once more overnight 
with IL-2 to remove contaminants resulting from the 
MACS enrichment procedure. This population was still 
heterogeneous with regard to CD16 antigen density on the 
cell surface. xCelligence assays were then performed with 
these cells using either SPM-1 or 4G7SDIE or control 
proteins as mediators of lysis. While the morphological 
and physiological properties of γδ T cells are likely 
to be affected by this ex vivo expansion, the use of this 
expanded population still permits us to conclude, whether 
γδ T cells as a defined T cell subset are capable in principle 
of achieving target cell lysis mediated by SPM-1.
Specific lysis values were calculated from the 
raw data and plotted for 3 different donors of γδ T cells 
at different E : T ratios as a function of time (Figure 6). 
Addition of SPM-1 caused a rapid increase in specific 
target cell lysis by γδ T cells from Donors 2 and 4 
within the first 3 hrs. Close to 100 % of specific lysis 
was achieved within 12 hrs. By contrast, γδ T cells from 
Donor 3 did not produce a similarly rapid lysis during the 
first hours, but showed a steady slow increase in target 
cell lysis over the entire 12 hr measurement period. The 
Figure 2: SPM-1 mediates lysis of a panel of CD19-bearing cell lines derived from various types of B cell malignancies. 
Dose response profiles from Redirected Lysis (RDL) assays performed with SPM-1 or control proteins plus ex vivo expanded MNCs from 
healthy donors. Calcein release assays as described in Methods. SEM cells were derived from a pro-B ALL, NALM-6 from a pre-B ALL, 
RAJI from a Burkitt’s Lymphoma, and ARH-77 from a multiple myeloma. MNCs were used at an 8 : 1 effector-to-target cell (E : T) ratio, 
corresponding to a net NK : target cell ratio of 2 : 1, because NK cells accounted for approx. 25 % of the expanded MNC population. 
SPM-1 concentrations in the reaction mixtures in pM units. Specific lysis plotted on the vertical axis was computed as explained in 
Methods. The control triplebody targeting HER2 failed to induce specific lysis at comparable concentrations as SPM-1, because this antigen 
was undetectable on the target cells used here. In combination with HER2-bearing targets this triplebody was active in positive control 
experiments, performed separately. Data points plotted here are mean specific lysis percentages ± standard error of the mean (SEM) from 
n = 4 to 5 separate experiments.
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Figure 3: SPM-1 mediates stronger lysis of primary lymphoma- and leukemia blasts from newly diagnosed patients 
than the therapeutic antibody Rituximab (MabThera®). Malignant cells from peripheral blood of newly diagnosed patients were 
used as targets in RDL and ADCC assays with SPM-1 and Rituximab, respectively. SPM-1 and Rituximab were present in the reaction 
volumes in the concentrations shown in pM units. NK cells were used at a net E : T ratio of 2 : 1, as defined for Fig. 2. Samples were 
from 1 patient with a mixed phenotype acute leukemia (MPAL(NOS); CD19+ CD20-); 2 patients with B-CLL (CLL: chronic lymphocytic 
leukemia; CD19+ CD20LOW); 1 patient with a Non-Hogkin Lymphoma (NHL; CD19+ CD20HIGH) and 1 patient with newly relapsed B-CLL 
(CD19+ CD20DIM). This patient had undergone 6 previous treatments with Rituximab. Insufficient primary material from this patient was 
available to perform the HER2-16-HER2 control, which is indicated by an asterisk (*).
Table 3: Target antigen densities and EC50 values for RDL / ADCC by SPM-1 or rituximab with primary lymphoma 
and leukemia blasts isolated from newly diagnosed patients
Patient
Antigen density [#] EC50 [pM]
CD19 CD20 SPM1 Rituximab
B-CLL 1 (at diagnosis) 9,600 ± 500 4,000 ± 100 15.8 247.5
B-CLL 2 (at diagnosis) 7,600 ± 1,900 3,900 ± 1,200 3.0 1,300
Relapsed B-CLL 6,500 ± 1,700 1,800 ± 300 27.0 -
MPAL(NOS) 8,400 ± 2,800 0 86.0 -
NHL 14,600 ± 7,700 19,400 ± 2,200 35.7 185.7
Antigen densities are given in copy numbers per cell.
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control triplebody SPM-2 with binding sites for antigens 
CD33 and CD123 [27, 34], which were not expressed on 
these targets, did not cause target cell lysis beyond the 
spontaneous antibody-independent lysis (AIC) of this 
batch of γδ T cells alone (Figure 6). Lysis mediated by 
SPM-1 showed a faster initial rise than lysis mediated 
by the Fc-optimized antibody 4G7SDIE, although 
towards the end of the measurement period the reaction 
rates mediated by both agents appear to have stabilized 
and to have reached close to constant values. The raw 
Figure 4: Triplebody SPM-1 performs equally well as other best-in-class CD19-specific agents in related molecular 
formats in comparative RDL/ADCC assays. A. Asterisks indicate positions of point mutations (substitutions S239D and I332E) in 
the Fc region of the Fc-engineered antibody 4G7SDIE. Single chain fragment variable (scFv) units used in the minibody and the triplebody 
are labeled. One minibody carried the non-engineered Fc-domain, the other the same 2 mutations S239D and I332E shown above for 4G7 
SDIE plus a third substitution A330L (third asterisk). B. RDL analysis of SPM-1 (filled black circles) compared with the best-in-class 
antibody 4G7SDIE (open triangles), the Fc-engineered minibody (open circles) and the non-engineered minibody (black squares). Target 
cells: SEM (top) and Namalwa (bottom).
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data for Donor 4 from this experiment are also shown 
in Supplementary Figure S1, because this representation 
visualizes in a particularly clear manner that the lytic 
process as followed by this assay did not proceed with 
a mono-phasic, but with an at least bi-phasic kinetics. 
This observation suggests that at least 2 different so far 
unknown molecular processes are at work at different 
stages of the overall reaction. In the Discussion section 
we attempt to relate these results to the different molecular 
architecture of these antibody-derived agents.
DISCUSSION
The key findings of this study are: 
• The humanized and optimized triplebody SPM-1 can 
be produced in sufficient quantity and purity with an 
industry standard production and purification process, 
which can be scaled up for large-scale production.
•  SPM-1 mediated efficient redirected lysis of CD19-
bearing target cells in cell culture assays not only by 
NK cells but also by γδ T cells from healthy donors.
•  In benchmark experiments with NK cells from healthy 
donors, SPM-1 was equally active as Fc-engineered 
antibody-derived proteins, including the CD19 
antibody 4G7SDIE. It was active at similarly low EC50 
concentrations in the picomolar range and mediated 
comparable maximum specific lysis as these best-in-
class reference proteins.
• SPM-1 mediated efficient lysis of primary cells from 
patients with various B lineage malignancies and of 
cell lines derived from various B cell neoplasms by NK 
cells from healthy donors. The agent produced stronger 
ADCC lysis than Rituximab of primary cells from 3 
Figure 5: Primary γδ T cells are activated for cytolysis by exposure to SPM-1 plus target cells. A. Fresh γδ T cells were 
prepared from healthy donors as described in Methods and exposed to SPM-1 with or without NALM-6 or SEM target cells. Degranulation 
of γδ T cells was monitored indirectly by cytofluorimetric measurement of the surface antigen density of the degranulation marker CD107a. 
B. Changes in intracellular TNFα concentrations in primary γδ T cells following exposure to SPM-1 plus/minus target cells were measured 
cytofluorimetrically as described in Methods. C. Changes in intracellular IFN-γ concentrations in primary γδ T cells occurring after exposure 
to SPM-1 plus/minus target cells were measured cytofluorimetrically as described in Methods. Of the 6 samples from different donors that 
were analyzed, 4 had a γδ T cell content above 2 % in their PBMC compartments and each of these responded to exposure to SPM-1 plus 
target cells by increased cytokine production and increased surface exposure of the degranulation marker in comparison to treatment with 
the control triplebody SPM-2 or exposure to the target cells alone without mediator proteins.
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B-CLL patients, one NHL patient and one MPAL 
(NOS) patient. 
• Non-expanded γδ T cells from freshly drawn PBMC 
samples of healthy donors were activated for cytolysis 
by exposure to SPM-1 plus target cells, as evidenced by 
surface exposure of the degranulation marker CD107a 
and elevated intracellular concentrations of TNFα and 
IFN-γ. 
• SPM-1 mediated lysis of surface-adherent target 
cells by both non-expanded and ex vivo expanded γδ 
T cells from healthy donors in the impedance-based 
xCelligence assay. 
• In the xCelligence assay, SPM-1 mediated a rapid 
initial phase of lysis of surface-bound targets, faster 
than lysis mediated by the Fc-engineered reference 
antibody 4G7SDIE.
The humanized and optimized triplebody SPM-
1 was equally potent in ADCC as the parental agent, 
and its production and purification by industry-standard 
procedures routinely used for commercial production 
of therapeutic antibodies was found to be possible. The 
ADCC assays presented here were performed with ex 
vivo expanded NK cells from healthy donors, which 
were pre-activated through long-term exposure to IL-
2. We anticipate that SPM-1 will also be active in 
patients with B-lymphoid malignancies by directing 
autologous NK cells, provided it is administered at a 
time, when endogenous NK cells are present in sufficient 
numbers and are cytolytically active. This is the case for 
example for pediatric patients with acute lymphoblastic 
leukemia in a post-transplant setting a few weeks after 
transplantation, where donor-derived NK cells rapidly 
reconstitute the patient's blood and marrow and are active 
in mediating graft-versus-leukemia (GvL) effects [37]. 
Figure 6: SPM-1 directs expanded γδ T cells from healthy donors for very rapid lysis of CD19-bearing MCF7-CD19 
tm target cells, monitored in a real-time assay. For γδ T cell donors # 2, 3 and 4 specific lysis curves were calculated from the cell 
indices (CI) of MCF7-CD19 tm cells, measured over the time course of the reaction with 1 nM SPM-1 or control proteins. SPM-2: control 
triplebody 33-16-123 with scFv binding domains for the target antigens CD33 and CD123, which are not carried by the MCF7-CD19 tm 
cells. CI values measured after treatment with control triplebody SPM-2 were comparable to those obtained with γδ T cell controls alone. 
Measurements were performed with the help of the label-free impedance-based xCelligence assay as described in Methods. Decreasing CI 
values are a correlate of and indicative of target cell lysis. In the presence of triplebody SPM-1, CI values decreased to approximately 9-fold 
lower values than after treatment with γδ T cells alone (Patient 4: 0.1 versus 0.9). Furthermore, specific lysis upon treatment with SPM-1 
was more rapid and efficient than after treatment with ADCC-optimized CD19-antibody 4G7SDIE.
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It remains, however, to be demonstrated in experiments 
with autologous NK cells from patients not treated 
by a stem cell transplant, that these cells also achieve 
a sufficiently strong ADCC lysis of their cancer cells 
mediated by SPM-1. Corresponding studies have been 
performed for triplebody SPM-2, which mediated ADCC 
of a patient's AML cells by autologous NK cells, when 
these were drawn in first remission after a successful 
induction therapy [34]. The issue is still debated, because 
in AML autologous NK cells have been reported to be 
reduced in numbers and specific lytic potential in the 
tumor environment [19–22]. It is not clear, whether this 
reversible functional attenuation is equally important 
in B-lymphoid malignancies as in AML, because it is 
supposedly mediated at least in part by soluble mediators 
and the hypoxic milieu present in the marrow of AML 
patients. The tumor environment may be quite different 
for B-lymphoid malignancies, which evolve at different 
sites and in different cellular environments. We do not yet 
know, whether γδ T cells are present in sufficient numbers 
and in an active state for ADCC in patients with B cell 
malignancies at the sites of the cancer cells.
Triplebodies such as SPM-1 achieve similar 
cytotoxic effects as conventional therapeutic antibodies 
in cell culture ADCC assays in far lower concentrations. 
Rituximab for example is used in lymphoma therapy 
at concentrations in the range of 10 mg/kg, while 
Blinatumomab is used at concentrations in the range of 
10 μg/kg, i.e. in approximately 1.000-fold lower doses 
[11]. In the results presented above with primary cells 
from patients with B cell malignancies (Figure 3), SPM-1 
was active in ADCC assays in concert with NK cells with 
EC50-values lower by 5- to 430-fold than those determined 
for Rituximab. This finding is consistent with the dose 
ranges of Rituximab and Blinatumomab used in clinical 
applications as quoted above. The primary cells from 
the relapsed B-CLL patient, which were not efficiently 
lysed by NK cells plus Rituximab (Figure 3), were not 
antigen-loss variants and still expressed surface CD20. 
More likely, they were resistant to ADCC by NK cells 
through a different mechanism. Such cases have been 
reported for other Rituximab-resistant patients. However, 
this resistance cannot have been a general resistance to 
all different pathways leading to death of target cells by 
ADCC, because the cells were still lysed by ADCC via 
NK cells plus SPM-1.
The Fc-engineered CD19 antibody 4G7SDIE, 
which is largely identical with the corresponding 
antibody XmAb5574 [9, 39, 41], has previously been 
shown to mediate potent ADCC by γδ T cells [41]. 
This T cell subset is particularly useful in combination 
with TCRαβ- and CD19-depleted allogeneic stem cell 
transplantation (allo-HSCT) [47]. In such cases, both 
γδ T cells and NK cells are available for graft-versus-
leukemia activity and can maintain a certain level of 
immune protection of the host. The γδ T cell population 
is small but potent, and does not only provide a natural 
anti-cancer activity, but is also unlikely to elicit graft-
versus-host-disease (GvHD), because of its independence 
from MHC-restriction. Furthermore these cells mediate 
significant anti-viral activity. Therefore, γδ T cells are a 
highly desirable population of immune effector cells for 
cancer immunotherapy [37, 38]. The results presented 
here establish that the CD16-binding module carried in 
SPM-1 is capable of engaging both NK and γδ T cells as 
effectors for lysis of leukemia cells. Efficient activation 
and engagement of γδ T cells by SPM-1 was demonstrated 
here, and the potential expansion of this leukocyte subset 
in vivo in response to activation holds promise for the 
treatment of leukemia patients with triplebodies triggering 
γδ T cells via CD16.
The most unexpected new finding of the present 
study was produced with the help of the xCelligence 
assay, which allowed us to follow a cytolytic reaction 
mediated by a triplebody in real time. The following 
unresolved problem has intrigued us for several years: 
the parental triplebody ds(19-16-19) of SPM-1 showed an 
approximately 3-fold stronger binding avidity to CD19 on 
leukemic target cells than the bispecific tandem diabody 
19-16, but had an approximately 25-fold greater cytolytic 
potential than this diabody for a number of malignant 
B-lymphoid cell lines and primary cell samples from a 
number of patients with different B-lymphoid cancers 
[26]. It was hypothesized that the triplebody may have led 
to the formation of a tighter synapse between the cancer 
cells and the NK cells, and that this in turn may have 
led to a stronger activation of the NK cells for cytolysis. 
However, no direct evidence in support of this hypothesis 
has been produced, because structural methods for a 
comparative analysis of the fine structure of the synapses 
produced by both agents were not available. It came as a 
surprise that progress towards solving this problem may 
come from improving the resolution of measurement 
methods for kinetic aspects of synapse formation and the 
cytolytic reaction.
The key observation reported here (Figure 6; 
Supplementary Figure S1) is that the cytolytic reaction, as 
followed by the xCelligence assay, occurred with a biphasic 
kinetic or a kinetic of even greater complexity. A rapid 
initial change in the cell index (CI), a measure of viability 
of the cells (equated with a rapid first phase of cellular lysis 
[42]), was followed by at least one more phase of slower 
viability changes. We do not know the precise correlation 
between the changes in the CI-value and cellular death, 
and whether a change in CI is only achieved when a target 
cell is completely lysed, or whether it also occurs, when 
a target cell is not yet irreversibly dead, but has engaged 
in the first steps of a multi-step pathway to death. Cell 
death mediated by NK cells through the degranulation of 
granzymes is death by apoptosis, and occurs through a 
succession of steps, which can be individually monitored. 
An example in case is the time-resolved study of apoptosis 
by cytofluorimetry with staining of the target cells by 
annexin V and propidium iodide [48]. In this case an early 
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pre-apoptotic phase can be distinguished, characterized by 
annexin V staining but yet no influx of PI into the nucleus, 
which is still reversible. A subsequent late apoptotic state is 
characterized by more intense staining with both annexin 
V and PI, which is irreversible. It is not clear, whether the 
initial rapid change in the CI-value, which was observed 
here, reflects a truly irreversible step towards cellular death 
and complete lysis, mediated by γδ T cells, or only a change 
in impedance, which may be associated with reversible pre-
apoptotic changes such as the rearrangements of the cellular 
membrane detected by binding of annexin V. Regardless 
of the precise correlation between events discovered by 
changes in CI in this assay and progressive stages on the 
path to cellular death as detected by other methods, the data 
shown here demonstrate the existence of more than one so 
far poorly understood reaction phases, which are likely to 
be highly informative about the mechanism of action of this 
triplebody.
A potential answer to the problem posed above, 
suggested by the results of the present study is that the 
strength of binding of a therapeutic protein to the target 
cell may not be the dominant determinant of its cytolytic 
potential. To build a productive cytolytic synapse, 
binding of the agent to the trigger on the effector cell is 
also important. Although the binding affinities of SPM-
1 for CD16 on effector cells and of the CD16 receptor 
on effector cells for the Fc-domain of Fc-engineered 
antibodies such as 4G7SDIE are in the same order of 
magnitude, it is still possible that the triplebody has faster 
access to CD16 on the γδ T cell (and thus a faster “on”-
rate) than the 4G7SDIE antibody. We suspect this to be the 
case, because the triplebody has only half the mass of the 
antibody and may have different space-filling properties 
and different flexibility, which may allow faster access to 
the CD16 epitope on the effector cell. This faster access 
may lead in turn to a faster formation of a synapse between 
the suface-adherent target cells and the triplebody-
decorated γδ T cells. This could lead to the differences in 
the initial phase of changes in the CI index, which were 
detected by the xCelligence assay. This difference in the 
early stage of the kinetics may not affect the EC50-values 
and the degree of maximum specific lysis, because both 
SPM-1 and the 4G7SDIE antibody mediated target cell 
lysis by NK cells with similar EC50-values and similar 
maximum specific lysis (Figure 4B). It could however 
still have an impact on the pharmacokinetic properties 
of both agents, and thus on their anti-cancer activities in 
vivo. Therefore, the xCelligence assay offers a welcome 
enrichment of the set of tools available to study cytolytic 
processes in detail, even if it still does not allow for single 
cell resolution. Combining high throughput real-time 
assays with single-cell resolution assays is an important 
area for future improvements, which promises to be highly 
informative [49].
Taken together, the data presented here permit us 
to conclude that SPM-1 in combination with NK cells is 
highly active in ADCC reactions against primary cells 
from patients with a variety of B-lymphoid malignancies. 
It is capable of recruiting γδ T cells for cytolysis, and 
reveals unsuspected rapid reaction kinetics in time-
resolved cytolysis assays. These properties make it both 
a valuable tool for further studies of the kinetics of the 
cytolytic process together with CD16-bearing effector 
cells, and a candidate for further clinical development as a 
highly potent alternative for the treatment of B-lymphoid 
malignancies with distinct advantages over available best-
in-class agents.
MATERIALS AND METHODS
Generation of triplebodies and other antibodies 
and antibody-derived proteins
To produce triplebody SPM-1, the CD19-specific 
scFv domains contained in the parental triplebody 
ds(19-16-19) [26] were humanized with procedures 
developed in the laboratory of Dr. A. Honegger [43, 
44]. The CD16-specific scFv was disulfide-stabilized 
according to published procedures [43]. SPM-1 
contains a C-terminal hexa-histidine tag for purification 
purposes. Potentially immunogenic sequences that 
resulted from the standard cloning procedures used 
for the generation of the parental ds(19-16-19) were 
removed from the final protein. The coding sequence 
for SPM-1 was optimized to minimize homologous 
recombination between cDNA sequences coding for 
the CD19 binding domains by introducing variations 
in the wobble bases of the coding triplets. The cDNA 
was subcloned into a pSecTag2-HygroC expression 
vector (Life Technologies, Darmstadt, Germany). The 
Her2-16-Her2 triplebody was constructed by replacing 
the N- and C-terminal scFvs of a humanized successor 
molecule of the published triplebody ds(19-16-19) [26] 
with Her2-specific scFvs from the pSecTag2-HygroC-
4D5-CD3 bispecific single chain Fv construct provided 
by Prof. M. Peipp [50] using standard molecular 
biology techniques.
The minibodies 4D5-IgG1-Fc and 4D5-IgG1-Fc 
engineered (provided by Prof. M. Peipp) contained a Her2 
(clone 4D5)-specific scFv, a modified hinge region from an 
IgG, which allowed for disulfide-bridge formation, and a 
modified Fc-domain, harboring the substitutions S239D/
I332E/A330L (SDIEAL) or no substitutions, respectively 
[50]. To generate the CD19-targeting minibodies, the 4D5-
scFv was replaced by the CD19-targeting scFv from SPM-1.
For the expression of all proteins, human FreestyleTM 
293-F cells (Life Technologies, Darmstadt, Germany) 
were transfected with the respective plasmid DNA using 
the 293fectinTM Transfection Reagent (Life Technologies, 
Darmstadt, Germany) according to the manufacturer´s 
instructions. Proteins were either expressed transiently 
or a pool of stably transfected cells was generated by 
continuous selection with 50 µg/ml hygromycin C.
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Recombinant proteins were captured from cell 
culture supernatants via their C-terminal hexahistidine 
tags by metal-ion affinity chromatography. SPM-1 
was further purified by anion- and cation-exchange 
chromatography. The scFv-minibodies and Her2-16-Her2 
were further purified by size exclusion chromatography. 
Protein concentrations were determined by absorbance 
measurements at 280 nm and using the molar extinction 
coefficient derived from the amino acid sequence.
The quality of purified recombinant protein batches 
was analyzed by analytical size exclusion chromatography 
to monitor the presence of monomeric protein, aggregates, 
breakdown products, incompletely synthesized products, 
contaminants and products generated by homologous 
recombination. An Äkta liquid chromatography system 
was used, equipped with a Superdex S200 5/150 GL 
column (GE Healthcare Europe, Munich, Germany). Total 
amounts of 25 µg of protein in 50 µl volumes were loaded 
onto the column followed by isocratic elution with SEC 
buffer (20 mM Histidine-HCl pH 6.0, 150 mM NaCl). 
Eluted proteins were monitored by absorbance at 280 nm 
and by SDS-PAGE.
The CD19 antibody 4G7SDIE was provided by Prof. 
G. Jung and Dr. L. Grosse-Hovest from the University of 
Tübingen, Germany. This antibody harbors an engineered 
Fc-domain with the same substitutions S239D and I332E 
as the CD19 antibody XmAb 5574 [9, 39, 41]. The 
therapeutic CD20 antibody Rituximab (MabThera®) was 
obtained from Roche Pharma AG.
Target cells and culture conditions
The RAJI, NALM-6, SEM, NAMALWA, ARH-77 
and MCF-7 cell lines were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). RAJI, NALM-6, NAMALWA 
and ARH-77 were cultured in RPMI 1640 medium 
(Invitrogen, Karlsruhe, Germany). MCF-7 and SEM cells 
were kept in EMEM and IMDM medium (Lonza, Basel, 
Switzerland), respectively. All media were supplemented 
with 10 % fetal calf serum or pooled human AB serum 
(Invitrogen, Karlsruhe, Germany), 100 U/ml penicillin, 
100 µg/ml streptomycin, 1 mM sodium pyruvate and 2 
mM L-glutamine (all reagents from Biochrome).
MCF-7-CD19 tm cells were generated as described 
[41]. Briefly, full-length cDNA coding for human CD19 
(GenBank BC006338.2) was purchased from Source 
Bioscience (Berlin, Germany) and cloned into a suitable 
cDNA expression vector. MCF-7 cells were transfected 
with this plasmid by electroporation, and CD19-expressing 
clones were selected and sorted by flow cytometric 
analysis, respectively.
Preparation of primary cells from blood of 
human donors
Peripheral blood samples were drawn from subjects 
into EDTA solution at the Medical Center of the LMU 
Munich or isolated from platelet-pheresis products 
provided by the Institute for Transfusion Medicine of 
the University of Tübingen after receiving informed 
written consent. The project was approved by the Ethics 
Committee of the University of Munich Medical Center. 
Mononuclear cells (MNCs) from leukemia patients 
and healthy donors were enriched by density gradient 
centrifugation using the Lymphoflot reagent (Biotest, 
Dreieich, Germany) or Biocol Separating Solution 
(Biochrom, Berlin, Germany) according to manufacturer’s 
instructions. PBMCs, also used as the source of leukemia 
cells from patient samples, were then either suspended in 
RPMI medium (Life Technologies) containing 10 % fetal 
bovine serum (FBS) with penicillin and streptomycin (PS) 
at 100 units/ml and 100 µg/ml, respectively, for immediate 
use, or stored frozen in a solution containing 90 % FBS 
and 10 % DMSO. Cell viability was assessed by Trypan 
blue exclusion before use.
Ex vivo expansion of MNCs as a source of NK 
cells from healthy donors
PBMCs were expanded ex vivo in RPMI medium 
containing Interleukin-2 (IL-2) plus 5 % human serum 
(Life Technologies) for 20 d after an initial period of 
culture in the presence of an OKT3 (CD3) antibody, 
and were then frozen in aliquots for subsequent use as 
described [30, 51]. Prior to use in cytolysis experiments, 
the cells were thawed and cultured overnight in RPMI 
medium containing 5 % human serum plus 50 units/ml 
and 50 µg/ml PS, respectively, but no additional IL-2.
Expansion of γδ T cells
PBMCs were seeded at 1.5 x 106 cells per well 
in 6-well plates and cultured in supplemented IMDM 
medium containing 100 IU/ml of recombinant human 
IL-2 (rhIL-2) (Novartis, Basel, Switzerland) and 400 
nM zolendronate (Hexal, Holzkirchen, Germany). After 
13 - 14 d of culture, expanded populations containing 
35.9 - 60.6 % of γδ T cells were positively selected 
using a Hapten-modified TCR-γδ antibody and FITC-
conjugated anti-Hapten MicroBeads with the autoMACS 
system (Miltenyi, Bergisch Gladbach, Germany). Purity 
of the isolated populations was (99.2 ± 0.8) % (n = 3) 
and isolated cells were incubated with 400 IU/ml rhIL-2 
overnight prior to functional assays. Isolated γδ T cells 
had lost their FITC-labeling and had restored surface 
expression of TCR-γδ after 24 hrs (U Seidel, unpublished 
data).
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Flow cytometric analysis
Flow cytometric analysis was performed with an 
Accuri C6 flow cytometer (BD Biosciences, Heidelberg, 
Germany). CD16- and CD56-specific monoclonal 
antibodies (mAbs) were used for the analysis of NK cell 
content in PBMC-preparations and measured against 
isotype control mAbs (Immunotech, Marseille, France). 
Unlabelled CD19- and CD20-specific and isotype control 
mAbs (BD Pharmingen) were used for the analysis of 
cell surface densities of the antigens on target cells. 
Surface expression was measured using a calibrated 
cytofluorimetric assay (QIFI KIT®; DAKO; Hamburg, 
Germany) as described [45, 52].
Determination of equilibrium binding constants 
(KD) and serum stability measurements of SPM-
1
Equilibrium binding constants (KD values) were 
measured using a flow cytometry method as previously 
described [46]. The KD values were calculated from the 
raw data by using a nonlinear regression curve fit with the 
help of GraphPad Prism 3 (Graph Pad Software, Inc, San 
Diego, CA). Measurement of in vitro stability of SPM-1 in 
human serum was performed as previously described [26].
Redirected lysis (RDL) assays using calcein 
release
Non-radioactive cytolysis assays based on the 
release of calcein from target cells were performed 
as previously described [30]. Calcein AM (Life 
Technologies)-labeled target cells were mixed with 
effector cells (ex vivo expanded MNCs) in RPMI 1640 
GlutaMAX medium supplemented with 10 % FCS and 1 
% Penicillin/Streptomycin at an E (NK cell) : T ratio of 
2 : 1. After addition of different concentrations of SPM-1 
or control antibodies and antibody derivates (minibodies), 
respectively, reactions were incubated at 37 °C with 5 % 
CO2 for 3 - 4 hrs. Calcein release was then determined by 
measuring the fluorescence intensity (relative light units, 
RLU) in the supernatant with a Tecan Infinite M1000 
microplate reader (Tecan Group Ltd, Männedorf) at 
485/535 nm. Maximum lysis was achieved by addition 2.5 
% Triton X-100. Specific lysis was calculated as follows:
Specific Lysis
RLU sample RLU background release
RLU lysis RLU background
%   100 *
[  ( )   ]
[  (max )  ( )]
( )
=
−
−
EC50-values (concentration of triplebody producing 50 
% of maximum specific lysis) were determined using 
sigmoidal dose-response curve fits (GraphPadPrism, San 
Diego, CA).
γδ T cell degranulation assay using detection of 
cell surface CD107a
The fraction of γδ T cells (CD3+, TCRγδ+) was 
determined by flow cytometry. Samples with γδ T cell 
counts above 1.5 % were selected for CD107a assays. 
Equal numbers of PBMC and NALM-6 or SEM cells were 
incubated with 1 nM SPM-1 or control triplebody Her2-
16-Her2, 2 µM GolgiStop reagent (BD Biosciences), 10 
µg/ml Brefeldin A (Sigma, Steinheim, Germany) and the 
fluorescent labeled CD107a-APC antibody (Biolegend, 
San Diego, USA) overnight in supplemented IMDM 
medium at 37 °C in an incubator with a 5 % CO2-
atmosphere. PBMCs were then stained for surface and 
intracellular markers and analyzed by flow cytometry.
Intracellular cytokine staining (ICS) of γδ T cells 
for TNFα and IFN-γ
Intracellular cytokine staining of γδ T cells was 
performed with IFNγ-BV711, TNFα-PB, and isotype 
control antibodies supplied by Biolegend (San Diego, 
CA, USA). Briefly, after incubation of γδ T cells with 
SEM or NALM-6 cells and SPM-1 triplebody or controls, 
cells were washed and resuspended in 100 µl of PBS : 
1 % albumin solution. Cells were then stained with γδ 
TCR mAb (BD Biosciences, Heidelberg, Germany) for 
30 min on ice. To distinguish TNFα and IFN-γ producers 
within the γδ T cell populations, cells were washed, 
fixed and permeabilized by incubation with 250 µl of 
Cytofix/Cytoperm solution (BD Biosciences, Heidelberg, 
Germany) for 15 min. Cells were then stained with either 
PE conjugated TNFα or IFN-γ mAbs versus a control mAb 
for 30 min on ice. The cells were finally washed twice, 
resuspended in FACS buffer (PBS containing 2 % fetal 
calf serum (FCS) plus 0.05 % sodium azide) and analyzed 
by flow cytometry. The percentage of cytokine-positive 
cells within the given γδ T cell treatment group was then 
calculated and plotted.
Impedance-based cytotolysis assay with human 
γδ T cells as cytolytic effectors
The cytolytic potential of expanded γδ T cells 
was analyzed in a real-time cytotoxicty assay with an 
xCelligence RTCA SP instrument (ACEA Biosciences, 
San Diego, CA) as previously described [41, 42]. Briefly, 
5x103 MCF-7-CD19 tm cells were seeded into each 
well. Expanded γδ T cells and 1 nM SPM-1 or control 
triplebody Her2-16-Her2, respectively, were added 24 hrs 
later. Cell viability was monitored every 15 min for 48 
hrs. Cell indexes (CI) were normalized to CI of the time-
point, when γδ T cells were added, and specific lysis was 
calculated relative to control cells without any added γδ 
T cells.
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CD19-specific triplebody SPM-1 engages NK and gd T cells for 
rapid and efficient lysis of malignant B-lymphoid cells
SUPPLEMENTARY FIGURE
Supplementary Figure S1: SPM-1 directs expanded γδ T cells from healthy donors for very rapid lysis of CD19-
bearing MCF7-CD19 tm target cells, monitored in a real-time assay. Raw data for the processed data of Donor 4 shown in 
Fig. 6. Cell indexes (CI) plotted here are a measure of the fraction of living cells contained in a population at the time of measurement. 
Adherent CD19-bearing MCF7-CD19 tm target cells were allowed to form a layer on the chip. Time of addition of the effector cells plus 
mediator protein (t0) is indicated by a vertical dashed line. Normalized cell indices (CI) were measured as described in Methods and are a 
close correlate of life cells on the chip. SPM-1 caused a substantially more rapid loss in viability of the target cells than the best-in-class 
CD19-antibody 4G7SDIE, and the kinetics of loss of viability was not mono-phasic but showed clear evidence for at least 2 phases of the 
reaction, as evidenced by the shoulders and secondary peaks in the reaction profile.
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3 Discussion 
 
The vast heterogeneity among different cancer entities and within an individual cancer as well as its 
continuous evolution, which also allows a quick adaptation to environmental pressures such as 
therapeutic agents, render neoplastic diseases particularly difficult to cure. In order to defeat them, 
treatments need to be highly adaptable and versatile. Introducing this level of flexibility into surgical, 
chemo- or radiotherapeutic approaches is almost impossible and has only been achieved to some 
extent by developing different kinds of cytostatic agents that may be exchanged for one another and 
used at different intensities. Accordingly, modern chemotherapeutic regimens lead to long-term 
remission in 50 to 80% of acute leukemia patients.3,4,7,8 Unfortunately the patients, who become 
therapy-refractory, have few options left: Immunotherapy offers a wider variety of mechanisms than 
conservative therapeutic approaches and achieves an unparalleled level of specificity, which reduces 
off-target side effects. The continuous improvement and development of new immunotherapeutic 
approaches thus remains an important task to help even more patients in the future. A particularly 
promising approach is the development of antibody derivatives that are capable of recognizing any 
desired tumor target antigen and that can activate any avenue of natural immune defense in order to 
exploit the extensive arsenal and versatility of leukocytes. The present work shows that triplebodies 
are capable of engaging αβ and γδ T cells as well as NK cells as effectors for the efficient and specific 
redirected lysis of cancer cells. Furthermore, dual-targeting of the lymphoid and myeloid 
differentiation antigens CD19 and CD33 was shown to lead to the selective and preferential lysis of 
biphenotypic leukemia blasts rather than single-positive cells in vitro. In addition, the author was 
involved in the preclinical development of NK cell-engaging triplebodies SPM-1 with specificity for 
CD19 and SPM-2 with specificity for CD33 and CD123. These developments provided convincing data 
that triplebodies can be produced in accordance with industry standard procedures for clinical use 
without any loss of activity. 
 
 
3.1 Efficient T cell recruitment with single-chain triplebodies 
 
T lymphocyte-dependent anti-cancer immunity is a particularly desirable immune response due to its 
high level of efficiency and the generation of immunologic memory. However, natural T cell 
responses are limited to cancer entities that display immunogenic TSA. In order to raise a T cell-
mediated immune response against cancer cells that express “self” antigens only, it is therefore 
necessary to bypass the regular route of T cell activation. This can either be achieved by modifying 
the T cells themselves with TAA-recognizing receptors or by the administration of T cell-engaging
Discussion 
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 immunotherapeutics that target TAAs.87,197 The cSMAC of the cytolytic T cell synapse, however, does 
not naturally contain soluble molecular mediators such as mAbs244 and TCR engagement in the 
absence of co-stimulatory signals can lead to T cell anergy.243,247 Nevertheless Anja Löffler and 
colleagues developed a CD19 and CD3ε bispecific scFv that induced lymphoma-directed cytotoxicity 
by non-stimulated T cells.156 This agent underwent clinical development and became blinatumomab 
(Blincyto®), the first-in-class bispecific antibody derivative for the treatment of relapsed/refractory B-
ALL.251,252 
 
Single-chain triplebodies and previously developed bispecific formats from the research group of 
Prof. Fey (FAU Erlangen-Nuremberg) were capable of engaging different FcR-bearing innate immune 
effector cell populations such as NK cells and macrophages211,214,253,254 as well as neutrophil 
granulocytes148 for the elimination of cancer cells. The engagement of T lymphocytes with 
triplebodies, however, was attempted for the first time in the present work: Prototype triplebody 
19-3-19 with bivalent monospecific targeting of CD19 and triplebody 33-3-19 with bivalent bispecific 
targeting of CD19 and CD33 were capable of efficient activation of healthy donor- and patient-
derived T cells. This was shown by the elevation of activation markers CD69, CD49d (C. C. Roskopf, 
unpublished data) and CD25 on the T cell surface and the secretion of pro-inflammatory cytokines 
IL-2, IL-6, TNF-α and IFN-γ.248,255 Importantly, polyclonal T cell activation was independent of the 
formation of an MHC : peptide-complex, but strictly required the presence of TAA and trigger 
antigen. Similar to BiTE®s157,160, the molecules could neither induce cancer cell apoptosis in the 
absence of immune effectors, nor could they induce T cell activation in the absence of TAA-positive 
target cells. This property suggests that T cell-engaging triplebodies will not produce off-target 
toxicity in vivo. It was not further investigated, why anergy induction in T cells was circumvented by 
19-3-19 and 33-3-19, but we hypothesize that it may involve TCR cross-linking after multiple specific 
binding events. In vitro the activated T cells eliminated more than 90% of target cells from B cell lines 
and primary patient samples within 24 hours. 
 
Both 19-3-19 and 33-3-19 also induced T cell proliferation, in particular proliferation of the subset of 
CD3+ CD45RO+ cells, which contains memory effector T cells that no longer require priming by APC. 
The fate of naïve T cells upon stimulation by the triplebodies is unknown. It was also confirmed that 
not only CD8+ effector T cells, but also the CD4+ T cell population was relevant for the lysis efficiency 
mediated by T cell-engaging triplebodies (C. C. Roskopf, unpublished data). 
 
While the difference in affinity for the target cell and the immune effector cell is not as pronounced 
in triplebodies as it is in the BiTE® blinatumomab (ΔKD = 40 nM vs. 200 nM, respectively)157,248, the 
target cells are still bound preferentially by the scTb. For BiTE® it has been suggested that the 
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T lymphocytes retain a high level of mobility as a consequence of this difference in affinity and the 
resultant preferential coating of target cells.160 This may be one determining factor for maintaining 
the T lymphocytes’ serial killing capacity. Importantly, bivalent cancer cell targeting by triplebodies 
implies that the combined affinities (i. e. avidity) of the two TAA-specific binding modules are 
stronger than the affinity of the single trigger antigen-specific binding module. By taking advantage 
of an avidity effect, it may therefore be possible to combine two low affinity TAA-specific binding 
moieties in a triplebody. This may further reduce the risk of killing single-positive healthy bystander 
cells. It remains to be determined, however, whether excessive triplebody concentrations can lead to 
an “oversaturation effect”. This refers to a situation in which cytolytic synapses between cancer and 
T cells are formed less efficiently, because both the target cells and the immune effector cells are 
coated by the immunotherapeutic molecules rather than being connected by them. 
 
As mentioned earlier, T cell activation by 19-3-19 and 33-3-19 led to the secretion of 
pro-inflammatory cytokines IFN-γ, TNF-α, IL-2 and IL-6, which was also reported for 
blinatumomab.166,173,256 Therefore, it is probable that T cell-engaging triplebodies will also produce 
cytokine release syndrome in some subjects in vivo. CRS can be a very severe complication that may 
lead to multi-organ failure as in the case of the anti-CD28 superagonist TGN1412188 or death as was 
recently reported in a patient receiving CD123-directed allogeneic CAR-T therapy.208 However, clinical 
expertise regarding CRS and its management has been gained in the last couple of years as T cell-
engaging cancer therapies have emerged.42,185,187,190,257 The short half-life of BiTE® and scTb 
therapeutics may moreover limit the severity and duration of CRS upon cessation of therapy. 
Therefore, this concern should not prevent further development of T cell-engaging triplebodies. 
 
The greatest shortcoming of the data presented on triplebodies 19-3-19 and 33-3-19 in the present 
work is the intrinsic instability and aggregation tendency of these molecules. These issues could not 
be resolved in spite of stabilization attempts by means of site-directed mutagenesis, introduction of 
an additional disulfide bond into the CD3ε scFv and different buffer formulations. Since the 
humanized CD19- and CD33-specific scFv that were used for the construction of 19-3-19 and 33-3-19 
were also used for construction of the NK cell-engaging triplebodies SPM-1 and SPM-2, which display 
excellent biochemical properties258,259, the OKT3-derived CD3ε−specific scFv appeared to introduce 
the molecular instability. However, this binding moiety is stable in the context of other trispecific 
molecules (M. Herrmann, unpublished data). Therefore the random combination of different scFv 
into a single polypeptide appears to be problematic, possibly due to intra- and interchain shuffling of 
the V domains that is dependent on the molecular context. The future construction of T cell-engaging 
triplebodies for use in vivo will therefore require more careful consideration and the individual 
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binding moieties may have to be stability-engineered (for example using the method by Xu et al. 
2013260) for their respective molecular context. Initial concerns regarding poor accessibility of CD3ε 
on T cells to the CD3ε-binding moiety of T cell-engaging triplebodies in comparison to BiTE® due to 
partial sterical hindrance by the second TAA-targeting scFv did not come true. 
 
Taken together, the present work has proven that triplebodies can engage T cells as well as NK cells 
for the efficient lysis of cancer cells. This establishes single-chain triplebodies as a molecular platform 
that allows for the flexible selection of an immune effector cell population. The choice of a suitable 
leukocyte population can thus be based on the immune state of individual patients, which adds a 
new layer to the personalization of cancer therapy. 
 
 
3.2 Selective lysis of biphenotypic blasts by dual-targeting of CD19 and CD33 
 
Multispecific targeting of more than one TAA is expected to hamper cancer immune escape by 
antigen loss, because the evolution of double- or multi-antigen-negative cancer cell clones is less 
probable than the evolution of single-negative clones.152,155 Although this approach cannot protect 
cancer patients from relapse due to other mechanisms of immune escape, it is another step towards 
defeating neoplastic diseases. Moreover, the identification and thus targeting of specific cellular 
subpopulations is easier with more than one phenotypic surface marker. Healthy tissues may be 
single-positive for one of the targeted antigens or may express several targeted TAA to a lower 
extent or at a different ratio than the cancer cells. Therefore, selective lysis by multispecific antibody 
derivatives based on multiple targeting may reduce “on-target off-cancer” effects on healthy tissues. 
Based on these considerations, triplebody 33-3-19 was designed for the selective lysis of 
biphenotypic B/myeloid leukemia cells with concomitant expression of CD19 and CD33. This 
phenotype does not occur on healthy cells, but is frequently observed in the blasts of infant patients 
with mll-rearranged acute leukemia and has a very poor prognosis.24,26,28 
 
The cytolytic potential of triplebody 33-3-19 against CD19 or CD33 single-positive as well as double-
positive target cells in standard redirected lysis assays in vitro was as high as that of mono-targeting 
BiTE®-like molecules.255 EC50-values were in the picomolar range and the efficiency of lysis was 
weakly correlated with antigen surface density (R2 = 0.71). However, CD19 and CD33 double-positive 
target cells were selectively lysed with a much higher efficiency than CD19 single-positive cells by 
33-3-19 plus T cells, when both target cell populations were simultaneously present in the reaction. 
Under such experimental conditions, the double-positive target cells displayed a 145-fold higher 
sensitivity towards T cell-mediated lysis than the single-positive non-target cells. In the case of the 
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antigen combination CD19 and CD33, this selectivity effect was concentration-dependent, i. e. 
double-positive target cells were only preferentially lysed at subsaturating triplebody concentrations. 
When 33-3-19 was present in sufficient quantity to coat double- and single-positive target cells, the 
selectivity effect was lost, possibly due to an “oversaturation effect”. This observation suggests that 
the concentration of multispecific agents for selective cancer cell lysis in a clinical setting would need 
to be adjusted depending on the antigen surface density and tumor burden of an individual patient. 
Nevertheless, there may be a concentration-dependent “selectivity window” for multispecifics that 
can potentially be maximized by affinity engineering261 of the TAA-specific binding moieties. This 
would enable an even better distinction between cancer and non-cancer tissues and thus less 
“on-target off-tumor” side effects. 
 
The data generated with 33-3-19 on the selective lysis of CD19 and CD33 double-positive target cells 
shows that this antigen pair is suitable for the distinction of biphenotypic B/myeloid leukemia blasts 
from single-positive bystander cells. In a similar manner, the antigen pairs CD19 and HLA-DR213, 
ErbB2 and ErbB3262, and EGFR and HER2263 have been shown to mediate preferential lysis of double-
positive target cells. Whether other target antigen pairs are also suitable for preferential lysis may 
not only depend on their combined density on the target cell surface, but also on their relative 
location to one another within the cell membrane: According to the “protein island”-model 
membrane proteins segregate into separate functional islands, some of which are anchored to the 
cytoskeleton while others can move fluidly across the membrane.264-267 If target antigen pairs reside 
in separate immobile protein islands that are spaced far apart, the binding moieties of multispecific 
antibody derivatives may not be capable of binding them simultaneously as they have a limited span 
(mAb: 15 nm, scTb: 20 nm254). For the future design of multispecific antibodies that target novel 
antigen combinations it may therefore be reasonable to determine the relative location of the target 
antigens towards one another within the cell membrane, since this probably affects the cross-arm 
binding efficiency268 of multispecific agents. 
 
 
3.3 NK cells as immune effector cell population to combat MRD in AML patients 
Although they have not received the same level of attention as CTL in recent years, NK cells are an 
immune effector cell population that also possesses a high cytotoxic potential and is therefore 
suitable for the redirected lysis of cancer cells.269,270 Furthermore, NK cells are also capable of serial 
lysis and can proliferate and expand upon stimulation. These considerations as well as the fact that 
NK cells secrete a different range and concentration of cytokines compared to CTL, which may 
produce less pronounced CRS upon their therapeutic exploitation, formed the original rationale for 
choosing NK cells as the immune effector cell population engaged by triplebodies including SPM-1 
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and SPM-2. In addition, NK cell reconstitution following myelo- and lymphoablative treatments as 
well as HSCT is faster than the reconstitution of T lymphocytes.270-272 These immune effectors may 
therefore be a better choice for eliminating MRD cells in acute leukemia patients by targeted therapy 
during maintenance treatment and in a post-transplant setting. 
 
It has been reported, however, that the NK cell compartment is functionally impaired in AML 
patients.273-276 Nevertheless, NK cell engaging-antibody derivatives that employ CD16-specific scFv 
rather than Fc-fragments for NK cell engagement were still capable of overcoming this functional 
impairment.277,278 SPM-2 is a CD33 and CD123-specific NK cell-engaging triplebody that was designed 
for the specific lysis of LICs, which are likely contained among MRD cells. In an attempt to determine 
whether SPM-2 is also capable of overcoming the functional impairment of NK cells in AML patients, 
the autologous NK cells of an AML-M1 patient at different stages of treatment were compared to the 
NK cell compartment of her healthy monozygotic twin.259 At initial diagnosis, the AML patient 
displayed a strongly reduced level of NK cells as well as of all other leukocyte populations, which was 
expected since the patient had 89.7% blasts in the bone marrow. The number of NK cells, however, 
normalized, when the patient achieved complete remission and was comparable to the healthy twin. 
Moreover, the expression level of activating natural cytotoxicity receptors (NCR) on the surface of 
the patient’s NK cells was identical to that of her monozygotic twin and not affected by the disease. 
Accordingly, the patient’s NK cells displayed the same cytotoxic potential in in vitro cytotoxicity tests 
with SPM-2 against autologous blasts from first diagnosis as the healthy twin’s NK cells. If functional 
impairment was present due to different mechanisms (for example the stimulation of inhibitory 
receptors by soluble factors secreted by the AML cells), it did not have any disadvantageous effect on 
the functional efficiency of SPM-2. In fact SPM-2 was capable of specifically reducing the CD34+ CD38-
/dim CD123+ AML-subpopulation, which is enriched for LIC, in primary samples from this patient. The 
clinical application of this dual-targeting agent in an MRD-setting may thus truly induce long-lasting 
remissions, because it can specifically eliminate a significant proportion of LIC. In additional 
experiments with primary samples from 29 AML patients and allogeneic NK effector cells, SPM-2 
mediated effective redirected lysis of bulk cells in all samples but one regardless of the AML subtype 
and genetic risk group (T. A. Braciak et al., manuscript submitted). Moreover, the CD34+ CD38-
/dim CD123+ blast subpopulation in two of these patient samples displayed and even higher sensitivity 
towards NK cell killing mediated by SPM-2 than the bulk AML blasts, which also suggests that the LIC 
population can be efficiently targeted and eliminated by this agent. Therefore the antigen pair CD33 
and CD123 and the engagement of NK cells as immune effectors appears to be suitable for targeted 
therapy of MRD in AML patients. 
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3.4 Engagement of γδ T cells by the CD16 binding moiety of SPM-1 
 
The research group of Prof. Fey (FAU Erlangen-Nuremberg) previously reported that the CD16+ 
mononuclear cell (MNC) compartment from the peripheral blood of healthy donors mediated 
cytotoxic activity against cancer cells together with antibody derivatives carrying the 3G8-derived 
CD16-binding moiety, which is also used in triplebodies SPM-1 and SPM-2, but has been 
humanized.146 This MNC compartment does not only comprise FcγRIII-bearing NK cells, but also 
macrophages and γδ T cells. 
 
 γδ T cells usually account for 1 to 10% of the peripheral blood lymphocytes and they are a potentially 
valuable immune effector cell population for targeted immunotherapy of acute leukemias.270,279 Their 
cytotoxic potential is as high as that of αβ T cells, but they do not cause GvHD and consequently they 
do not necessarily have to be depleted from hematopoietic stem cell transplants.270,279 Instead, they 
can naturally enhance anti-viral immune responses in a post-transplant setting and contribute to the 
graft-versus-leukemia (GvL) effect, because they are not MHC-restricted and can recognize 
phosphoantigens (non-peptidic prenylpyrophosphate moieties), which are highly expressed by 
malignant B cells.270 
 
Other immunotherapeutics have been described that successfully engaged γδ T cells via the 
activating receptor NKG2D for the lysis of lymphoma cells in vitro280 and via Vγ9 for the lysis of 
pancreatic adenocarcinoma cells in vitro and in vivo281,282, respectively. Furthermore, an 
Fc-engineered CD19-specific antibody – 4G7SDIE – was reported to engage γδ T cells effectively for 
ADCC of primary B-ALL cells.250 During the preclinical development of SPM-1 in cooperation with the 
research group of Prof. Lang from the children’s hospital Tübingen, we could show that triplebodies 
carrying a CD16-binding moiety are also capable of activating non-stimulated γδ T cells for the 
redirected lysis of cancer cells. This highlights the capacity of triplebodies to recruit different kinds of 
immune effector cells for the targeted immunotherapy of cancer and thus the platform character of 
the single-chain triplebody technology.  
 
 
3.5 Difference in γδ T cell and NK cell response kinetics between mAbs and triplebodies 
 
In the present work, triplebody SPM-1 induced the efficient redirected lysis of B lymphoma and 
leukemia cells at 5 to 430-fold lower concentrations than the CD20-specific mAb rituximab 
(MabThera®). The triplebody produced EC50-values of 3 to 86 pM, when used against primary patient 
blasts, and was thus similarly potent as the BiTE® blinatumomab (Blincyto®) during its preclinical 
development: EC50-values in the high femtomolar range were reported for this T cell-engaging 
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agent.157 While this high cytotoxic potential may in part be explained by the higher antigen surface 
density of CD19 compared to CD20 on the majority of tested target cells, the lack of an Fc-region in 
SPM-1 and similar antibody derivatives is certainly another very important contributing factor. 
FcR-bearing immune cells throughout the body produce an “antigen sink” effect for mAb, but not for 
antibody derivatives that lack the Fc. Moreover, the direct ligation of the FcγRIII on NK and γδ T cells 
by the CD16-binding moiety of triplebodies appears to produce a highly efficient cytolytic synapse: As 
observed by Kellner et al. in 2008211, the scTb displayed 3-fold stronger binding of target cells than 
bispecific scFv but 25-fold better lysis. One possible explanation is that triplebodies produce a tighter 
cytolytic synapse than bispecific scFv or mAb. This may result in prolonged activating receptor 
signaling and the exertion of physical forces that benefit NK cell-mediated cytolysis as it has been 
described for the cytolytic T cell synapse.243,246,283 Evidence for this hypothesis was provided by the 
biphasic lysis kinetics of CD19-positive target cells that were observed during an impedance-based 
real-time cytotoxicity assay with SPM-1 and γδ T cells.258 While both SPM-1 and the CD19-specific 
Fc-optimized mAb 4G7SDIE induced similar absolute target cell lysis within 24 hours, the triplebody 
caused a much more rapid elimination of CD19-positive target cells during the initial phase of the 
assay. Observations from cytotoxicity tests with CD123-positive target cells and SPM-2 plus 
pre-stimulated NK cells in single-cell cytometry assays284 provided further evidence for the “tight 
synapse” hypothesis, as rapid killing of target cells by NK cells within the first hour after triplebody 
addition was observed. This killing behavior was attributed to the pre-stimulation of the NK cells, 
which results in a high intracellular concentration of lytic granules at the time of assay 
commencement. However, the presence of SPM-2 in the single-cell cytometry assay also appeared to 
have an influence on the speed of lytic granule replenishment or other metabolic processes during 
later stages of this assay. Thus triplebody involvement in cytolytic synapse-formation appears to 
influence intracellular signaling of the cytolytic machinery. 
 
 
3.6 Perspective 
 
The present work has established single-chain triplebodies as a highly versatile molecular platform 
for efficient targeted immunotherapy. Triplebodies can be used for the engagement of various 
desirable immune effector cell populations and for the highly selective lysis of cancer cells based on 
suitable antigen pairs for dual-targeting. The preclinical development of triplebodies SPM-1 and 
SPM-2 has further proven that such molecules can be produced in accordance with industry standard 
procedures, which may readily be scaled up. However, the problematic biochemical properties of the 
T cell-engaging triplebodies 19-3-19 and 33-3-19 also imply that individual molecular optimization 
will be necessary. 
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With dual-targeting triplebodies SPM-2 and 33-3-19 for the treatment of AML and MPAL, 
respectively, two immunotherapeutic agents have been developed that will potentially be useful for 
the selective and efficient treatment of AML and MPAL patients with high risk disease in the future. 
First it needs to be determined, however, whether the selectivity of lysis that these agents display in 
vitro for double-positive target cells translates into selective lysis in vivo and thus into reduced 
“on-target off-tumor” toxicity. Should this be the case, then these agents may induce deep 
remissions and prevent immune escape by antigen loss in some patients. However, since cancer can 
also exploit other avenues – including immunosuppression – to achieve immune escape, multispecific 
targeting of more than on TAA will probably be insufficient to cure advanced neoplastic disease by 
immunotherapy. Therefore a combination of multispecific agents that engage different immune 
effector cell populations for cancer cell lysis with other immunotherapeutic approaches such as 
checkpoint blockade seems to be a promising approach for the cure of cancer. 
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Figures 
 
Figure 1: Models of tumor heterogeneity. Tumors are composed of phenotypically and functionally 
heterogeneous cells. There are two theories as to how this heterogeneity arises, which are 
particularly relevant in acute leukemia. The clonal evolution model and the cancer stem cell model 
[based on John E. Dick, 2008]48 17 
 
Figure 2: Schematic representation of IgG domains and 3D structure of IgG based on x-ray 
crystallography studies. (a) IgG is composed of 2 heavy and 2 light chains. V domains (VL/VH) at the 
N-terminal end of the polypeptide chains, which form the antigen-binding clefts, are followed by one 
(CL) or three (CH1-3) constant domains, respectively. Each domain has one internal disulfide bond. The 
two heavy chains are linked via two cystines in the highly flexible hinge region. The light and heavy 
chains are also connected via a disulfide bond between the CL and CH1 domains. The CH2 and CH3 
domains form the fragment crystallizable (Fc), while the V domains plus the CL and CH1 domains in the 
two identical arms with antigen binding activity form the antigen-binding fragments (Fab). (b) Three-
dimensional structure of mouse IgG2a antibody Mab231 based on x-ray diffraction data (blue shades: 
constant domains; orange shades: variable domains). The distinct barrel-shaped structure that is 
constructed from two β sheets in each Ig domain is clearly discernible. The junction between the V 
domains and the CL/CH1 domains (elbow region) confers additional flexibility [adapted from Harris et 
al., 1997].116 22 
 
Figure 3: Anti-tumor mechanisms mediated by IgGs. (a) IgGs bind to pro-tumorigenic chemokines 
and cytokines and thereby neutralize them. (b) Antibodies opsonize (i.e. coat) the tumor cell and 
block pro-tumorigenic receptors and/or interactions with the tumor microenvironment. (c) Tumor-
specific antibodies recruit complement to the tumor cell surface, thereby labeling the cell for 
destruction. (d) Antibody-dependent cellular cytotoxicity (ADCC) is initiated by the recognition of IgG-
coated tumors by FcR, which are expressed on immune effector cells such as NK cells, macrophages 
and neutrophils. These interactions lead to ADCC and tumor cell apoptosis through the delivery of 
perforin and granzymes. (e) The IgG-coated apoptotic tumor cells can bind FcR on phagocytes and 
initiate Fc-dependent phagocytosis, leading to the lysosomal degradation of the tumor cell. (f) 
Peptides derived from lysosomal degradation of tumor cells can be loaded onto MHC class II 
molecules, leading to the activation of CD4+ T helper cells. In addition to CD4+ T cell activation, DCs 
can cross-present tumor antigen-derived peptides and prime cytotoxic CD8+ T cells [based on Weiner 
et al., 2010].118 24 
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Figure 4: Schematic representation of bispecific antibody and antibody-derived formats that are 
investigated in clinical trials. Left panel: Bispecific full-length IgGs. Right panel: Bispecific antibody 
fragments [based on Hess et al., 2013].84 26 
 
Figure 5: Domain arrangement and putative 3D shape of a single-chain triplebody based on small 
angle x-ray scattering (SAXS) data. (a) Block-structure of the gene cassette for a scTb is shown 
[based on Kellner et al., 2008].211 (b) Schematic representation of a scTb. (c) An overlay of the shape 
of triplebody [19x16x19] predicted from SAXS data [Nadja C. Fenn, unpublished] and the three-
dimensional structure of 3 scFvs based on x-ray crystallography is shown. The two distal scFvs have a 
putative spread of 20 nm [adapted from Georg H. Fey, 8th Fabisch-Symposium, March 21st 2012]. 30 
 
Figure 6: Schematic representation of the molecular structure of CD19. The extracellular region of 
CD19 with its two C2-type Ig-like domains forms a co-receptor complex together with CD21/CD35, 
CD225 and CD81. Signaling through CD19 can either be triggered upon cell autonomous aggregation 
or upon ligand-binding to the mature BCR. This results in sequential phosphorylation of the indicated 
tyrosine residues in the cytoplasmic tail of CD19 and subsequent activation of multiple signaling 
cascades that induce B cell proliferation and differentiation [based on Wang et al., 2012 and Carter et 
al., 2002].216,220 32 
 
Figure 7: Schematic representation of the molecular structure of CD33. The extracellular region of 
CD33 is composed of two Ig-like domains of the V- and C2-set with intra-domain disulfide-links. CD33 
recognizes specific sialylated glycans and thereby mediates cell-cell interactions. Intracellular 
signaling is modulated by CD33 upon phosphorylation of specific tyrosine residues within the ITIM 
and ITIM-like motifs in its cytoplasmic tail and upon ubiquitination [based on Laszlo et al., 2012].227 34 
 
Figure 8: Schematic representation of the molecular structure of CD123, the alpha-chain of the IL-3 
receptor. Two isoforms of CD123 exist with three (SP1) and two (SP2) extracellular domains, 
respectively. Both isoforms have a transmembrane domain and identical short cytoplasmic domains 
with a membrane-proximal proline-rich region. CD123 is involved in activation of the STAT signaling 
pathway and in cell survival. The N-terminal Ig-like D1 of the SP1 isoform of CD123 is flexible and can 
adopt an open and a closed conformation, whose biological function is unclear [based on Blalock et 
al., 1999].237 36 
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Appendix A: Sequence Data 
 
 
Name of scFv 
 
Amino acid sequence 
Details from bioinformatic analysis 
 
 
muCD3ε (OKT3-derived)134 
245 aa, 26.6 kDa, VH → VL 
 
DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGY
INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDD
HYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASP
GEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSG
SGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK 
 
Isoelectric point (pI) 8.67, molar extinction coefficient (ext. coeff.) 
61,560 M-1 cm-1, grand average of hydropathicity (GRAVY) -0.592 
 
Mutants of muCD3ε scFv  
 muCD3ε C105S285 DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGY
INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDD
HYSLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASP
GEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSG
SGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK 
 
 dsmuCD3ε DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQCLEWIGY
INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDD
HYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASP
GEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSG
SGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGCGTKLELK 
 
 dsmuCD3ε C105S DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQCLEWIGY
INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDD
HYSLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASP
GEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSG
SGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGCGTKLELK 
 
 
dshuCD16 (3G8-derived)253 
250 aa, 26.5 kDa, VL → VH 
 
DIVLTQSPSSLSASVGDRVTITCKASQSVDFDGDSFMNWYQQKPGKAPKLLI
YTTSNLESGVPSRFSASGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGCG
TKVEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGDVQPGGSLRLSC
AFSGFSLRTSGMGVGWIRQAPGKCLEWVAHIWWDDDKRYNPSVKGRFTI
SKDTSSNTVYLQMNSLRAEDTAVYYCAQINPAWFAYWGQGTLVTVSS 
 
pI 5.20, ext. coeff. 53,775 M-1 cm-1, GRAVY -0.331 
 
huCD19 (4G7-derived)249 
254 aa, 27.1 kDa, VL → VH 
DIVMTQSPATLSLSPGERATLSCRSSKSLLNSNGNTYLYWFQQKPGQAPRLL
IYRMSNLASGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQHLEYPLTFGQ
GTKVEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGDVQPGGSLRLS
CKASGYTFTSYVMHWVRQAPGKGLEWVGYINPYNDGTKYNESVKGRFTLS
SDKSSSTAYLQMNSLRAEDTAVYYCARGTYYYGSRVFDYWGQGTLVTVSS 
 
pI 8.58, ext. coeff. 49,070 M-1 cm-1, GRAVY -0.374 
 
 
 
 
 
 
huCD33 (AG Fey)286 
243 aa, 25.9 kDa, VH → VL 
 
 
EVQLVESGGGLIQPGGSLRLSCAASGFPLTSYGVSWVRQPPGKGLEWLGVI
WGDGSTNYHSALISRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYYPY
YAMDYWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGD
RVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGT
DFTLTISSLQPEDFATYYCQQHYSTPLTFGQGTKLEIKRS 
 
pI 8.32, ext. coeff. 53,080 M-1 cm-1, GRAVY -0.330 
 
dshuCD123 (AG Fey)287 
250 aa, 26.7 kDa, VH → VL 
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYYMSWVRQAPGKCLEWLALI
RSKADGYTTEYSASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARDAA
YYSYYSPEGAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS
LSASVGDRVTITCKASQNVDSAVAWYQQKPGKAPKALIYSASYRYSGVPSRF
SGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPWTFGCGTKVEIKR 
 
pI 7.74, ext. coeff. 57,675 M-1 cm-1, GRAVY -0.378 
 
huHer2 (4D5-8-derived)288 
248 aa, 26.3 kDa, VL → VH 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSA
SFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKV
EIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASG
FNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNT
AYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 
 
pI 8.81, ext. coeff. 50,100 M-1 cm-1, GRAVY -0.363 
 
muTCR (BMA031-derived)289 
243 aa, 25.9 kDa, VH → VL 
EVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMHWVKQKPGQGLEWIG
YINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVHYCARGSYY
DYDGFVYWGQGTLVTVSAGGGGSGGGGSGGGGSAQQIVLTQSPAIMSAS
PGEKVTMTCSATSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGS
GSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK 
 
pI 8.53, ext. coeff. 58,580 M-1 cm-1, GRAVY -0.425 
 
 BLACK - framework residues, BLUE – complementarity determining 
regions (CDR), GREEN – residues for potential disulfide-stabilization 
 
